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Summary 
 
The ultimate aim of the work described in this thesis was to (1) utilise PAMAM 
dendrimers as a tool to achieve differential transport across the intestinal 
mucosa and the blood brain barrier, where these dendrimers can be used to 
achieve oral bioavailability but avoid BBB penetration and CNS access and (2) 
to create cannabinoid-dendrimer conjugates that are active in their own right 
and whose penetration to the brain is prevented but whose intestinal activity is 
afforded for the treatment of IBD.  
 
Overall, the work described in this thesis has promoted a strategy whereby an 
active polymer (dendrimer)-drug conjugate could be formed that is active in its 
own right and where the polymer can serve to provide differential biological 
barrier transport which with regard to cannabinoid pharmacology obviates 
adverse CNS effects. 
The work in this thesis describes the design and synthesis of novel and active 
cannabinoid structures that should have commercial interest. These novel 
compounds served to further elucidate SAR in amino alkyl indole cannabinoids. 
SAR findings have revealed a site on these cannabinoids that can be 
functionally altered without loss of pharmacological activity.   
Additionally, studies in this thesis have led to the development of a novel 
radiolabelling strategy for anionic polymers that offers a number of distinct 
advantages over other approaches. 
Ultimately, a novel stable Dendrimer-cannabinoid conjugate has been 
synthesised but to date has not shown biological activity in the models utilised 
in this work.  
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1.1 Dendrimers 
 
1.1.1 Overview 
 
Dendrimers are iteratively branched, mono-disperse polymers that emanate 
from a functional core [1, 2]. The word ‘dendrimer’ is derived  from the Greek 
words ‘dendron’ and ‘meros’ meaning ‘tree’ and ‘parts’ , respectively [3]. The 
first controlled dendrimer synthesis was achieved and reported by Vögtle’s 
group in Bonn in 1978 [4]. It wasn’t until 7 years later, however, that 
dendrimers started to raise interest in the medical field upon the publication of 
Tomalia’s seminal work on the subject in 1985 [5].    
Dendrimers generally possess three distinctive features: An encapsulated core, 
multiple branching units, and an outer shell that comprises multiple surface 
groups and is the major contributor to the dendrimer’s physical chemical 
properties and reactivity [3, 6, 7]. The iterative branching of dendrimers that 
occurs at specific focal points can define the dendritic structure in terms of 
‘generations’ where each layer that is formed at every subsequent branching 
step marks a new generation that increases in number from 0. ‘the zeroth’ 
generation is generally attributed to the generation number for the core itself 
[8]. Figure ‎1.1 gives a better understanding of dendritic generational structure.  
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Figure ‎1.1  A typical dendrimer displaying a core from which multivalent branching occurs 
creating multiple layers commonly known as generations. The generation number increases 
from G0 at the core to G4 at the surface at every layer as shown. ‘S’ denotes surface groups. 
 
Among the first fully synthesised and characterised dendrimers are Starburst® 
PAMAM dendrimers  [5]. 
PAMAM dendrimers possess a nitrogen based core (ammonia or 
ethylenediamine) to which multiple amines are covalently attached by amide 
bonds forming iterative ‘amidoamine’ branches which grow radially from the 
core [5].  These dendrimers can be cationic, anionic or neutral when they 
possess positively charged amine groups, negatively charged carboxylic groups 
or neutral hydroxyl groups, respectively, on their surfaces [9]. 
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1.1.2 Dendrimer Syntheses 
 
Dendrimers are generally synthesised using the divergent or the convergent 
approach [10]. In the divergent approach, dendrimers are synthesised from a 
core where multiple protected monomers are attached at multiple steps. Each 
step forms a new generation where the protection groups are removed and 
more monomers are added to form another generation and so on. This 
method, although simple, has many draw-backs including the occurrence of 
undesirable side reactions causing synthetic errors and higher polydispersity, 
ultimately leading to lower final yields. The convergent method on the other 
hand, first developed by Frechét et al. [11], applies a counter intuitive 
approach where dendrimer synthesis starts from its outer shell: multiple 
dendrimer segments, often called dendrons or dendritic wedges, are 
synthesised independently and attached in the last step to form the final 
dendrimer.  Figure  1.2 shows the difference between the divergent and 
convergent approaches. 
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Figure ‎1.2 Dendrimer Syntheses. The Divergent (A) and the convergent (B) approaches 
 
The convergent approach offers a more controlled technique in dendrimer 
synthesis. Simply in the convergent method, less reactive sites are exposed at 
each synthetic step. The presence of less reactive sites at every step in polymer 
synthesis decreases the chances of undesired side reactions and hence 
increases the efficiency of the synthesis leading to more mono-disperse 
products at lower costs. .  The divergent approach, on the other hand, exposes 
the entirety of the dendrimer surface to reactions at each step of its synthesis. 
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1.1.3 General Characteristics and Properties 
 
The branched structure that is observed in a typical dendrimer is far from 
uncommon in biological systems. In fact, it’s one of the most recurring 
structures that are observed in life. Dendritic structures can be observed 
through a wide scale extending from the branching structure of trees and their 
roots, to the circulatory and neuronal structures in higher organisms. One of 
the hypotheses behind the universal evolution of these structures in life is that 
they provide an extended interface for interaction with the environment. It can 
be argued that this is the same reason behind the vitality of dendrimers as a 
new class of synthetic polymers in the biomedical field [12]. 
One of the major attributes that distinguish dendrimers from conventional 
synthetic polymers is their multivalency: a property that increases the available 
interaction sites on the dendrimer, hence enhancing its binding affinity in 
biological systems. Dendrimer’s polyvalent properties facilitate the efficient 
conjugation of these polymers to various drugs. Dendrimers’ multivalent 
surface groups make them generally highly water soluble. PAMAM dendrimers 
possessing charged amine or carboxylic groups on their surfaces, for instance, 
are highly water soluble, which facilitates their application in the biomedical 
field. 
Dendrimer molecular diameters have been shown to range between 1.1nm (G1 
dendrimers) and 12.4nm (G10 dendrimers)[9]. They hence possess a molecular 
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size range that is similar to that of endogenous proteins. Another attribute that 
distinguishes dendrimers is their tendency to form three dimensional globular 
spheres at higher generations (G4 and higher)[13]. Because of their similar 
molecular sizes and globular structures [12, 14], higher generation dendrimers 
have been proposed as protein mimics. Unlike proteins, however, dendrimers 
are more robust and less flexible as they are formed entirely from covalent 
bonding.  
Although highly robust, dendrimer topology is highly affected by the polarity 
and the acidity of the solvent in which it is dissolved, adapting either a denser 
or a more extended conformation according to the conditions of the solvent. 
This is essentially due to the different repulsion and attraction forces that are 
formed between the interior and the exterior of the dendrimer in different 
solvents [15, 16]. 
Higher generation dendrimers, because of their globular and branching 
structures, contain many intra-molecular cavities. These cavities can serve as 
pockets where (hydrophobic) drugs can be noncovalently encapsulated for 
controlled drug delivery purposes [17]. 
Unlike conventional polymers, dendrimers have very precise structures with 
extremely narrow polydispersity indices. This comes as a result of the 
controlled stepwise fashion in which they are synthesised[5].  
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Because of their structure, dendrimers generally form tight spheres when in 
solution, in contrast to linear or conventionally branched polymers which 
extend when dissolved. This makes dendrimer solutions less viscous than 
solutions of linear polymers of similar molecular weights, a property that 
facilitates their use in the medical field [7]. 
Dendrimers display toxicity profiles that are a function of the chemical nature 
of their surface groups and the core. The relative effects of the surface groups 
and the core on the toxicity of the dendrimer depend on the size or generation 
of the said polymer. The surface groups are the major contributor to larger 
sized dendrimers’ toxicity while the core can have a significant effect on the 
biocompatibility of smaller dendrimers. The reason behind this discrepancy is 
that the core in larger sized dendrimers is less accessible to the cells as it is 
protected by the dendrimer branching and terminal groups [18].   
Cationic (PAMAM) dendrimers, like most cationic macromolecules, are 
expected to display some degrees of toxicity in-vitro and in-vivo. Cationic 
macromolecules are generally more toxic because of the vigorous interactions 
that occur between their strong positive charge and the negatively charged 
cellular membranes; this leads to membrane rupture and cell lysis[19]. Roberts 
et al.[20] have shown that cationic PAMAM dendrimers display a generation 
dependant toxicity in-vitro and in-vivo with higher generations (possessing a 
greater number positive charges) being more toxic than lower generation 
dendrimers. Anionic PAMAM dendrimers, on the other hand, display 
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significantly lower toxicity profiles both in-vitro[21, 22] and in-vivo[23]. It has 
also been shown that the modification or coverage of the cationic surfaces of 
some PAMAM dendrimers using PEG branches significantly decreases their 
toxicity [22, 24].  
Dendrimers’ chemistry and structure can offer a versatile platform for 
manipulating biological barrier permeability to these polymers and their 
conjugates. Given the large size of dendrimers (especially at higher 
generations), it is expected that dendrimer-drug conjugates will have 
characteristics that are more similar to the dendrimer itself than with the 
conjugated drug.  
In addition to the high molecular size, the high water solubility of PAMAM 
dendrimers is expected to make them less likely to permeate across tight 
biological barriers such as the BBB.  However, lower generations of these 
globular polymers (G2.5 and lower) can still theoretically permeate across the 
intestinal barrier utilising the paracellular pathway as it has been shown that 
molecules up to 3nm in diameter can still pass between the tight junctions of 
the intestinal epithelium in the rat [25]. It has also been suggested that larger 
dendrimers can cross the intestinal barrier through uptake by enterocytes in a 
transcytotic mechanism [26].  
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1.1.4 General Biomedical Applications 
 
The distinguishing properties of dendrimers that were discussed in the 
previous section have encouraged scientists to exploit them in the biomedical 
field. Since they emerged in the early 1990s on the hands of Tomalia et al., 
Starburst® dendrimers1  have been utilised in many aspects of the biomedical 
field.  
Dendrimers have been extensively used in the field of anticancer 
chemotherapy and radiotherapy. Barth et al.[27] were among the pioneering 
groups that conjugated boronated monoclonal antibodies (MAb) to dendrimers 
to achieve better tumour targeting. Highly water soluble PAMAM G3.5-
Cisplatin conjugates have been designed for the slow release of platinum in 
cancer therapy  displaying superior anti-tumour activities in-vitro and in-vivo 
[23].  
Cationic dendrimers can serve as good gene transfection agents because their 
cationic amine terminals can readily interact with the phosphate groups that 
constitute the plasma membrane [28] and hence cationic dendrimers have 
been widely used in gene transfection where they serve as non-viral gene 
vectors that transfer specific genes into the cell [29]. A few dendrimer based in-
vitro transfection agents have been commercialised (PolyFect® and SuperFect®).  
                                                     
1 The term ‘Starburst dendrimers’ was adopted by Tomalia et al. [5] to describe classical 
dendrimers with radial architectures that were first synthesised by the same group 
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Dendrimers were also applied in the field of imaging diagnostics where 
traditional contrast agents in Magnetic Resonance (MR) imaging like 
gadolinium ions are conjugated to dendrimers’ surfaces.  The attachment of 
gadolinium ions to robust structures with high molecular sizes such as 
dendrimers improves their specificity and sensitivity as contrast agents [30], 
dendrimers have been implemented in the specific MR imaging of organs such 
as kidney [31] and tumour blood vessels [32]. Dendrimers have been utilised in 
the field of in-vitro diagnostics as well: fixed dendrimer-immunoglobulin 
conjugates were used for the rapid detection of cardiac-muscle damage related 
proteins in blood samples in a method developed by Dade International Inc. 
[28].   
Dendrimer structures afford them the potential use for the solubilisation of 
hydrophobic drugs. Several groups have exploited the dendritic structure that 
usually possesses hydrophobic cores with hydrophilic surfaces (e.g. cationic 
and anionic PAMAM dendrimers) creating a form of unimolecular micelles that 
can encapsulate hydrophobic drugs and enhance their aqueous solubility [33, 
34].   
Dendrimers have also been used as therapeutic agents by their own virtue and 
have shown intrinsic therapeutic activities against many diseases. Dendrimers  
have shown microbiocidal activity  against sexually transmitted viruses such as 
HIV [35] and HSV [36] . Indeed, a dendrimer based product, VivaGelTM from 
StarPharma, which is a vaginal gel that can be used to protect women from HIV 
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and HSV based STDs, has already shown promising results in clinical trials [37, 
38]. Dendrimers have also shown activity against prion related diseases and 
Alzheimer’s [39, 40] ; it has been proposed that dendrimers can alter the 
nucleation and elongation rates of prions and hence have the potential to 
modulate the aggregation processes of these proteins [40]. Additionally, 
quaternary ammonium functionalised dendrimers have shown potent 
antimicrobial and biocidal effects that are superior to effects exhibited by 
conventional polymers of similar structure and size [41]. Dendrimers have also 
been shown to display intrinsic activities against cancer [42] and inflammation 
[43].   
 
Dendrimers in Different Delivery Routes 
 
Dendrimers have been proposed as carriers in the delivery of various drugs 
through almost every major drug delivery route from intravenous to ocular 
delivery. 
Dendrimers have been proposed as drug carriers in many parental routes such 
as intravenous [23, 44] and intramuscular routes[45]. One of the major 
obstacles that stand in the path of developing parental dosage forms is the low 
aqueous solubility of hydrophobic drugs [46, 47]. Dendrimers, as discussed 
earlier, can aid in the solubilisation of hydrophobic drugs to overcome this 
obstacle.[46] Additionally, the most common route for the administration of 
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anti-cancer drugs is usually the parental one and the fact that dendrimers can 
be administered intravenously while causing only weak or no immunogenic 
responses[20] facilitates the future in-vivo application of the many dendrimer-
anti cancer formulations that have been developed so far. In the field of 
chemotherapeutics also, intra-tumoural [48] and intra-peritoneal [49] 
preparations of dendrimer-anticancer agents have been applied at an in-vivo 
level. 
Bai et al.[50] reported that their in-vivo results in the rat lung showed that 
cationic dendrimers can enhance the pulmonary delivery of enoxaparin, a low 
molecular weight form of heparin. Morris et al. [51] studied the transport of 
various anionic PAMAM dendrimers across the intact rat lung and showed a 
size dependant trend in their permeation across the lung epithelium.  
Transdermal delivery (TDD) is also one of the routes where dendrimers were 
proposed as carriers. TDD offers a controlled delivery of the drug to the 
systematic circulation and maintains stable effective concentrations without 
peaks and troughs in the blood [52]. The skin, however, represents a thick 
barrier that can hinder the absorption of various drugs. (Cationic) PAMAM 
dendrimers with their hydrophobic interiors and hydrophilic exteriors can act 
as transdermal enhancers that enhance the solubility of hydrophobic drugs and 
disrupt the epidermal barrier facilitating more drug absorption across the skin 
[53].  
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Oral drug delivery remains as one of the most prevalent routes that are 
exploited in the drug industry as it offers the most convenient method for the 
administration of multiple dosage forms. It remains a serious challenge, 
however, to get many drugs to permeate across the intestinal epithelium to 
the systematic circulation and achieve acceptable oral bioavailability levels due 
to various reasons like poor aqueous solubility, stability in the gastrointestinal 
environment and efflux transporters[54]. The oral route is one of the most 
explored routes in dendrimer drug delivery. Various in-vitro transport studies 
across cells that simulate the intestinal lumen, such as the CaCo-2 and the 
MDCK-II cell lines, have shown that various PAMAM dendrimers can permeate 
to extents that correlate with orally bioavailable compounds [24, 55, 56]. 
Dendrimers, as previously discussed can offer an avenue for the evasion of 
efflux transporters and can hence enhance oral bioavailability of small 
molecular weight drugs that are substrates of P-gp. Wiwattanapatapee et 
al.[26]  have shown that both anionic and cationic dendrimers can permeate 
across the rat gut sac at different rates. Florence et al. [57] have studied the 
uptake and translocation of poly-lysine dendrimers and shown that they can 
permeate across the rat intestine in-vivo.  
The ocular region is one of the delivery routes that present many challenges in 
drug formulation: while the ideal ocular formulation is one that achieves long 
residence times and acceptable bioavailability at the intended site of action in 
the eye, most drugs fail to cross the barriers presented by the eye (such as the 
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cornea and conjunctiva) [58]. These issues have instigated the search for 
different carriers of drugs that target the eye tissue, and various (polymeric) 
preparations were used to address the issues in ocular delivery[59]. 
Dendrimers have been suggested as ophthalmic carriers in this context. 
Vandamme et al. [58] have shown that the concomitant presence of various 
cationic and anionic PAMAM dendrimers of various sizes with pilocarpine and 
tropicamide can increase the residence time of these drugs in the albino 
rabbit’s eye cornea. Shaunak et al. [60] developed novel glucosamine-PAMAM 
(G3.5) conjugates that displayed anti-angiogenic and anti-immunogenic 
activities when applied on the albino rabbit’s eye.  
 
1.2 Cannabinoids  
 
Marijuana, Hashish or Cannabis are terms that describe the pyschomimetically 
active resin of the Cannabis Sativa flowers [61]. It is one of the most widely 
used recreational drugs [62]. The biological activities exerted by Marijuana 
stem from its most (psycho)active chemical constituent Δ9-
Tetrahydrocannabinol (THC), which has been first isolated and characterised by 
Gaoni et al. in 1964. [61].  The exploitation of cannabis as a therapeutic, 
however, is far from recent. In fact, the use of cannabis for medicinal purposes 
dates back to the third millennium BC as evident from ancient Chinese texts 
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that described the use of the psychoactive herb in treating stomach pain and 
cramps [63]. 
Cannabinoid compounds can be generally classified into four major groups 
based on their chemical structure:  (1) classical cannabinoids, whose prototype 
is Δ9 – THC, and are generally naturally derived. (2) Non-classical (bicyclic) 
cannabinoids, such as CP 55,940. (3) Fatty acid amides or esters (eicosanoids), 
which are generally produced endogenously in the body such as the 
endogenous cannabinoid anandamide, or (4) aminoalkyl indoles, whose 
prototype is known as WIN 55,212-2. 
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Figure ‎1.3 The four different classes of Cannabinoid Agonists: 1- Classical cannabinoids such as 
the natural compound THC, and its synthetic derivative HU-210, 2- Bicyclic (Non-classical) 
cannabinoids such as CP55,940, 3- aminoalkylindoles such as  WIN 55,212-2 and JWH-007, and 
4- Endogenous cannabinoids such as anandamide. Last panel shows two cannabinoid 
antagonists The CB1 selective SR141716 and the CB2 selective SR144528. 
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Cannabinoid agonists exert their effects through interacting with specific G-
protein coupled receptors which are expressed in many body tissues. Those are 
primarily the cannabinoid receptors CB1 and CB2. The CB1 receptor is most 
abundant in the central nervous system [64] and its activation mediates the 
psychoactive effects of cannabinoid agonists [65]. The CB1 receptor however is 
also expressed in other body tissues such as in the gastro-intestinal tract [66] 
and can mediate therapeutic effects that will be later discussed in this chapter. 
The CB2 receptor on the other has a very low expression in the CNS and does 
not mediate any psychoactive effects upon activation [67], it has been shown 
however that CB2 is not completely absent from the CNS and that it is 
expressed at the mRNA and protein level in the rodent spinal cord [68]. CB2 is 
mainly expressed in immune organs and white blood cells such as 
macrophages, neutrophils and basophils [69]. Its activation mediates anti-
inflammatory and analgesic effects that will be discussed later in this chapter.  
 
1.2.1 Therapeutic uses of Cannabinoids 
1.2.1.1  Pain 
Several groups have shown that cannabinoids can exert antihyperalgesic 
effects either through central CNS or peripheral mechanisms. The first 
evidence showing an involvement of cannabinoid  receptors in antinocicpetion  
was introduced by Calignano et al. [70] who demonstrated that the 
endogenous cannabinoid palmitoylethanolamide (PEA) can produce pain relief 
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effects in rats using the formalin test; this effect was blocked using a selective 
CB2 antagonist, SR144528, indicating that the antinociceptic effect is 
predominantly mediated via the CB2 receptor. These findings were further 
supported by the development of CB2 selective agonists that lack CNS activity 
such as HU308 and AM1241 but which both resulted in pain relief while 
exerting no centrally mediated effects. Hanus et al. [67] showed the exclusivity 
of CB2 receptors in mediating antinocicpetion responses through 
demonstrating that the selective CB1 antagonist SR141716A does not block the 
analgesic effects of different cannabinoid agonists in contrast to the CB2 
selective antagonist, SR144528.  
The mechanism through which CB2 activation result in anti-hyperalgesic 
mechanism is not completely understood, but it is hypothesised that this is 
mediated through neuronal mechanisms through activation of CB2 receptors 
present at nerve termini and the spinal cord [68] and non-neuronal 
mechanisms mediated via CB2 receptors present at  
 
1.2.1.2  Cardiovascular effects 
Cannabinoids exert benefits in cardiovascular disorders through many 
pathways. Bouchard et al. [71] investigated the cardio-protective effects of the 
endogenous mixed cannabinoid agonist, palmitoylethanolamide (PEA) in 
isolated perfused rat hearts exposed to ischemic reperfusion. The group 
showed that this agonist decreased myocardial damage upon pre-conditioning 
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ischemic reperfusion. This effect was blocked upon the use of the CB2 selective 
antagonist SR144528 which indicates that CB2 receptors play a major cardio-
protective role upon ischemic reperfusion. The cardio-protective effect exerted 
by stimulating CB2 receptors in the heart upon ischemic reperfusion have also 
been demonstrated in-vivo where pre-conditioning the heart with the mixed 
cannabinoid agonist WIN 55,212-2 decreased infarct size after re-perfusion, an 
effect that was blocked by the selective CB2 antagonist AM251 [72]. 
Cannabinoid drugs have also been shown to have an anti-arrhythmic effect. 
The endogenous cannabinoid agonist, anandamide, was reported to decrease 
the occurrence of ischemic-induced ventricular fibrillation in rodents [73]. This 
anti-arrhythmic effect seems to be exclusively mediated through the CB2 
pathway as it was only selective CB2 antagonists that blocked this effect and 
not CB1 antagonists [74].  
The cannabinoid system seems to have a role in heart failure as well. It was 
shown that animals experiencing experimentally induced heart failure with the 
selective CB2 cannabinoid antagonist SR141716A increases blood pressure and 
has a negative effect upon the survival rate of the treated animals [75]. Wagner 
et al. have additionally shown that the mixed cannabinoid agonist HU-211 
improves cardiac function in animals with induced chronic myocardial 
infarction as evident from an increase in diastolic and systolic cardiac pressure 
in the ventricles and atria [76].  
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1.2.1.3    Cancer 
The first reported evidence behind the anti-neoplastic effects that can be 
exerted by a cannabinoid dates back to 1975 when Munson et al. showed that 
THC can inhibit the growth of Lewis lung cancer through blocking DNA 
synthesis in malignant cells [77, 78]. Various reports followed showing that 
cannabinoids can inhibit the growth of a number of cancer cell lines such as 
L1210 and K-562 leukemia cell lines also through blocking DNA synthesis [79, 
80].  
Further studies showed that cannabinoids can inhibit the tumour growth and 
induce apoptosis in a number of common cancers such as gliomas, lymphomas, 
breast, prostate, skin, and pancreatic cancers [81]. The mechanism by which 
these cannabinoids inhibit tumour growth has not been completely elucidated 
yet, although it has been shown that cannabinoids exert these effects through 
mechanisms that are receptor mediated where CB1/CB2 activation by 
cannabinoid agonists leads to the down regulation of protein kinase B (Akt), 
phosphoinositide 3-kinase (PI3K), and extracellular signal-regulated kinase 
(ERK) signalling pathways which all play a role in tumour growth [82]. Anti-
tumour activities were also displayed by cannabinoid agonists through non-
receptor mediated mechanisms [83].  
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1.2.1.4    Appetite 
The endocannabinoid system and appetite to food seem to be strongly 
correlated in humans. Activation of Cannabinoid receptors using cannabinoid 
agonists seems to stimulate appetite. Few studies reported that administration 
of low oral doses of THC (2.5mg) can induce food appetite in people who suffer 
cancer or AIDS related anorexia [84, 85] . Mattes et al. additionally conducted a 
comprehensive study which investigated the appetite inducing effects of oral, 
rectal and pulmonary delivery of THC, which all resulted in an increase in 
appetite to varying extents.  
Reversely, inhibiting cannabinoid receptors using cannabinoid antagonists 
suppresses appetite [86]. In fact, Riminobant, selective CB1 antagonists has 
been commercialised as a weight loss drug until its license was withdrawn by 
the FDA due to its psychiatric side effects which include depression and 
suicidality [87].  
 
1.2.2 Irritable bowel disease and the role of Cannabinoids 
Inflammatory bowel disease (IBD) is a term that covers two distinct chronic 
inflammatory bowel conditions: Crohn’s disease (CD) and ulcerative colitis (UC) 
[88]. Whilst Crohn’s can affect any part of the gastrointestinal tract i.e. from 
the mouth to the anus, ulcerative colitis is restricted to the colon.  Additionally, 
a key difference between the two disorders is that CD affects the entirety of 
the bowel wall (transmural) while UC is restricted to the epithelial barrier of 
the gut (non-transmural) [89].  
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IBD disorders generally cause an increase in intestinal motility and faecal 
transit, leading to poorer digestion and consequently pain and diarrhoea which 
make medical treatment essential. In fact, up to 50% of those suffering from 
IBD would ultimately require surgical intervention at some point during their 
illness [90].  IBD is classically treated with anti-inflammatory salicylates (such as 
Mesalazine, olsalazine and sulfasalazine) [91-93] and steroids (such as 
hydrocortisone, budesonide and cortisone) [94-97]. Immunosupressants such 
as azathioprine, tacrolimus and methotrexate are also used [98-101].   Despite 
this wide range of therapeutics that is used in the treatment of IBD, patients 
constantly develop resistance to these drugs. This justifies the continued 
efforts to find alternative therapies for these gastrointestinal disorders. 
Massa et al. [102] have been among the first to suggest that the cannabinoid 
system can play a significant role in protecting the gut from chronic 
inflammations. In fact cannabinoids can help patients suffering IBD through 
interacting with two distinct cannabinoid receptors that are present in the gut 
and in plasma; CB1 and CB2. 
Griffin et al. [66] showed that CB1 receptors, unlike CB2, are expressed at the 
mRNA level in the guinea pig myenteric plexus, while both CB1 and CB2 
receptors were detected in the whole gut, possibly due to contamination with 
macrophages which highly express the CB2 receptor. CB1 receptors have been 
additionally shown to be expressed at the mRNA level in the human stomach 
and colon [103]. Furthermore, CB1 receptors have shown immunoreactivity in 
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the mysenteric plexus of the ileum and colon of the pig gut in 
immunohistochemistry studies [104].  
CB2 receptors on the other are more associated with the body’s immune 
system which plays a vital role in IBD. CB2 receptors have been shown to be 
highly expressed in monocytes, macrophages and B and T immune cells at the 
mRNA level through RT-PCR analyses [105, 106]. Using flow cytometry, Graham 
et al. [69] recently reported the protein expression of CB2 receptors in natural 
killer (NK) cells, B-lymphocytes, monocytes and neutrophils.  
Cannabinoid agonists can exert their virtues in the therapy of IBD and 
gastrointestinal disorders in general through a multitude of pathways.  
The cannabinoid agonist WIN 55,212-2 has been shown to significantly reduce 
stress induced gastric ulcers in rodents which were specifically blocked by CB1 
antagonists and not CB2 antagonists indicating that the anti-ulcerative effect is 
exclusive to the CB1 pathway [107]. This effect could be associated with the 
demonstrated ability of WIN 55,212-2 to inhibit the pentagastrin induced acid 
secretion in the rat gut [108]. 
Additionally, Cannabinoid receptor agonists (such as WIN 55,212-2, Δ9- 
tetrahydrocannabinol (THC) and cannabinol) have been shown to modulate 
gastric motility and emptying only through CB1 receptors [109, 110] as evident 
from the exclusive ability of CB1 selective antagonists to block this effect.  
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CB1 receptors seem to play an important role in the inhibition of intestinal 
motility and are up-regulated in inflammatory bowel disease [111].   
Cannabinoid agonists have been shown to inhibit electrically induced 
contractions in the guinea pig myenteric plexus in a manner similar to that 
mediated by ɑ2-adrenoceptors and µ-opioid receptors. Using ɑ2-adrenoceptor 
and µ-opioid antagonists however does not block the activity of cannabinoid 
agonists, unlike the selective CB1 cannabinoid antagonist SR141716A which 
blocked the effect of WIN 55,212-2 in inhibiting electrically induced 
contractions of intestinal segments. This proves that the intestinal motility 
inhibitory effects exerted by cannabinoid agonists are purely and directly 
mediated through the cannabinoid system. 
CB2 receptors also play a vital role in the treatment of IBD. CB2 activation by 
mixed cannabinoid agonists such as WIN 55,212-2 has been shown to 
attenuate the LPS induced acceleration of gastrointestinal transit in rats [112].  
CB2 activation also leads to suppressing the levels of cyclooxygenases and 
inducible nitric-oxide synthase, which indicates that nitric oxide and 
prostaglandins play a role in mediating the CB2 mediated effect upon intestinal 
motility and transit. Cannabinoids have also been reported to exert an anti-
inflammatory effect in mice that were chemically induced with colitis [102].  
It can also be argued that CB2 receptors play a role in pain management in IBD. 
As previously mentioned, CB2 receptors mediate antinociception effects when 
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activated by agonists [67, 70] which can offer the additional benefit of pain 
relief in patients suffering from IBD.  
 
Figure ‎1.4 Role of Cannabinoids in the treatment of inflammatory bowel disorders. CB1 
receptors, present in intestinal tissue, mediates intestinal and gastric motility and supresses the 
formation of gastric ulcers. CB2 receptors which are present in a number of white blood cells 
such as macrophages, neutrophils and monocytes suppresses inflammation by inhibiting the 
release of pro-inflammatory mediators such as prostaglandins, cyclooxygenase, Nitric oxide 
(NO2) and TNF-ɑ also mediates anti-hyperalgesic effects 
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CNS Adverse effects of Cannabinoids 
 
Despite the previously discussed virtues of cannabinoids in the biomedical 
field, the CNS adverse effects that are produced by these compounds remain a 
major obstacle that limits the application of cannabinoids in the treatment of 
many illnesses.  
The first accounts of the documented CNS effects produced by cannabinoids 
come from various anecdotal reports that recorded observed psychotic effects 
in people who smoked cannabis [113-117]. The reported effects varied, but 
among the common psychotic effects reported were paranoia, persecutory and 
grandiose delusions, hallucinations, depersonalisation and memory 
impairment.  
In a more controlled study, the LaGuardia Committee reported in 1944 that 
12.5% of subjects who were exposed to 30-50mg oral or 8-30mg inhaled 
cannabis suffered from different CNS adverse effects [118]. Similarly Ames 
studied the effect of orally ingested THC at doses of 50-70mg with 12 subjects. 
They reported classical psychotic effects such as paranoia, thought and action 
dissociation, hallucinations and memory impairment [119]. In a more 
comprehensive study, D’Souza et al. investigated the dose dependant CNS 
effects of intravenously injected THC and showed a clear association between 
THC dose and CNS effects such as memory impairment in verbal recall, 
attention and memory [120].  
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The resemblance between the mental symptoms produced by cannabinoid 
consumption and schizophrenia is strong and was recently reviewed by Sewell 
et al. [121]. Positive symptoms manifested in schizophrenia such as 
suspiciousness, paranoia,  grandiose delusions and fragmented thinking have 
been also reported in subjects treated with varying doses of THC [119, 120, 
122]. Negative symptoms observed in schizophrenia such as emotional 
withdrawal and psychomotor retardation have been similarly reported in 
healthy volunteers getting I.V. doses of THC  [120]. Cognitive deficits such as 
difficulties in learning and impairment of short-term memory and failure in 
decision making, that are produced upon consuming cannabis are very 
common in patients suffering from schizophrenia. Retardation in verbal 
memory seems to be the most expressed cognitive deficit produced upon 
cannabis consumption [123] and observed in schizophrenia patients [124].  
Biomarkers in the nervous system were used to study the effect of 
cannabinoids on brain function. These biomarkers are measured as a function 
of electroencephalography (EEG) responses to various stimuli. These include 
‘auditory sensory gating’ which is a measure for salient (auditory) stimuli. 
Auditory sensory gating can be disrupted as a result of acute exposure to 
cannabinoid agonists in animals [125, 126] and chronic exposure in humans 
[127, 128]. Another biomarker, P300, which is associated with memory 
updating and attention, has been shown to be altered upon acute exposure to 
cannabinoids [129].  
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Although it can be argued that cannabis, despite its obvious transient 
alteration of mental function, is relatively a safer drug to be consumed than 
alcohol [130], the chronic exposure of the CNS to this compound has been 
shown to be highly associated with the development of psychotic disorders 
such as schizophrenia in later life [131]. The extent of cannabinoid harmfulness 
in the short and long term might be disputed, but there is a consensus in the 
scientific community that the CNS dangers produced by cannabinoids cannot 
be overlooked if these compounds were to be used in the treatment of chronic 
diseases such as IBD. It is hence vital to find an avenue where cannabinoids can 
be therapeutically used in the periphery while averting access to the CNS which 
might lead to the previously discussed adverse effects.  
A few groups attempted to therapeutically exploit the cannabinoid receptors in 
the periphery while maintaining minimal access to the brain. Cluny et al. [132] 
reported a mixed cannabinoid agonist, SAB-378, which was successful in 
suppressing intestinal motility in mice through the CB1 receptor and had 
minimal effect upon psychomotor function in mice. The drug however, failed in 
decreasing the degree of colitis when experimentally induced in mice. 
Additionally, Mitchell et al. [133] reported a THC derivative (ajulemic acid) that 
exerted anti-hyperalgesic activity in mice but did not disrupt psychomotor 
function in mice.  
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1.3 Aims and Objectives 
 
The work described in this thesis aims at identifying possible pathways through 
which a cannabinoid drug can be stably conjugated to a polymer while 
maintaining its pharmacological activity. It is hypothesised that stably 
conjugating a cannabinoid compound to an anionic PAMAM dendrimer can 
maintain oral bioavailability of the said cannabinoid while retarding its access 
across the blood brain barrier.  
If such a conjugate is pharmacologically active and can still activate 
cannabinoid receptors, this would achieve the therapeutic aim of cannabinoid 
agonists in the treatment of many diseases such IBD when administered orally. 
Additionally, the hydrophilic and molecularly large nature of the polymer is 
expected to retard the access of the conjugate across the tight blood brain 
barrier which would lead to avoiding the many adverse CNS effects that are 
exerted by cannabinoid agonists. The major two objectives of this thesis are 
hence: 
1- Identifying a chemical pathway through which a cannabinoid agonist 
can be modified and conjugated to a polymer without any loss in its 
pharmacological activity. 
2- Proving that PAMAM dendrimers, which are to be conjugated to the 
cannabinoid agonist, are capable of permeating across the intestinal 
mucosa and not the blood brain barrier.  
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Chapter 2 looks into the biopharmaceutics of PAMAM dendrimers and the 
permeability of different in-vitro cell models to these dendrimers. This chapter 
aims at showing that anionic PAMAM dendrimers permeate readily across in-
vitro intestinal models such as the CaCo-2 cell model. Additionally the transport 
of these dendrimers across tighter cell monolayers that have been used as in-
vitro models for the blood brain barrier is also investigated. This chapter looks 
additionally into the effect of pro-inflammatory mediators upon the 
permeability of different cell barrier models to PAMAM dendrimers.  
 
Chapter 3 in this thesis aims at a better understanding of the structure activity 
relationship (SAR), and identifying sites on specific cannabinoid agonists that 
can be chemically modified without any loss of pharmacological activity in 
preparation for conjugating it to a PAMAM polymer. Specific functional groups 
can then be introduced through this site which facilitates the interaction 
between the cannabinoid agonist and the PAMAM polymer to create a stable 
conjugate which is the ultimate aim of this chapter. To achieve these 
objectives, a series of different novel cannabinoid agonists were synthesised in 
house with different modifications. The pharmacological activity of these 
compounds was tested using a macrophage cell model to assess the anti-
inflammatory activity of these novel cannabinoids.  
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Chapter 4 describes two different PAMAM conjugations and aims at:  
1- Synthesis of PAMAM-radiolabel conjugates using an amide linkage and 
testing stability of these conjugates in biological conditions. These 
radiolabelled dendrimer were synthesised to probe the stability of the 
amide linkage in biological conditions to assess its ability for the stable 
coupling of a cannabinoid to a dendrimer. Additionally, the radiolabelled 
PAMAM dendrimers can be used as a tool to probe their biopdistribution 
in future in-vivo studies. 
2- Synthesis of a PAMAM-cannabinoid conjugate using a similar amide 
linkage and assessment of the pharmacological activity of the conjugate. 
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Chapter 2 
Dendrimer Transport across Biological 
Barriers 
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2.1 Introduction 
2.1.1 The Intestinal Barrier 
The intestinal barrier represents the largest interface between a higher 
organism’s systemic circulation and its environment. While it plays a significant 
role in protecting the body from the permeation of many xenobiotics and 
micro-organisms, it also offers a large surface area and a long transit time 
where useful nutrients and drugs can permeate to the blood.   
The interface between the intestinal lumen and the blood includes many 
components that influence intestinal permeability [134]. 
The unstirred water layer is estimated to be between 200µm and 800µm in 
depth [135], this outermost component of the intestinal barrier can limit the 
absorption of many hydrophobic compounds. The mucous layer can protect 
the intestinal epithelia from bacterial adhesion, physical friction and chemical 
interaction with the contents of the intestinal lumen but it can limit the 
permeation of many compounds. The epithelial layer represents the most 
important barrier between the intestinal lumen and the systemic circulation 
where tight junctions can restrict the permeation of potentially harmful 
substances such as endotoxins, and consequently many drugs and therapeutic 
molecules.  
  CHAPTER 2 
36 
 
The connective tissue plays a very limited role in the intestinal permeability to 
most compounds. Ghandehari et al.[136] showed that the connective tissue 
doesn’t play a role in the passage of macromolecules.  
The intestinal restrictiveness is usually assessed by investigating the 
permeation of different paracellular markers (sugars like sucrose and mannitol 
and high molecular weight markers such a PEG polymers) and transepithelial 
markers (hydrophobic molecules such as propranolol) across the intestine. 
Intestinal restrictiveness can be also assessed and quantified in terms of 
transepithelial electrical resistance (TEER) which is a measure of the 
restrictiveness to ion transport across the epithelial barrier and is measured as 
a function of the area of the barrier in Ω.cm2.  
Mannitol permeability coefficients across the rat intestine have been reported 
to range between 1.5x10-6cm.s-1 in the colon to 5.5 x 10-6 cm.s-1 in the jejunum 
while propranolol permeability coefficients ranged between 20x10-6 cm.s-1 and 
120x10-6 cm.s-1 in the rat jejunum and colon, respectively [137].   These results 
come in correspondence with reported TEER values in the rat intestine: 20-60 
Ω.cm2 in the jejunum, and up to 180 Ω.cm2 in the colon. [137, 138] 
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2.1.2 The Blood Brain Barrier 
The central nervous system (CNS) is protected from harmful compounds by the 
blood brain barrier (BBB), a barrier that is far more restrictive than the 
intestine. Whilst the physical barrier of the BBB is primarily formed by the tight 
apposition of endothelial cells lining the microvasculature, the restrictiveness 
of the barrier is further governed through the interplay between astrocytes, 
pericytes and the brain endothelial microenvironment in general [139]. 
 Astrocytes envelop the majority of the microvascular endothelial 
surface in the brain (>99%)[140] and play an important role in the 
restrictiveness of the BBB.  This is evidenced by increases in TEER and 
decreases in mannitol permeability across brain microvascular 
endothelial cells when cultured in the presence of astrocytes [141, 142] 
.  It is thought that astrocytes enhance BBB restrictiveness through up 
regulation of tight junctional proteins and efflux transporters such as P-
gp [143].  
 
 Pericytes are smooth muscle cells located on the microvascular surface 
of the BBB. Pericytes contribute to vessel formation and blood flow 
regulation in the brain [144]. Recently, it has been suggested that 
pericytes can enhance the restrictiveness of the BBB to a wide variety of 
compounds through expressing a number of digesting enzymes that can 
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limit the entry of their substrates [145, 146]. Additionally, pericytes play 
a role in the phagocytosis of other molecules [147].  
Unlike the intestinal barrier, which is permeable to a wide variety of 
compounds, most xenobiotic molecules have limited or no access to the CNS 
due to the blood brain barrier’s high restrictiveness. BBB TEER values, for 
instance, were reported to be between 1500 and 2000 Ω.cm2 [148, 149] where 
the permeability coefficient of [14C] Mannitol across the blood brain barrier of 
the rat has been shown to be as  low as 0.085x10-6 cm.s-1 [150] 
Table ‎2.1 summarises the essential differences between the previously 
discussed intestinal and blood-brain barriers studied in-vivo. 
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Table ‎2.1 Comparison between the intestinal and the blood brain barriers 
Barrier Property Intestinal Barrier Blood Brain Barrier 
Major cellular component Epithelial layer [134] 
 
Capillary endothelial 
layer [139] 
 
Components contributing 
to restrictiveness 
 
Unstirred water layer 
Mucous gel 
Capillary endothelium 
[134] 
 
Astrocytes 
Pericytes 
[139] 
in-vivo 
TEER (Ω.cm2) 
 
20 – 60 (Small Intestine) 
100 - 180 (Colon) 
[137, 138] 
1500 – 2000 
[148, 149] 
Permeability to 
[14C] Mannitol 
x(10-6 cm.s-1) 
 
5.5 (Small Intestine) 
1.5 (Colon) 
[137] 
0.085 
[150] 
 
Expression of Efflux 
Transporters 
 
Moderate 
 
Very High 
  
 
2.1.3 in-vitro Assessment of transport across the intestinal and blood 
brain barriers.  
 
One of the most efficient methods that can provide some judgement on the 
rate and extent of absorption of new molecular entities across different 
biological barriers is the assessment of their transport across in-vitro cell 
monolayers that in some way mimic the biological barrier of interest. The 
transport of a molecule across a cell barrier is typically expressed in the terms 
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of a ‘permeability coefficient (Papp)’ which expresses the relative rate of a 
drug’s transport across a cell line normalised to the applied mass of molecule.   
CaCo-2 cells are human derived epithelial adenocarcinoma cells. CaCo-2 cell 
monolayers are utilised as an in-vitro model for intestinal absorption. Transport 
data from CaCo-2 cell models has been very well correlated with the intestinal 
barrier permeability to many small molecular weight drugs [151, 152] as shown 
in Figure  2.1. 
 
Figure ‎2.1 % Absorption in humans Vs. apparent Papp across CaCo-2 monolayers [151] 
 
This model has been hence used as an in-vitro tool to predict the intestinal 
absorption of various drugs [153].  
Another tool used for the in-vitro screening of intestinal permeability is the 
Canine Madin-Darby Canine Kidney (MDCK II). Like CACO-2 cells, MDCK cells 
can develop into epithelial cells and form tight junctions [154]. Chao et al. [155] 
was among the first to discuss the use of the MDCK cell line as an in-vitro 
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barrier for assessing intestinal transport . Papp data in the MDCK II model has 
been shown to strongly correlate with human absorption data and not 
surprisingly with Papp data in CACO-2 cells [156].  
The blood brain barrier is far more restrictive than the intestinal barrier as 
previously discussed. Therefore, an in-vitro system that models the blood brain 
barrier has to be a very restrictive one. The previously discussed MDCK cell line 
comprises two different clones. The MDCK II, has been extensively used to 
predict intestinal permeability. The MDCK I clone however is significantly more 
restrictive and can achieve transepithelial electrical resistance (TEER) values of 
more than 2000Ω.cm2. Although the MDCK I is not a perfect model for the BBB 
as it doesn’t simulate metabolism and efflux mechanisms expressed in-vivo, its 
high resistance and the ease with which the cells can be grown has led many to 
use it as a permeability screen for BBB penetration of various drugs [157].  
 
2.1.4 Aims and Objectives 
The ultimate aim of the work in thesis as described earlier is to create 
dendrimer-cannabinoid conjugates that achieve oral bioavailability and 
pharmacological effect in the treatment of IBD in the periphery while limiting 
CNS access and hence central side effects of the cannabinoids. The work 
described in this chapter aims to investigate the transport of different anionic 
and cationic dendrimers across different in-vitro barrier models. These studies 
were conducted to predict the transport extents of dendrimers with various 
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sizes across different biological barriers such as the intestinal mucosa and the 
blood brain barrier. This was attempted to test the hypothesis that dendrimers 
can serve as vehicles for drugs with CNS side effects such as cannabinoids to 
achieve selective transport across the intestinal barrier and not the BBB. 
Additionally, it was attempted to predict the influence of pro-inflammatory 
mediators such as TNF-ɑ which are over expressed in illnesses such as IBD upon 
the permeability of the intestinal barrier to different dendrimers, as it was 
hypothesised that inflamed intestinal tissue would be more permeable to 
dendrimers than non-inflamed tissue which would achieve  better targeting in 
the therapy of IBD.  
 
2.2 Materials and Methods 
2.2.1 Materials 
PAMAM dendrimers (G1.5, G3.5, G3, G4 and G5.5), sodium fluorescein (F-Na), 
sodium fluorescein isothiocyanate (FITC) and N-hydroxysulfosccinimide (sulfo-
NHS) were from Sigma-Aldrich (Poole, UK). Oregon Green 488-cadaverine was 
from Invitrogen (Paisley, UK) 1-Ethyl-3(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) was from Pierce (Cramlington, UK). Radiolabeled 
compounds [14C] Mannitol and [3H] Propranolol American Radiolabeled 
Chemicals (St. Louis, USA). All other chemicals were from Fisher Scientific 
(Loughborough, UK). 
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2.2.2 Methods  
Synthesis and purification of Oregon Green- anionic PAMAM conjugates 
 
Dendrimers are fluorescently labelled to allow analysis and quantification in 
cell transport studies. Anionic PAMAM dendrimers were fluorescently labelled 
with Oregon Green cadaverin 488 (OG). Anionic PAMAM dendrimers (supplied 
as 10% wt. /v solutions in methanol) were transferred to a round bottom flask 
and dried at 40oC in vacuo.   The PAMAM residue was then redistilled in 
phosphate buffer saline (PBS), pH 7.4 to create a final concentration of 10mg 
PAMAM/mL. After 5 minutes of stirring, 30 fold excess of EDC and 10 fold 
excess of sulfo-NHS were added to the flask. The solution was then allowed to 
stir for 30 minutes. Three molar equivalents of pre-prepared 5mg/mL OG-
cadaverine solution in DMSO were added to the mixture and the reaction 
mixture was allowed to react overnight in the dark and samples were taken 
periodically for thin layer chromatography (TLC) analysis using methanol as a 
mobile phase. Crude reaction mixtures were dried at 40oC in vacuo and 
reconstituted in 1mL of distilled water.  PAMAMs G3.5, G5.5 were then purified 
from unreacted fluorophore, buffer salts and catalysts by gel filtration 
chromatography using disposable PD-10 columns (GE healthcare, UK) for three 
consecutive times. G1.5 PAMAM reconstituted solutions were transferred to 
disposable dialysis chambers (MWCO 1,000, Float-A-Lyzer, Spectrum Europe 
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BV) and thoroughly dialysed overnight against large volumes of distilled water 
and further purified using gel filtration chromatography (Sephadex G10).   
 
Synthesis and purification of fluorescein isothiocyanate (FITC) - cationic 
PAMAM conjugates 
 
Cationic PAMAM dendrimers (G3 and G4) were fluorescently labelled with 
fluorescein isothiocyanate (FITC).  Cationic PAMAM dendrimers (supplied as 
10% wt. /v solutions in methanol) were transferred to a round bottom flask 
and dried at 40oC in vacuo.   The PAMAM residue was then re-distilled in 
phosphate buffer saline (PBS), pH 7.4 to create a final concentration of 10mg 
PAMAM/mL. After 5 minutes of stirring, 1.5 molar equivalents of pre-prepared 
FITC solution in acetone were added to the mixture and the reaction mixture 
was allowed to react overnight in the dark and samples were taken periodically 
for thin layer chromatography (TLC) analysis using methanol as a mobile phase. 
Crude reaction mixtures were dried at 40oC in vacuo and reconstituted in 1mL 
of distilled water.  PAMAMs G3 and G4 were then purified from unreacted 
fluorophore and buffer salts by gel filtration chromatography using disposable 
PD-10 columns (GE healthcare, UK) for three consecutive times.  
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Cell cultures 
CaCo-2, MDCK I and MDCK II cells were obtained from the European Tissue 
Culture Collection ECACC (London, UK) and cultured using Dulbeco’s Modified 
Eagle medium (DEMEM) supplemented with 10% (v/v) heat inactivated FBS 
and 2% penicillin G/Streptomycin (100U/mL). Cell cultures were maintained at 
37oC in 5% CO2/ 95% atmospheric air and relative humidity. While cells were 
grown in T-25 and T-75 culture flasks, they were routinely cultured to 70-80% 
confluence. CaCo-2 cells were seeded at densities of 250,000 cells/cm2 while 
MDCK I and MDCK II cells were seeded at densities of 45,000 cells/cm2 on 
Transwell® clear culture inserts (24 well, 6.5mm diameter, 0.4µm pore size, 
Corning, UK). CaCo-2 cells were cultured on inserts for 21-28 days post 
confluence and MDCK I and MDCK II cells were cultured for 3-4 days in 
preparation for cell transport studies.  
Transport Studies 
Transport studies were conducted upon CaCo-2, MDCK I and MDCK II cell 
monolayers that displayed TEER values of at least 300 Ω.cm2, 3000 Ω.cm2 and 
120 Ω.cm2, respectively. TEER values were measured using an EVOM volt-ohm 
meter (Word Precision instruments, Sarosota, USA) connected to an Endohm 
chamber.  
Culture media was aspirated and the apical media was carefully washed twice 
with warm PBS. The inserts were transferred to fresh 24 well plates. Pure 
DMEM F-12 (without phenol red) media was applied to the washed apical and 
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basal compartments of the inserts and the cells were left to equilibrate for 30 
minutes at 37oC. 200µL doses of the probe (PAMAM dendrimers, Sodium 
Fluorescein, Oregon Green, [14C] mannitol or [3H] Propranolol) were carefully 
added to the apical chamber. Inserts were then placed on an orbital shaker 
rotating at 50RPM at 37oC. Cumulative transport of probes was assessed by 
quantifying the probe in 200 µL samples that were taken at pre-determined 
time points over 2 hours. All aspirated samples were directly replaced with the 
same volume of blank DMEM-F12.  
PAMAM-OG  and PAMAM-FITC conjugate stability in transport studies 
 
Stability of fluorescent PAMAM conjugates (including OG and FITC) was tested 
in all transport studies by analysing samples before and after the transport 
studies conducted across cells at 37oC in relative humidity using gel filtration 
chromatography. PD-10 pre-packed columns (comprising Sephadex G25 gel) 
were used to analyse all dendrimers except PAMAM G1.5 whose smaller 
molecular size has necessitated the use of a gel with a smaller pore size, 
Sephadex G-10. All the used gels were validated using known high molecular 
size and small molecular size markers. 
Analysis of fluorescent and radiolabeled probes 
Fluorescent Samples were analysed using micro plate fluorescence reader 
(FLUOstar Optima, BMG) using excitation and emission wavelengths of λex 
485nm and λem 520nm, respectively for PAMAM-OG, PAMAM-FITC and F-Na. 
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Fluorescent readings were quantified using calibration curves constructed in 
cell transport media (i.e. DMEM F-12). Background fluorescence values were 
subtracted from the calibration curve and the total mass of the probe absorbed 
was quantified by correcting to the total volume of the receiver chamber and 
loss during sampling.  
Analysis of radiolabeled probe accumulation in the receiver chamber was 
determined using liquid scintillation counter (LSC) (Wallac 1409, PerkinElmer 
Life Sciences, Boston, MA, USA). 
Biocompatability Testing 
The effect of PAMAM dendrimers on the integrity of the monolayers in 
transport studies was assessed by measuring TEER before and after transport 
experiments and by the assessment of the permeation of the paracellular 
marker, [14C] mannitol and the transcellular marker [3H] Propranolol across the 
monolayers in the presence or absence of co-incubated PAMAM dendrimers. 
Isolated Perfused Rat Gut (IPrG) 
Male Sprague Dawley Rats (weight 250-350g) were euthanized using terminal 
anaesthesia delivered as an intraperitoneal injection of 200mg/kg 
pentobarbital (Euthatal®) followed by cervical dislocation. The rat was placed 
on a heating plate to maintain a warm temperature during the procedure. The 
abdomen was excised and the intestines were exposed and gently moved to 
the left-hand side of the animal to expose the mesenteric artery. The 
mesenteric artery was pierced using a G25 needle and a PE-10 tubing (attached 
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to a perfusate reservoir) through a peristaltic pump is inserted to the 
mesenteric artery through the formed piercing and tied using a surgical stitch. 
The portal vein is then located at proximity of the liver and incised using 
surgical scissors. A PE-50 tubing is inserted to the vein and secured by tying it 
using surgical stitches.  
The perfusate was an isotonic, buffered (pH 7.4) solution of Glucose (2.0g/L) , 
KCl  (0.35g/L),  MgSO4.7H2O (0.29g/L) , NaHCO3
  (2.10g/L) , CaCl2.2H2O  
(0.37g/L) , NaCl (6.92g/L) , KH2PO4
  (0.16g /L), Bovine Serum Albumin (BSA) 
(40.0g/L) in distilled water. 
The perfusate (warmed at 37oC, continuously bubbled with 95% CO2/5% O2 and 
continuously stirred using a magnetic stirrer) is pumped through the 
mesenteric artery at 8mL/min and the blood was cleared out from the 
mesenteric bed and drained out of the portal vein for two minutes before 
redirecting the out flow from the portal vein to the feeding perfusate reservoir 
to create a closed re-circulating system.  
The intestines are then clamped using two clamps, one positioned at 4 cms 
down from the stomach and one 8 cms down from the stomach. The clamped 
section is rested on gauze wetted with warm saline and is continuously wetted 
with warm saline to maintain its humidity. A 2mL probe solution dissolved in 
PBS, pH 7.4 is intraluminally injected between the two clamps, and the needle 
is then secured in the injection site to avoid fluid leakage out of the lumen. 
Figure  2.2 displays the setting of the experiment.   
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Figure ‎2.2 Experimental setting for the isolated perfused gut model. Adapted from [158] 
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2.3 Results and Discussion 
2.3.1 Synthesis, Purification and Stability Testing of anionic PAMAM –
OG and cationic PAMAM-FITC conjugates 
The lack of a chromophore that absorbs UV light at wavelengths in PAMAM 
dendrimers makes it very difficult to quantify these polymers at low 
concentrations. Hence, it was necessary to fluorescently label both anionic and 
cationic PAMAM dendrimers to facilitate their quantitation in cell transport 
experiments. Oregon Green Cadaverine (OG) was the fluorescent label of 
choice for labelling anionic PAMAM dendrimers as it contains a free amine that 
can react with the carboxylic groups at the surface of these negatively charged 
polymers. Figure ‎2.3 illustrates the synthesis and purification of a PAMAM 
G3.5-OG conjugate. All other anionic PAMAMs where conjugated to OG 
cadaverine using the same methods. 
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Figure ‎2.3 (A)  Schematic showing the synthesis of conjugating an anionic PAMAM dendrimer 
to OG cadaverine. (B)  GPC chromatogram (using PD-10 columns) of a crude PAMAM G3.5-OG 
synthesis mixture after a 16 hour reaction. (C)  GPC chromatogram (using PD-10 columns) of 
the PAMAM G3.5-OG conjugate after its purification from the crude mixture using GPC. 
 
After purification, the number of OG molecules attached to each dendrimer 
was quantified by UV analysis. Although 3 molar equivalents of Oregon Green 
were used in each reaction, the average number of Oregon Green molecules 
attached to each dendrimer ranged between 1 and 1.4.  
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Cationic PAMAM dendrimers were labelled using fluorescein isothiocyanate 
(FITC) which readily reacts with the free amines present on the cationic 
PAMAMs’ surfaces. Figure  2.4 illustrates the synthesis and purification of a 
PAMAM G3-FITC conjugate. All other cationic PAMAMs where conjugated to 
FITC using the same methods. 
 
Figure ‎2.4 (A) Schematic showing the procedure of conjugating a cationic PAMAM dendrimer to 
FITC. (B) GPC chromatogram (using PD-10 columns) of a crude PAMAM G3-FITC synthesis 
mixture after a 4 hour reaction. (C) GPC chromatogram (using PD-10 columns) of the PAMAM 
G3-FITC conjugate after its purification from the crude mixture using GPC. 
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Figure  2.4 (B) shows the GPC chromatogram of the crude reaction mixture of 
PAMAM G3 dendrimer and FITC after a 4 hour reaction period. It displays high 
cationic PAMAM - FITC reaction efficiency in comparison to OG - anionic 
PAMAM reactions. This can be noticed from the GPC chromatogram which 
shows that the area corresponding to the free fluorescent label (eluting at 10-
20mL) is significantly smaller than that corresponding to the fluorescently 
labelled dendrimer (In contrast to the GPC chromatogram of crude anionic 
PAMAM-OG reaction (Figure  2.3) which displays that a significantly larger 
fraction of free OG is left unreacted after a 24 hour reaction period although 
OG and anionic PAMAM dendrimers were used in the same stoichiometric ratio 
that was used in FITC-cationic PAMAM reactions.) This has necessitated the use 
of a lower stoichiometric ratio of FITC-cationic PAMAM dendrimer than that 
used in OG anionic PAMAM reactions to achieve similar fluorescent dye: 
dendrimer ratios for both anionic and cationic dendrimers. Hence, only a 1.5 
molar ratio of FITC : cationic PAMAM dendrimer was used in labelling cationic 
dendrimers while a molar ratio  3:1 of OG : anionic PAMAM was used in 
labeling anionic PAMAM dendrimers. Using the molar ratios described above in 
labelling cationic and anionic dendrimers, UV analyses have shown that the 
pure FITC: dendrimer ratio in a fluorescently labelled cationic dendrimer was 
between 1.2 and 1.4 which is similar to that achieved in anionic PAMAM – OG 
reactions).  
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To test the stability of anionic PAMAM-OG and cationic PAMAM-FITC 
conjugates in cell culture conditions, the purity of these PAMAM dendrimers 
was assessed before and after 24 hour incubations in cell culture media 
including 10% FBS at 37oC and relative humidity using GPC chromatography.   
 
Figure ‎2.5 Stability of anionic PAMAM-OG and cationic PAMAM-FITC conjugates over 24 hours 
in physiological conditions as evidenced from gel permeation chromatography. (A) GPC 
(Sephadex-G10) chromatograms of PAMAM G1.5-OG. (B) GPC (PD-10) chromatograms of 
PAMAM G3.5-OG (C) GPC (PD-10) chromatograms of PAMAM G5.5-OG. (D) GPC (PD-10) 
chromatograms of PAMAM G3-FITC 
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Chromatograms shown in Figure  2.5, show that free fluorescent label signals 
corresponding to free OG or FITC do not appear at the expected elution volume 
(10-20mL in sephadex G-25 and 25-35mL in Sephadex G-10) before or after the 
incubations described earlier. This shows that all tested dendrimer-fluorescent 
label conjugates showed high stability in physiological conditions over 24 hours 
with minimal to no dissociation between the dendrimer and the fluorescent 
label.  
The stability of fluorescently labelled dendrimers is vital for transport studies to 
ensure that transport data only reflects the transport of the dendrimers and 
not the free fluorophore which is much smaller than the dendrimers and is 
expected to pass through at much higher rates and can lead skewing the 
results.  
2.3.2 Assessment   CaCo-2 monolayers for Transport Studies 
Assessment of the CaCo-2 monolayer integrity is crucial to ensure that any 
generated results reflect on permeation across intact monolayers.  
Assessment of the integrity of the monolayers was carried out through 
measurement of TEER and assessment of CaCo-2 permeability to paracellular 
marker [14C] Mannitol and trans-cellular probe [3H] Propranolol.   
Cell monolayers with TEER values that are less than 300 Ω.cm2 were not used 
for any of the permeability studies. Figure ‎2.6 and Table  2.2 summarise  the 
CaCo-2 monolayers’ TEER and permeability to *3H] Propranolol and [14C] 
Mannitol. 
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Figure ‎2.6 Cumulative transport of transcellular probe [
3
H] Propranolol and paracellular 
markers [
14
C] Mannitol and Na-Fluorescein across CACO-2 monolayers. Results are Mean ± S.D., 
n=4 
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Table ‎2.2  Table summarising TEER, and permeability to [14C] Mannitol and [3H] 
Propranolol across a sample of CACO-2 monolayers used for transport experiments, 
n=4  
Property of CACO-2 monolayer Value 
TEER (Ω.cm2) 447 ± 17 
[3H] Propranolol Permeability Coeff. (x10-6 cm.s-1) 7.24 ± 0.37 
[14C] Mannitol Permeability Coeff.  (x10-6 cm.s-1) 0.68 ± 0.044 
Na- Fluorescein Permeability Coeff. (x10-6 cm.s-1) 0.36 ± 0.036 
  
These results show the integrity of the CaCo-2 monolayers (as judged by TEER 
measurements and Papp of [
14C] Mannitol and [3H] Propranolol across the 
monolayers). Permeability data shows a high paracellular restrictiveness across 
CaCo-2 monolayers used in the transport studies as they displayed 10 fold 
lower permeability to hydrophilic paracellular markers [14C] Mannitol and Na-
Fluorescein than to the lipophilic transcellular probe [3H] Propranolol.   
Measured TEER values were significantly higher for these monolayers and were 
above the minimum accepted used in the literature of 250Ω.cm2 [151]. 
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2.3.3 Transport of anionic PAMAM –OG conjugates across CaCo-2 
monolayers 
 
The transport of a range of anionic PAMAM dendrimers (G1.5, G3.5, G5.5) was 
assessed across CACO-2 monolayers. 
The donor concentration of PAMAM dendrimers used on the apical surfaces of 
cells was 0.5mM. A→B Permeability coefficients were then calculated using the 
following equation: 
       
  
  ⁄
    
  ……………….. Equation 2.1 
 
Where (dQ/dt) is the rate of cumulative transport, (A) is the area of the 
monolayer, and (C0) is the donor concentration of the probe on the apical 
surface. 
Fluorescence Standard curves for sodium fluorescein, Oregon green and all 
fluorescently labelled PAMAM dendrimers showed linearity over the 
experimental range. A standard curve for F-Na is shown in Figure  2.7 for 
demonstration purposes.  
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Figure ‎2.7 Standard Curve for F.Na over a concentration range of 0-200nM. Linear regression 
was performed using Graphpad Prism 5.0, R
2
 = 0.9999.  
 
 
Figure ‎2.8 (A) The linear transport of 
14
C Mannitol, Oregon Green Cadaverine, PAMAM 1.5-OG, 
PAMAM 3.5-OG and PAMAM 5.5-OG across CACO-2 monolayers over 120 minutes.(B) 
Calculated P.app values of the previous probes displayed as a bar chart. Results are Mean ± 
S.D., n=4.   
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Figure ‎2.8 (A) shows the percentage transported across CaCo-2 monolayers for 
each probe over 120 minutes. The Papp values were calculated for these probes 
according to the cumulative data of the probes’ transport across CaCo-2 and 
are presented in Figure ‎2.8 (B).  
The transport data of anionic PAMAM dendrimers data therefore shows a size 
dependant trend, with permeability coefficients being highest for smaller 
PAMAM dendrimers and lowest for larger ones. This is displayed in Figure ‎2.9 
which shows an inverse relationship between the Papp values of the different 
probes across CaCo-2 monolayers and the reciprocal cube root of their 
molecular weight. This trend infers that the paracellular pathway is 
predominant in governing the transport of anionic PAMAM dendrimers across 
CaCo-2 monolayers. The results show that PAMAM dendrimers’ permeation is 
hindered by the restrictiveness of the tight junctions as the increment in the 
dendrimer’s size leads to a decrease in its overall transport.   
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Figure ‎2.9  Relationship between probes’ molecular weight (expressed as 1 / 
3
√ molecular 
weight (Mwt)) and their permeability coefficients across CACO-2 monolayers. Results are Mean 
± S.D., n=4. best fit line generated using linear regression (Graphpad Prism), R
2
= 0.9840. 
 
Table ‎2.3 summarises the permeability coefficients of the tested anionic 
PAMAM-OG conjugates and smaller molecular weight compounds (Oregon 
Green Cadaverine and [14C] Mannitol) across CaCo-2 cell monolayers.  
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Table ‎2.3 Molecular weights, molecular diameters, and permeability coefficients of 
different anionic PAMAM-OG conjugates and small molecular weight compounds 
across CACO-2 monolayers. Data shown for permeability coefficients and TEER values 
are Mean ± S.D. (n=4) 
Probe 
Molecular 
Weight 
Molecular 
Diameter (Å) 
CACO-2 TEER 
(Ω.cm
2
) 
Papp  (x10
-6 
cm.s
-1
)  
[14C] Mannitol 189 6.5 [159] 529 ± 22 0.59   ± 0.017 
OG Cadaverine 497 11    515 ± 15 0.39   ± 0.037 
PAMAM 1.5-OG 3425 29 [9] 539 ± 39 0.22   ± 0.035 
PAMAM 3.5-OG 13200 45 [9] 531 ± 29 0.048 ± 0.012 
PAMAM 5.5-OG 54000 67 [9] 543 ± 14 0.022  ± 0.0069 
  
 
To validate that fluorescence measurements in transport studies correspond 
only with fluorescently labelled PAMAM dendrimers and not the free Oregon 
green label that dissociated during the experiment, Gel permeation 
chromatography was performed for all PAMAM-OG conjugates before and 
after the transport experiments to assess if any dissociation of the free 
fluorescent label has occurred during the experiment.  
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Figure ‎2.10 Stability of anionic PAMAM-OG conjugates during transport studies across CACO-2 
studies. (A) GPC chromatograms (Sephadex G10) of PAMAM G1.5-OG before and after 
transport experiments. (B)  GPC chromatograms (PD-10) of PAMAM G3.5-OG before and after 
CACO-2 transport experiment. (C)  GPC chromatograms (PD-10) of PAMAM G5.5 –OG before 
and after transport experiments. (D)  GPC chromatograms (PD-10) of free Oregon Green 
Cadaverine before and after transport experiments. 
 
Figure  2.10 shows that the anionic PAMAM-OG conjugates remain stable 
during the course of the 2 hour experiment as it clearly exhibits that no peaks 
associated with free OG peaks appear in the Sephadex G-10 chromatograms 
(where free OG elutes at 25-35 mL) or in the Sephadex G-25 chromatograms 
(were free OG elutes at 10-20mL). 
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2.3.3.1 Effect of anionic PAMAM dendrimers on monolayer integrity 
 
The effect of anionic PAMAM-OG conjugates on the cell monolayer integrity 
was studied by investigating the influence of co-incubated dendrimers on TEER 
and permeation of an independent paracellular marker, 14C Mannitol and a 
transcellular marker, [3H] Propranolol. 
 
Figure ‎2.11 The influence of OG and anionic PAMAM-OG conjugates on the cumulative 
transport of  [
14
C] Mannitol (A) , [
3
H] propranolol (B), as compared to control (no co-incubated 
compounds). Results are Mean ± S.D., n=4 
 
Figure  2.11 shows the cumulative transport of [14C] Mannitol and [3H] 
Propranolol across CaCo-2 cells in the presence and absence of different 
anionic PAMAM dendrimers. This clearly shows that co-incubation of PAMAM 
dendrimers does not influence the transport of [14C] Mannitol or [3H] 
Propranolol (maintaining a 10 fold difference in the transport of both probes) 
across CaCo-2 cells when co-incubated with these marker over 120 minutes. All 
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Transport profiles in the presence and absence of co-incubated anionic 
PAMAM dendrimers show linearity over 120 minutes and are similar in the 
presence and absence of the labelled dendrimer indicating the stability of the 
monolayer over the duration of the transport experiment in the presence of 
these dendrimers.  
 
Table ‎2.4 Effect of Oregon green and different anionic PAMAM-OG conjugates on 
CACO-2 monolayer integrity observed through changes in TEER and permeation of [14C] 
Mannitol and [3H] Propranolol. Results are Mean ± S.D., n=4. 
Treatment Control 
Oregon 
Green 
PAMAM 
1.5-OG 
PAMAM 
3.5-OG 
PAMAM 
5.5-OG 
TEER Before 
Experiment 
 
529 ± 22 515 ± 15 539 ± 39 531 ± 29 543 ± 14 
 
TEER  After 
Experiment 
(% Change) 
 
535 ± 13 
(+1.2%) 
511 ± 4 
(-0.9%) 
551 ± 36 
(+2%) 
537 ± 26 
(+1.1%) 
545 ± 8 
(+0.4%) 
 
[14C]Mannitol 
Perm.Coeff 
(x 10-6 cm.s-1) 
 
0.84 ± 0.14 0.75 ± 0.09 0.78 ± 0.16 0.92 ± 0.13 0.81 ± 0.02 
 
[3H]Propranolol 
Perm. Coeff. 
(x 10-6 cm.s-1) 
7.94 ± 1.04 7.17 ± 0.47 7.73 ± 0.99 7.08 ± 0.59 7.18 ± 0.56 
 
Table ‎2.4 shows that like [14C] Mannitol and [3H] propranolol transport across 
CACO-2 cells in the presence and absence of co-incubated anionic PAMAM 
dendrimers, TEER values haven’t changed over the duration of the 2 hour 
transport experiment.  
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These results clearly indicate that the labelled PAMAM dendrimers did not 
influence the integrity of the monolayers, and the generated data for their 
transport across CACO-2 monolayers has not been skewed by negative effects 
inferred by these dendrimers upon the CACO-2 monolayers. 
Ensuring that the tested probes do not alter the integrity of the cell barrier is 
vital to ensure that calculated rates of transport of these probes reflect only 
their inherent permeation and are not skewed due to altering the 
restrictiveness of the monolayers which can lead to the generation of 
misleading data that exaggerates the permeation rates and extents of certain 
compounds.    
Although only a limited number of groups studied the transport of anionic 
PAMAM dendrimers across CaCo-2 cells, the literature nevertheless displays an 
extreme discrepancy over the P.app of these dendrimers across CaCo-2 
monolayers: Kitchens et al. [160] reported P.apps that were greater than 5x10-6 
cm.s-1 (PAMAM G3.5) and 2x10-6 cm.s-1 (PAMAM G2.5) while Jevprasesphant et 
al.[161]  reported significantly lower values for P.app of 0.02x10-6 cm.s-1 and 
0.15x10-6 cm.s-1, respectively; issues of different cell toxicity can be excluded as 
a basis. 
Other studies looked into the transport of PAMAM dendrimers across CaCo-2 
monolayers in the context of bypassing the P-gp efflux transporter and showed 
that conjugating P-gp substrates to PAMAM dendrimers increases their 
absorptive transport and uptake by CaCo-2 cells [162-164]  
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2.3.4 Transport of Cationic PAMAM-FITC conjugates across CaCo-2 
monolayers. 
Two cationic PAMAM dendrimers were chosen for transport studies across 
CaCo-2 monolayers, PAMAM G3 and PAMAM G4. Both dendrimers were 
conjugated with FITC as a fluorescent label.  
 
Figure ‎2.12 Stability of cationic PAMAM-FITC conjugates during transport studies across CACO-
2 monolayers. (A) GPC chromatograms (PD-10) of PAMAM G3-FITC before and after transport 
experiments. (B) GPC chromatograms (PD-10) of PAMAM G4-FITC before and after CACO-2 
transport experiment. 
  
Figure ‎2.12 shows the GPC chromatograms of PAMAM G3 and PAMAM G4 FITC 
conjugates before and after transport experiments. While free FITC would only 
elute between 10-20mL as explained earlier, these chromatograms clearly 
show that the dendrimer-FITC conjugates were completely stable during the 2 
hours when CACO-2 transport experiments had been conducted as no elution 
of free FITC appears after the two hour experiments.  
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Results presented for permeation of cationic PAMAM-FITC conjugates in these 
studies hence, only represent the transport of the intact PAMAM-FITC 
conjugate with no contamination from the free unconjugated fluorescent label 
as no dissociation of the label occurs during the entirety of the experiment.  
Figure  2.13 shows the cumulative transport of FITC labelled cationic PAMAMs 
G3 and G4 across CACO-2 cells. Both PAMAM dendrimers show fairly linear 
trends although transport seems to slightly accelerate after 90 minutes.  
 
 
Figure ‎2.13 Cumulative transport of cationic PAMAM-FITC conjugates G3 and G4 across CACO-2 
monolayers. Data shown is mean ± S.D., n=4. 
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Table ‎2.5 Molecular weights, stoke’s diameters, and permeability coefficients of two 
cationic PAMAM-FITC conjugates across CACO-2 monolayers. Data shown for 
permeability coefficients and TEER values are Mean ± S.D. (n=4) 
Dendrimer 
Molecular 
Weight (Da) 
Molecular 
Diameter 
(Å) 
CACO-2 TEER 
(Ω.cm2) 
Permeability 
Coefficient 
(x10-6 cm.s-1) 
PAMAM G3 – 
FITC 
 
6,909 36 533 ± 12 0.096 ± 0.0012 
PAMAM G4 - 
FITC 
14,215 45 544 ± 18 0.22 ± 0.05 
 
Results in Table ‎2.5 and Figure  2.13 show that the permeation of cationic 
PAMAMs G3 and G4 is directly proportional to their molecular size where 
CaCo-2  monolayers exhibited  greater permeability to the larger dendrimer 
(PAMAM G4 – FITC) than to the smaller G3 cationic PAMAMs. This contrasts to 
CaCo-2 permeability to anionic PAMAM dendrimers where smaller dendrimers 
displayed higher permeation than PAMAMs with greater size.  
In comparing permeability data in anionic and cationic dendrimers, it is noted 
that while anionic dendrimers and PAMAM G3 dendrimers show similar 
permeability according to their molecular sizes (Figure  2.14), PAMAM G4 
shows a significantly greater permeability given its molecular size across the 
monolayers when compared to other PAMAMs.  
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Figure ‎2.14 Permeability coefficients of anionic and cationic PAMAM dendrimers corrected to 
molecular size. Data is expressed as permeability coefficient (x10
-6
 cm.s
-1
) x molecular weight 
(Da). Results are Mean ± S.D.  , n=4.  
 
 
The high permeation of PAMAM G4 dendrimers across CaCo-2 may be 
attributed to its deleterious effects upon the cell monolayers because of the 
high positive charge density on its outershell which can vigorously interact with 
the negatively charged plasma membrane resulting in cell lysis [19] .  
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Effect of Cationic PAMAM dendrimers on monolayer integrity  
 
The effect of cationic PAMAM dendrimers upon the integrity of CaCo-2 
monolayers was tested by assessment of the polymers’ effects upon TEER of 
CaCo-2 monolayers and permeability to [14C] Mannitol in their presence and 
absence as shown in Figure 2.15.  
 
Figure ‎2.15 Effect of Cationic PAMAM dendrimers (G3 and G4) on the integrity of CACO-2 
monolayers as evident from effect on TEER (A) and the permeability coefficient of the 
independent paracellular marker [14C] Mannitol. Results are Mean ± S.D., n=4. * indicates P<0.05, 
One Way Anova, Dunnet’s post-test. 
 
Figure  2.15 shows the effect of cationic PAMAM dendrimers upon the integrity 
of CaCo-2 monolayers through displaying their effect upon TEER and the 
monolayers’ permeability to *14C] mannitol when co-incubated with this 
paracellular marker. Results show that both cationic PAMAMs G3 and G4 
compromise CaCo-2 monolayer integrity as evidenced from the decrease in 
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TEER and the increase in the permeability coefficients of the independent 
paracellular marker  [14C] Mannitol.  
Interestingly, CaCo-2 permeability to PAMAM G3-FITC was similar to anionic 
PAMAM dendrimers given the molecular size. PAMAM G3-FITC however, unlike 
anionic PAMAM dendrimers has compromised the monolayer integrity and 
increased  permeability to an independent paracellular marker. This indicates 
that the observed permeability coefficient for this dendrimer is higher than it 
should be which suggests that the cationic PAMAM dendrimer may have a 
lower intrinsic permeability than other anionic PAMAM dendrimers given its 
molecular size. This can be attributed to the binding that cationic molecules 
display in general to the negatively charged lipid membranes [165] which 
decreases their overall permeation. Indeed, this comes in agreement with 
Witwanapatapee’s results which suggest that anionic PAMAM dendrimers 
cross the intestinal barrier at quicker rates than cationic ones which display 
more tissue association [26].  
The detrimental effect of PAMAM G4 upon CaCo-2 monolayers however, was 
more pronounced in both decreasing TEER values and increasing [14C] Mannitol 
permeation which could explain its high permeation across CACO-2 monolayers 
given its molecular weight.  
It is hence very important to handle data of cationic PAMAM dendrimers with 
care as it can be very misleading if the appropriate controls are not conducted 
and taken into consideration.  
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El-Sayed et al. [55] studied the permeability of CaCo-2 cells to fluorescently 
labelled cationic PAMAM dendrimers that range from G0 – G4. Their results 
have shown that the permeability coefficient of the tested cationic PAMAM 
dendrimers increases with the increase in the concentration and incubation 
time of these polymers. The same group also reported that the transport of the 
independent paracellular marker, [14C]-Mannitol, increases in the presence of 
cationic PAMAM dendrimers. Other studies have shown that while cationic 
PAMAM dendrimers show higher apparent rates of transport across CaCo-2 
cells when compared to anionic PAMAM dendrimers of similar molecular sizes, 
the cationic species display concentration dependant toxicities to this cell line 
[161].   
Some groups suggested that an endocytic mechanism is involved in the 
transport of PAMAM dendrimers across CaCo-2 cells, evidenced by the 
observed decreased transport of these dendrimers at 4oC and in the co-
presence of endocytic inhibitors such as colchicine [162]  
Because of their delitrious and toxic effects on cell monolayers however, it was 
decided to avoid the use of cationic PAMAM dendrimers in future studies as it 
is difficult to investigate their biopharmaceutical behaviour when they exert 
these effects on biological systems. 
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2.3.5 Transport of anionic PAMAM dendrimers across MDCK I and 
MDCK II monolayers  
 
MDCK I and MDCK II cells are both derived from cocker spaniel dog kidney 
[166]. MDCK I cells have been reported to exhibit TEER values that are far 
higher (>3000Ω.cm2) than MDCK II strains (~200 Ω.cm2). While MDCK I cells 
display properties of the kidney distal tubule epithelium, MDCK II cell line 
displays properties that are associated with the proximal tubule epithelium 
[167]. MDCK I cells, which possess higher TEER are derived from earlier 
passages of cells isolated from the canine’s kidney while MDCK II cells 
domineer in earlier passages. The reason behind the discrepancy in the 
restrictiveness between the two cell lines lies behind the fact that the tight 
junctional protein Claudin-2 is expressed in MDCK II cells but not in MDCK I 
[168].  
MDCK I cells represent a very restrictive barrier with TEER values that are 
reminiscent to values observed across the blood brain barrier, while MDCK II 
cell monolayers represent a less restrictive barrier with TEER values similar to 
those reported for the epithelial barrier of the gut. The two strains show a high 
degree of similarity in most biological aspects but exhibit a significant 
difference in paracellular restrictiveness. This makes the two strains a suitable 
in-vitro platform to help in the comparisons between intestinal absorption and 
blood brain barrier penetration of a certain compound.  
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In fact, the MDCK-II cell line has been extensively used as an in-vitro model to 
predict the intestinal absorption of drugs intended for oral use [169]. 
 
In these studies, Sodium fluorescein (F-Na), a fluorescent paracellular marker, 
was used as a control to provide a quantitative indicator of paracellular 
restrictiveness in the two strains of MDCK cells.  
 
 
Figure ‎2.16 The cumulative transport of F-Na, a paracellular marker, across MDCK I and MDCK 
II monolayers. Results are Mean ± S.D., n=4.  
 
Figure  2.16 shows the transport of the paracellular marker F-Na across MDCK I 
and MDCK II monolayers. It is clear from results displayed in this figure that F-
Na displays a significantly higher permeation rate and extent across the less 
restrictive MDCK II than across the tight MDCK I. This provides quantitative 
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evidence about the discrepancy in the restrictiveness between the two cell 
lines. 
Given this quantitative evidence using a small molecular weight marker like F-
Na, the transport of PAMAMs G1.5 and G3.5 was then examined across the 
two MDCK strains to investigate the differential effect of barrier restrictiveness 
on the permeability to these polymers.  
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Figure ‎2.17 (A) Cumulative transport of PAMAM 1.5-OG.  (B)  Cumulative transport of PAMAM 
3.5-OG, all across MDCK I and MDCK II cell lines. (C)  Permeability coefficients PAMAM 
dendrimer and F-Na across MDCK I and MDCK II cell lines.   
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Table ‎2.6 Permeability Coefficients of Sodium Fluorescein (F-Na), PAMAM G1.5-OG and 
PAMAM G3.5-OG as calculated across MDCK I and MDCK II cell lines. Results are Mean 
± S.D. n number specified in the table. 
Monolayer/ 
Property 
MDCK I MDCK II 
MDCKII/ 
MDCKI 
ratio 
 
TEER Ω.cm2 
2959 ± 72 
(n=12) 
223 ± 4 
(n=12) 
0.075 
 
 
F-Na 
(Papp) x10-6 cm.s-1 
 
 
0.16 ± 0.028 
(n=4) 
 
 
0.53 ± 0.05 
(n=4) 
 
3.3 
 
PAMAM G1.5-OG 
(Papp)  x10-6 cm.s-1 
 
≤ 0.021 
Based on LOQ 
 
0.30 ± 0.06 
(n=4) 
 
> 14 
Based on 
LOQ 
 
PAMAM G3.5-OG 
(Perm. Coeff.) x10-6 cm.s-1 
 
≤ 0.02 
Based on LOQ 
 
0.057 ± 0.01 
(n=4) 
 
> 3 
Based on 
LOQ 
 
Data shown in Figure  2.17 and Table  2.6 summarise the permeation results of 
PAMAMs G1.5 and G3.5 (and F-Na for direct comparison) across MDCK I and 
MDCK II cell lines. Not surprisingly, all these compounds showed a lesser extent 
of transport across the more restrictive MDCK I cell line when compared to the 
less restrictive MDCK II strain. Further, across the MDCK II cells, the 
permeability showed a progressive decrease as the molecular weight of the 
probe increases. Such that Papp for PAMAM G3.5 is some x10 fold lower than 
that for F-Na, and some x5 fold lower than that for PAMAM G1.5. Across MDCK 
I, the transport for both PAMAMs was so low as to be below the limit of 
quantitation (LOQ) for the entirety of the 2 hour experiment. This comes 
despite the use of the very highly fluorescent dye, Oregon Green, to label the 
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anionic dendrimers. Radiolabeling of the dendrimers was attempted as 
explained later in chapter 4, but the achieved specific radioactivity for these 
dendrimers would result in limits of quantitation similar to those with the 
fluorescently labelled dendrimers.  
Because no PAMAM dendrimer could be quantified over the entirety of the 
experiment, Papp values for these PAMAM dendrimers were based upon the 
theoretical maximum according to the LOQ. In reality, it is the LOQ that sets 
the limit on the ratios and profoundly so for PAMAM G3.5 as it has a 
significantly lower rate of transport across MDCK II when compared to PAMAM 
G1.5. This means that the ratios of MDCK II : MDCK I transport of >14 : 1 for 
PAMAM G1.5 and >3:1 for G3.5 represent the minimum theoretical possible 
ratios in the transport of these dendrimers which could indeed be significantly 
higher than that.  
The maximum amount of PAMAM - OG that could have been transported was 
calculated according to the fluorescent limit of quantitation (LOQ). LOQ was 
calculated as follows:  
LOQ = BR + (10 ● STDEV of BR) ……………….. Equation 3.2 
BR symbolises the background fluorescent reading from cell culture media.  
The reason behind this discrepancy in the differential transport of F-Na and 
PAMAM 1.5-OG across MDCK I monolayers and  the less restrictive MDCK II 
monolayers can be attributed to the larger size of the G1.5 polymer.  
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It seems from results described earlier, that the increase in the molecular size 
of a certain probe has a greater impact upon decreasing the transport of this 
probe across a highly restrictive monolayer than across a less restrictive one as 
visualised in Figure  2.18. 
 
Figure ‎2.18 Hypothesised effect of molecular weight upon the permeability of a probe across 
the tight MDCK I and the less restrictive MDCK II. Graph shows that increment in molecular 
weight leads to higher difference in permeability between the two strains. Values are arbitrary. 
 
This high degree of differential transport between restrictive and leaky barriers 
that is particularly exhibited by high molecular weight compounds has been 
described before in the context of targeted delivery to tumorous tissues that 
exploits the leakiness of tumour vasculature in contrast to the restrictiveness 
of vasculature that feeds healthy tissues in what is known as the enhanced 
permeation retention (EPR) effect [170].  
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Another group has investigated the permeation of cationic (but not anionic 
dendrimers) PAMAM dendrimers across MDCK II cells (but not MDCK I) 
Tajarobi et al.[56] inspected the transport of different cationic PAMAM 
dendrimers (G0-G4) and showed that they all permeate across the MDCK II 
monolayers at different rates that didn’t correlate with the sizes of these 
dendrimers.  These results, as described earlier, can be misleading as cationic 
dendrimers affect the integrity of cell monolayers and don’t hence reflect the 
true intrinsic permeability of these dendrimers.  
 
2.3.6 Permeability Studies with Intrinsically Fluorescent Dendrimers 
in MDCK I and MDCK II cell lines.  
 
All permeation studies discussed so far were with dendrimers that have been 
labelled in house using a fluorescent dye such as Oregon Green or FITC. This is 
because dendrimers themselves are extremely difficult to be quantified as they 
do not contain any chromophores such as benzene rings where luminescent 
spectroscopy can be applied to quantify these polymers. The large size and 
high charge density makes their analysis difficult by mass spectrometry 
methods.   
Even with OG labelling, detection issues were experienced. Although this might 
have been avoided by increasing the labelling stoichiometry, this would have 
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altered the physicochemical properties of the dendrimers and their overall 
transport across biological barriers, especially for smaller dendrimers. 
To achieve dendrimers that can be more easily detected, a collaboration with 
polymer chemists was established, and novel dendrimers were developed 
comprising a fluorescent core, where it was hypothesised that with the 
fluorescent label being an integral part of the dendrimer at the core from 
which the dendrimer emanates, a better quantum yield of fluorescence can be 
achieved. 
Dendrimers with fluorescent cores are shown in Figure  2.19. Synthesis of the 
dendrimer starts from the fluorescent dye and higher generations are achieved 
by attaching successive Dendrons onto to the fluorescent core rather than 
attaching a fluorescent dye at the surface.  
Initial studies with these dendrimer however have shown that their 
fluorescence quantum yields are significantly lower than dendrimers labelled 
with Oregon green. Additionally, fluorescence of these dendrimers seems to 
decrease with the increase in generation making it more difficult to analyse 
larger dendrimers comprising the fluorescent dye as a core.  
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Figure ‎2.19 Poly(amido-amine) Dendrimers bearing a fluorescent core, (7H-
benz[de]benzimidazo[2,1-a]isoquinoline-7-one), from where amido-amine dendrons emanate.   
 
 
Figure ‎2.20 Permeability Coefficients of a group of intrinsically fluorescent poly(amido-amine) 
(G0.5, G1.5 and G2.5) across MDCK I and MDCK II monolayers.  The permeability coefficients of 
G1.5 across MDCK I and G2.5 across MDCK I and MDCK II monolayers were calculated 
according to their limits of fluorescent quantification as no dendrimer was detected at the final 
120 minute time point. Results are Mean ± S.D., n=4.  
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It has also been ensured that these novel anionic dendrimers do not 
compromise the integrity of the monolayer integrity of either MDCK I or MDCK 
II. TEER values before and after incubation with these dendrimers have been 
measured and have been shown to be unaltered as previously shown with 
other dendrimers. 
 
2.3.7 The effect of Tumour Necrosis Factor - ɑ (TNF-ɑ) on MDCK-II and 
CACO-2 restrictiveness and permeability to anionic PAMAM-OG 
dendrimers. 
 
Cytokines are cell-signalling proteins that are produced by a number of 
immune cells and play a vital role in inflammation. These include a wide variety 
of Interleukins, inteferons, and tumour necrosis factors.  
Many groups have shown that a few cytokines such as interferon-ɣ, interleukin-
1β, interleukin-12 and tumour necrosis factor-ɑ (TNF-ɑ) while playing a vital 
role as pro-inflammatory mediators, cause disruption of the intestinal barrier, 
modulation of its tight junctional properties and consequently increasing its 
overall paracellular permeability [171-173].  
Because the aim of the transport studies in this chapter is to exploit PAMAM 
dendrimers as a delivery tool for cannabinoid drugs to be used in the 
treatment of IBD which is correlated with  high blood levels of cytokines such 
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as TNF-ɑ [174], it was important to study the effect of these mediators upon 
the overall transport of dendrimers and their conjugates. Clearly, inflammatory 
mediators which are predicted to alter the permeability and pharmacokinetic 
properties of the local barrier at which they are released as described earlier, 
can serve our strategy in using dendrimer-cannabinoid conjugates in the 
treatment of inflammatory bowel disease where the conjugate can be better 
directed to the inflamed and more permeable regions of the intestinal tissue 
than the healthy restrictive regions.  
The effect of TNF-ɑ on PAMAM dendrimer permeation across CaCo-2 and 
MDCK II cells was investigated.   
Reported serum concentrations of TNF-ɑ in patients suffering from Ulcerative 
Colitis and Crohn’s disease ranged between 5 and 15 µg/mL [174]. To 
investigate the effect of pro-inflammatory cytokines on the restrictiveness of 
in-vitro cell monolayers, TNF- ɑ was used with the cell lines MDCK-II and CaCo-
2. An intermediate concentration of 10µg/mL and a lower concentration of 1 
µg/mL were used for the experiments where cells were pre-incubated with the 
pro-inflammatory cytokine for a period of 20 hours before conducting the 
studies. 
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Figure ‎2.21 The effect of 20 hour pre-incubation with TNF-ɑ at 1µg/mL and 10µg/mL on the 
cumulative transport of (A) PAMAM G3.5-OG and (B) 
14
C Mannitol(expressed as % of donor 
mass) across MDCK II cells over 90 minutes. Results are Mean± S.D.  * indicates P<0.05 when 
compared to control. Two Way Anova Analysis, Bunferroni’s post-test. 
 
 
Table ‎2.7 Effect of TNF-ɑ when applied at concentrations of 1µg/mL and 10µg/mL over 
20 hours on TEER, PAMAM G3.5 and 14C Mannitol permeation (expressed as 
permeability coefficient x 10-6 cm.s-1) across MDCK II cells grown on semi-permeable 
inserts. 
Treatment in MDCK II Control 
TNF - ɑ 
(1µg/mL) 
TNF - ɑ 
(10µg/mL) 
 
TEER (Ω.cm2) 
 
127 ± 7 259 ± 9 259 ± 23 
 
PAMAM G3.5-OG 
P.app (x10-6 cm.s-1) 
 
0.057 ± 0.007 0.021 ± 0.0029 0.022 ± 0.004 
 
[14C] Mannitol 
P.app (x10-6 cm.s-1) 
 
0.83 ± 0.1 0.44 ± 0.04 0.41 ± 0.05 
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Figure  2.21 shows the cumulative transport of PAMAM G3.5-OG and [14C] 
Mannitol across MDCK II cells in the presence and absence of TNF-ɑ. It is clear 
from the cumulative transport trend that TNF-ɑ decreases the permeability of 
MDCK II cell monolayers to both the polymer and the paracellular marker. 
Results detailed in Table  2.7  show that TNF-ɑ  increased the restrictiveness of 
the MDCK II monolayers as evident from the doubling in TEER values as 
compared to control treatments (No TNF-ɑ) and a significant decrease in the 
permeability of the monolayers to the paracellular marker [14C] Mannitol.  
The increase in the restrictiveness of these cells has also resulted in about 50% 
decrease in PAMAM G3.5-OG permeation across MDCK II monolayers when 
compared to control treatments where no TNF-ɑ was applied. The reason 
behind this result is not known, although a similar effect of TNF-ɑ has been 
previously reported with MDCK II cells where incubation of MDCK II cells with 
TNF-ɑ resulted in an increase in TEER of the monolayers [175]. Another group 
however, has showed that the incubation of MDCK cells with TNF-ɑ at similar 
concentration significantly increase [3H] Mannitol flux across MDCK 
monolayers [176].   
The effect of TNF-ɑ on CaCo-2 monolayers, however, was different. As shown 
in Figure  2.22, the incubation of fully differentiated CACO-2 monolayers with 
TNF-ɑ at concentrations of 1µg/mL and 10µg/mL did not alter the 
restrictiveness of these monolayers as clearly evidenced from TEER 
measurements.  
  CHAPTER 2 
88 
 
 
Figure ‎2.22 Effect of TNF-ɑ at concentrations of 1µg/mL and 10µg/mL on CACO-2 TEER 
(expressed as Ω.cm2). Data are Mean ± S.D., n=4. Two way anova analysis, Bunferroni’s post-test 
show no significant difference between TEER values at any time point for all treatments. 
 
  
2.3.8 Isolated Perfused Rat  gut (IPrG) 
A few groups have studied the transport of dendrimers across intact tissues. 
Florence et al. [57] studied the in-vivo translocation and uptake of a 
radiolabeled G4 poly-lysine dendrimer (MW 6,400) from the rat intestine. They 
reported that these dendrimers permeate across the rat intestine, albeit only 
to low extents, with maximum concentrations in blood at 6 hours not 
exceeding 3% of the administered dose. Wiwattanapatapee et al. [26], 
investigated the transfer and uptake of radiolabeled anionic and cationic 
PAMAM dendrimers in the everted rat gut sac. Their results showed a 
discrepancy in the transport between anionic and cationic PAMAM dendrimers 
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where the former displayed serosal transfer rates across the gut sacs that were 
higher than natural macromolecules of comparable sizes, while cationic 
PAMAM dendrimers displayed higher tissue association and lower transfer 
rates.  Morris et al. [51] studied the transport of a range of fluorescently 
labelled anionic PAMAM dendrimers (G1.5 – G5.5) across the intact rat lung. 
Their results showed that all these PAMAM dendrimers permeate across the 
rat lung in a size dependant trend with smaller dendrimers displaying highest 
rates of transport.  
 
After the success in assessing the permeability of different in-vitro barriers to 
different PAMAM dendrimers, the aim was to  assess transport across an ex-
vivo isolated perfused gut model. An ex-vivo model should more accurately 
predict the in-vivo permeability of the gut barrier to PAMAM dendrimers. An 
ex-vivo model can give a better prediction about the permeation of different 
PAMAM dendrimers across the gut as the model represents the gut barrier 
with its full architecture including unstirred water layer, mucus barrier, 
endothelium and connective tissue (unlike in-vitro intestinal models that 
generally only incorporate the epithelial barrier). Additionally, in comparison to 
the whole body pharmacokinetic oral dosing, an ex-vivo model can simplify the 
quantitation of dendrimer permeation across the gut as it isolates the 
circulation from the liver where metabolism can occur and from the whole 
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body in general. i.e. it is a direct measure of permeation from gut lumen to 
mesenteric blood vessels . 
As explained in the methods section, in the isolated perfused gut model a 
perfusate circulates  from the mesenteric artery across the mesenteric capillary 
bed and out  to the portal vein, where the perfusate is re-circulated again. To 
visualise that the perfusate is circulating across this path, trypan blue was 
mixed with the circulating perfusate. Visual observation of the distribution of 
the perfusate confirmed recirculation across the mesenteric bed as expected. A 
part of the dyed mesenteric bed is shown in Figure  2.23. Full videos of the 
process were also captured during the setup.  
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Figure ‎2.23 A part of the mesenteric bed after5 minute perfusion with buffer containing trypan 
blue (5 mg/mL) 
  
To assess the integrity of the isolated perfused gut model, the permeation of 
two different paracellular markers, Na-Fluorescein and [14C] Mannitol, and a 
transcellular marker, [3H] Propranolol, were studied. These molecules were 
added to the perfusate circulating across the mesenteric bed and transport was 
investigated over 60 minutes. It is expected that the lipophilic transcellular 
marker [3H] Propranolol would display a significantly higher permeation rate 
and extent across the gut barrier than the hydrophilic paracellular markers 
[14C] Mannitol and Na-Fluorescein. 
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Figure ‎2.24 Cumulative transport of [14C] Mannitol, F-Na and [3H] Propranolol over 60 minutes 
across the isolated perfused rat gut. 
 
Figure ‎2.23 shows the cumulative transport of the two paracellular markers, F-
Na and [14C] Mannitol and the transcellular marker [3H] Propranolol across the 
isolated perfused gut to the circulating perfusate over 1 hour. These results 
show that the gut barrier was apparently more permeable to the paracellular 
probe than the transcellular probe. Although propranolol is reported to be a 
substrate for P-glycoprotein the more likely explanation of the data is that   the 
integrity of the barrier was compromised.  Indeed the formation of intraluminal 
oedema was evident within 10 minutes of most experiments as a result of 
apparent leakage of the circulating perfusate into the intestinal lumen. This 
issue is probably a result of the absence of an efficient oxygen carrier in the 
perfusate, the perfustae used was a Krebs buffer supplemented with 4% 
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Bovine serum Albumin. Successful application of the isolated perfused gut 
previously reported utilise whole rat blood as the perfusate of choice instead of 
krebs buffer [158, 177, 178]. The erythrocytes present in the blood can aid as 
an oxygen carrier which keeps the barrier in a viable state and consequently 
intact against any fluid leakage.   
The substantially higher cost of using whole rat blood to conduct these 
experiments together with the development time that would be demanded 
meant that IPG studies were suspended as a tool for predicting the intestinal 
absorption of PAMAM dendrimers. 
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2.4 Summary 
 
Studies conducted in this chapter have resulted in the following findings: 
 OG labelling of anionic PAMAM dendrimers and FITC labelling of 
Cationic PAMAM dendrimers serves as a valuable tool to fluorescently 
analyse and quantify these dendrimers. The labels are biocompatible 
and completely stable in experimental conditions. 
 
 Anionic PAMAM dendrimers are biocompatible at a generation range 
G1.5-G5.5 and their permeation across biological barriers is highly 
dependent on their molecular size with larger anionic dendrimers 
displaying less permeation across in-vitro cell monolayers than their 
smaller counterparts.  
 
 
 Cationic PAMAM dendrimers on the other hand are not as 
biocompatible to in-vitro cell monolayers as their anionic counterparts. 
Cationic PAMAM dendrimers display toxicity and compromise the 
integrity of monolayers that increases with the increment of their 
molecular weight. Transport data generated from cationic PAMAM 
dendrimers have to be hence analysed carefully as results can be 
misleading. 
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 Anionic PAMAM dendrimers display more pronounced differential 
transport across highly restrictive and less restrictive barriers than small 
molecular weight markers such as F-Na. This was displayed through the 
high difference in the transport of PAMAM dendrimers across the tight 
MDCK I barrier and the less restrictive MDCK II; a difference that was 
more pronounced than that displayed by the small molecular weight 
marker F-Na. This supports the hypothesis that PAMAM dendrimers are 
a suitable candidate to achieve oral bioavailability across the relatively 
less restrictive intestinal mucosa while avoiding access to the CNS 
across the highly restrictive blood brain barrier. 
 
 In-vitro barriers are a poor model to use for predicting the influence of 
pro-inflammatory mediators upon the permeability of biological 
barriers. TNF-ɑ did not display an effect upon CaCo-2 monolayers while 
it surprisingly increased the restrictiveness of MDCK II monolayers. 
Another model might be more suitable to test the effect of TNF-ɑ upon 
paracellular restrictiveness. 
 
 The isolated perfused Gut was designed as a simple model to study the 
total permeability of the intestinal mucosa to dendrimers and other 
probes in isolation issues such as distribution and metabolism because 
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the circulation is isolated within the mesenteric system. This system has 
failed, probably due to issues of poor oxygen delivery to the epithelium. 
Whole blood is probably needed to be used to perfuse the system 
rather than the conventional Krebs based perfusate that has been used 
in these studies. The use of whole blood however is very expensive and 
would render the use of such a system impractical. 
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Chapter 3 
Synthesis and Pharmacological Evaluation 
of Novel Cannabinoid Derivatives 
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3.1 Introduction 
 
3.1.1 Cannabinoid Receptor Pharmacology  
The mechanism through which cannabinoids exert their effects (particularly 
psychoactive effects) was unclear until the mid-1960s. Before then the 
misconception that predominated the field of cannabinoid pharmacology was 
that these hydrophobic compounds exert their effects through nonspecific 
disruption of lipid membranes due to their highly lipophilic nature [179, 180]. It 
was later revealed however, that Δ9- tetrahydrocannabinol (THC), a natural 
cannabinoid agonist, produces its effects through a receptor mediated 
mechanism. This was  demonstrated  by  showing that  THC exerts specific 
pharmacological effects (such as the negative regulation of cAMP) in 
neuroblastoma cells, but not in other types of cells such as sperm cells [181].  
Devane et al. [64] were among the first groups to study the presence of 
cannabinoid receptors in the CNS in 1988. The presence of such receptors in 
the brain was shown through demonstrating a saturable specific binding 
process of a radiolabeled full cannabinoid agonist, [3H] CP 55490, with rat brain 
membrane preparations. The same ligand has also been used to demonstrate 
the presence of cannabinoid receptors in rat brain homogenates and whole rat 
brain sections [182, 183]. The binding of [3H] CP 55490 to receptors in rat brain 
tissue has been also shown to be competitively inhibited by other 
cannabimimetic compounds. Furthermore, the extent of specific binding of [3H] 
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CP 55490 to receptors in the rat brain tissue correlated with the cannabinoid 
agonist’s psychoactive effects in-vivo, and its ability to inhibit the release of 
adenylate cyclase in-vitro [65].  
Later on, two cannabinoid receptors were fully identified and characterised, 
CB1 and CB2, both of which are G-coupled protein receptors [62]. A third G-
coupled protein cannabinoid receptor, GPR55, has been suggested to play a 
role in the interaction with cannabinoid compounds [184]. CB1 and CB2 
receptors were first identified through molecular cloning in 1990 and 1993, 
respectively [185, 186]. Upon cloning, both of these receptors showed 44% 
identity (68% similarity in transmembrane domains) in their amino acid 
sequences [187]. 
In-vitro experiments with neuroblastoma cells and kidney COS cells 
(transfected with CB receptors) showed that both cannabinoid receptors CB1 
and CB2 are predominantly coupled to G protein subtypes Gi and G0 [188, 189]. 
This has been shown through demonstrating that their activation upon the use 
of agonists (quantified by the accumulation cAMP), could be  inhibited by 
pertussis toxin, guanosine-5’-O-(2-thiodiphosphate) and N-ethyl-maleimide 
[189], [190], [191], [192]. 
CB1 receptors have been shown to be predominantly present in the brain. 
Although highly expressed in the brain, CB1 receptors are not homogenously 
present in the CNS region. It has been shown that CB1 receptors are most 
highly expressed in the cerebral cortex and hippocampus which are responsible 
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for motor function and movement, i.e. functions that are affected by 
cannabinoid drugs [193]. Other groups showed later that the presence of CB1 
receptors is not exclusive to the brain but is also expressed at various extents 
in different parts of the periphery including intestines, urinary bladder, heart, 
lung, bone marrow, adrenal glands, testicles,  immune cells and the intestines 
[66, 105, 194-196].  
CB2 receptors on the other hand have a very low expression in the brain in 
comparison to CB1 receptors. CB2 is present at a high density in immune related 
tissues such as the tonsils, macrophages, mast cells and monocytes [105]. CB2 
receptors are additionally present in bone and cirrhotic cells of the liver (in 
cases of liver cirrhosis) [197].  
It was demonstrated that interaction between cannabinoid agonists and the G-
coupled CB1 receptors can lead to inhibition of calcium currents. Cannabinoid 
agonists (of CB1 receptors) such as WIN 55,212-2 have been shown to be highly 
potent in inhibiting calcium currents. The mixed cannabinoid agonist, WIN 
55,212-2 exhibited activity at low concentrations of 1nM and also showed high 
stereoselectivity in its action; ( The [-] enantiomer of WIN 55,212-2 showing no 
inhibition of currents up to concentrations of 1µM) [190]. This clearly indicates 
a specific ligand receptor interaction mediated effect. Additionally, other 
cannabinoids such as CP 55,940, Δ9- tetrahydrocannabinol (THC) and the 
endogenous anandamide demonstrated calcium channel inhibitory activity in 
various in-vitro cell models [191], [189], [192]. Although cannabinoid agonists 
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play an important role in the regulation of adenylate cyclase (AC), the 
inhibition of calcium currents exerted by these compounds is not mediated 
through AC (as evidenced by the fact that this calcium current inhibitory effect 
could not be reversed through the use of AMP analogues such as dibutyryl-
cyclic AMP). The inhibition of calcium currents is mediated instead through N-
type channels [190]. CB1 receptors can additionally mediate the enhancement 
of inwardly rectifying potassium channels; Mackie et al [198] showed that WIN 
55212,2 exhibits a stereoselective enhancement of these potassium channels 
in Xenopus laevis oocytes and murine tumour AtT-20 cells only when they’re 
transfected with CB1 receptors, confirming that these effects are CB1 mediated.  
CB2 receptors, on the other hand, do not couple to calcium channels or 
inwardly rectifying potassium channels and hence don’t exert any effects on 
these ion channels. Felder et al. [188] showed that intracellular calcium levels 
are inhibited by the non-selective cannabinoid agonist WIN 55,212-2 only when 
these cells are transfected with CB1 receptors but not when they’re transfected 
with CB2 receptors. Similarly, Felder’s group showed, using WIN 55,212-2 as an 
agonist, that only CB1 receptors and not CB2 receptors are involved in 
activation of inwardly rectifying potassium channels in the same cell line [188].   
Figure ‎2.1 outlines the major pharmacological pathways of CB1 and CB2 
receptors.   
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Figure ‎3.1 Activation of signal transduction pathways via Cannabinoid receptors. Cannabinoid agonists 
can activate the Gi/0 protein coupled CB1 and CB2 receptors. This results in the inhibition of adenylyl 
cyclase and the activation of the extracellular signal-regulated kinase (ERK) cascade. Additionally, CB1 
receptors can induce the inwardly rectifying potassium (K+) channels and the inhibition of calcium 
channels as previously described.  
 
Inhibition of calcium currents and activation of potassium conductance (which 
are both exclusively mediated through CB1 receptors) are both related to the 
neuronal effects exerted through cannabinoid mixed agonists. This, in addition 
to the fact that CB2 receptors are dramatically less expressed in the CNS than 
CB1 receptors strongly suggest that neuronal effects of different cannabinoid 
agonists are mediated exclusively through CB1 and not CB2 receptors. This was 
further supported with the synthesis of a number of selective CB2 agonists, 
such as HU-308 and AM1241 which didn’t show any CNS side effects when 
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administered in in mice in a tetrad of behavioural tests, unlike classical mixed 
cannabinoid agonists such as Δ9-tetrahydrocannabinol (THC) [199].  
3.1.2 Endogenous Cannabinoids  
After the identification of cannabinoid receptors, it was revealed that the brain 
produces its own endogenous cannabinoids which are capable of acting as 
agonists at CB1 receptors. The most popular of these endocannabinoids, and 
the first to be discovered, is arachidonoyl ethanolamide, more commonly 
known as Anandamide, shown in Figure ‎3.2. This endogenous cannabinoid 
discovered by Devane et al. in 1992, has demonstrated high affinity to CB1 
receptors and produced THC-like effects when interacting with these receptors 
in the brain. However, later studies showed that Anandamide, albeit being a 
very weak CB2 agonist, has a high affinity to CB2 receptors and can hence act as 
a CB2 antagonist.   
Anandamide is released from neurons and is regulated by a number of 
mechanisms. A carrier mediated Anadamide transport mechanism contributes 
to the removal of the endogenous cannabinoid from its sites of action. 
Additionally, Anandamide is metabolised intracelluarly via enzymatic hydrolysis 
(using the enzyme Anandamide amidohydrolase) [200].  
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Figure ‎3.2 Chemical structure of anandamide, an endogenous cannabinoid 
 
Subsequently, several other endocannabinoids have been discovered; these 
include 2-arachidonoylglycerol (2-AG) whose concentration is significantly 
higher than anandamide and is a more potent agonist at both CB1 and CB2 
receptors when compared to anandamide.  
 
3.1.3 Structure Activity Relationship (SAR) of Cannabinoids 
  
The first systematic study investigating the relationship between cannabinoid 
chemical structure and pharmacological activity dates back to 1942 and 
involved a dog ataxia test as the biological model to assess the pharmacological 
end point of different cannabinoid drugs [201].   
SAR studies of cannabinoid drugs were initially based on the natural 
cannabinoid THC (shown in Figure  3.3, B) which is the prototype for a classical 
cannabinoid (Figure  3.3, A). SAR investigations on THC utilised a number of 
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different biological models where the psychoactive and locomotor effects of 
the cannabinoid agonist are assessed. These models included the dog ataxia 
test, the mouse ring immobility test, monkey behavioural tests, and 
behavioural studies in humans [202]. SAR studies reveal the following key 
properties in the structure of THC as upon clinically testing a variety of 
cannabinoid compounds in human behavioural tests [203]: 
 
 
Figure ‎3.3 General Structure of a classic cannabinoid (A) and  Δ9-Tetrahydrocannabinol (THC)    (B) 
 
1- The benzopyran ring system (A and B rings as shown in Figure  3.3, A) is 
essential for pharmacological activity, although benzopyran doesn’t 
confer activity by its own virtue.  
2- The attachment of an aliphatic cycle (i.e. ring C) to the benzopyran ring 
is essential, for activity. However, this aliphatic cycle can be spatially 
separated from the B ring through a methyl spacer as in BRL-4664 
(Nonabine). Additionally, replacing the alicyclic ring with a heterocyclic 
one doesn’t seem to alter activity.  
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3- The methyl group at position 9 is redundant for pharmacological activity 
and can be replaced with a number of substituents such as hydroxyl, 
hydroxymethyl, or a ketone group without any loss in activity.  
4- Although the phenolic alcohol at position 1 is of vital importance in the 
cannabinoid’s activity, it can be substituted with an ester group without 
any loss in activity. Elimination of this group usually leads to complete 
abolishment of activity or, as in the case of JWH-133 which is a classical 
cannabinoid that lacks this phenolic alcohol (Figure ‎3.4), elimination of 
this group can lead to CB2 selectivity. 
 
Figure ‎3.4 Structure of JWH-133: a classical CB2 selective cannabinoid  
 
5- A carbon chain at position 3 (R) is pivotal for activity, but can vary in 
length and structure.  Decreasing the chain length to less than 3 
carbons, however, diminishes pharmacological activity. The structure of 
the chain nevertheless can have an effect on the differential effect of 
the cannabinoids on CB1 and CB2 receptors. The alkyl chain can be 
attached directly to the benzene ring or through an ethereal linkage 
without loss or alteration in activity.  
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6- The stereochemistry of the classical cannabinoid is of key importance. It 
has been shown that most stereoisomers of classical cannabinoids are 
inactive. It has been shown that some of the inactive stereo-isomers of 
a number cannabinoids can still bind the cannabinoid receptors without 
mediating any pharmacological activity and can hence be used as 
competitive antagonists at the cannabinoid receptors [204].  
Since its discovery and characterisation more than 40 years ago, immense 
chemical research has been taking place to improve the potency and selectivity 
of THC through creating a number of its derivatives and analogues which are 
generally much more diverse than the natural product. Among these, are 3-
arylcyclohexanols such as CP-55 940, and aryl alkyl indoles (AAIs) such as the 
prototype cannabinoid WIN 55212,2 which has been extensively used as a 
cannabinoid drug in many areas of research. The structure of WIN 55,212-2 is 
shown in Figure  2.5. Although it might appear that it doesn’t share any 
commonalities with the natural product THC at a first glance, It has been 
postulated that the two structures share three major overlapping regions 
[205]: 
1- The naphthyl ring in WIN 55,212-2 and the cyclohexene in THC 
2- The carbonyl region in WIN 55,212-2 and the phenolic alcohol in THC 
3- The morpholine unit in WIN 55,212-2 and the alkyl chain at position 3 in 
THC. 
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WIN 55,212-2 has been shown to have a 30-fold higher affinity to the CB1 
receptor and >100 fold higher affinity to the CB2 receptor as compared to the 
natural compound THC [205]. 
 
Figure  3.5 Structure of WIN 55,212-2 
 
Aung et al. working the lab of JW Huffman [206] attempted to further elucidate 
the SAR of WIN 55212,2 through the synthesis of a number of cannabimimetic 
indoles in which the morpholine units of WIN 55,212-2 are replaced with alkyl 
hydrophobic chains of different lengths, as shown in Figure ‎3.6. 
 
Figure ‎3.6 The general structure of a cannabimimetic aryl alkyl indole  
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The same group showed that the length of the alkyl chain is vital for affinity to 
both CB1 and CB2 receptors. Similarly to THC, reducing the length of the N-1 
alkyl chain in these cannabimimetic indoles (which putatively overlaps the alkyl 
chain on position 3 in THC) completely abolishes affinity to both cannabinoid 
receptors. A 3-carbon long chain (propyl) is minimal for any binding to either 
CB1 or CB2. Increasing the chain length beyond that to Butyl, pentyl and hexyl 
carbon chains increases affinity to both cannabinoid receptors, while increasing 
the length beyond 6 carbons abolishes affinity to both receptors. The length of 
this chain seems to play a role in the selectivity of the cannabinoid to either of 
the two CB receptors; using a propyl chain, for instance, as in JWH-015 
(Figure ‎3.7, B) seems to shift affinity to the CB2 receptor (CB2/CB1 affinity = 6) 
in contrast to the pentyl chain in JWH007 (Figure ‎3.7, A) which has virtually 
identical affinity to both CB1 and CB2 receptors (CB2/CB1 affinity = 1.1). 
 
Figure ‎3.7 Two amino alkyl indole cannabinoids: (A) JWH007, a nonselective CB agonist with a 
pentyl chain at position 1. (B) JWH015, significantly CB2 selective cannabinoid with a propyl 
chain at position 1. 
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The carbonyl group has also been shown to be vital for activity of these 
cannabimimetic indoles, where eliminating it using LiAlH4 completely abolishes 
activity. It hasn’t been shown however if replacing the carbonyl region with 
other oxygen containing groups (such as esters and ethers)  would alter affinity 
as it has been shown that despite the vitality of the phenolic alcohol in THC 
(which putatively overlaps the carbonyl region in WIN 55,212-2), it can be 
substituted with an ester without any loss of activity.  
The group also showed that attaching a methyl group at position 2 (as in the 
case with WIN 55,212-2), doesn’t alter the affinity of the cannabinoid to its 
receptors.  
The naphthoyl ring on the other hand is vital for activity. The addition of 
different groups to the ring significantly alters activity, and the addition of 
longer chains significantly attenuates CB1 and CB2 affinities.  
The effect of adding different groups to the indolic benzene group (positions 4, 
5, 6 and 7) has not been investigated so far.  
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3.1.4 Assessment of anti-inflammatory activity of Cannabinoid 
compounds 
 
The first evidence of the involvement of cannabinoids in anti-inflammatory 
activity stems back to the mid-1980s when it was shown that THC can supress 
the production of pro-inflammatory cytokines IFN-ɑ and IFN-β in murine spleen 
cells following exposure to LPS stress in-vitro and in-vivo with mice infected 
with the herpes simplex virus [207, 208]. Additionally, other cannabinoids such 
as WIN 55,212-2 and the THC derivative, HU-210, have been shown to play a 
role in supressing the release of cytokines TNF-ɑ and interleukin-12 (IL-12) in 
mice injected with LPS [209]. Klein et al. [210] have additionally shown that 
cannabinoid agonists THC and II-hydro-THC exhibit an immune-modulatory 
function through the suppression of the cytolytic activity of Natural Killer (NK) 
cells.  
This effect of cannabinoid agonists is a property of the CB2 receptor which is 
responsible for suppressing the release of cytokines and inflammatory 
mediators from immune cells. A few groups showed that CB2 receptors are 
expressed in monocytes, macrophages and B and T immune cells [105, 106]. It 
has also been shown the CB2 receptors are expressed in the murine 
macrophage cell line RAW 264.7 [211]. Additionally, Hunter et al. [212] showed 
that challenging RAW 246.7 cells with CB2 antisense significantly decreased the 
THC induced release of arachidonic acid indicating the functionality of these 
receptors in this cell line. Furthermore, several groups demonstrated the 
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functionality of CB2 receptors in RAW 264.7 with decreases in LPS-regulated 
release of nitric oxide from this cell line upon the use of THC as a cannabinoid 
agonist [213, 214] . Gallily et al. [215] also demonstrated that the CB2 selective 
THC derivative HU-211 supresses LPS-regulated production of TNF-ɑ by the 
same murine macrophage cell line.  
The ability of cannabinoids to suppress the release of different pro-
inflammatory cytokines can be exploited as a tool for the rapid in-vitro 
screening of the anti-inflammatory activity of different cannabinoid 
compounds. This is further facilitated by the development of reliable and quick 
methods for high sensitivity Enzyme linked Immunosorbent assays (ELISA) in 
the quantification of a range of different cytokines.   
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3.1.5 Aims, Objectives and Overall Strategy 
The aim of studies described in this chapter was to assess SAR of 
cannabimimetic indoles, as a potent class of cannabinoid compounds that has 
been extensively used in the literature, and to investigate possible sites at 
which chemical modifications can be implemented while maintaining the 
cannabinoid’s pharmacological activity. This involves the identification of sites 
that are not vital for pharmacological activity and studying the effect of 
modifying them upon the overall pharmacological activity of the cannabinoid. 
This is done in the ultimate goal of conjugating a cannabinoid to a PAMAM 
dendrimer in later studies (discussed in Chapter 4). An amine group has to be 
present in a compound to facilitate its conjugation to an anionic PAMAM 
dendrimer (containing amine-reactive carboxylic groups on its surface), and 
therefore one of the aims in this chapter was the synthesis of a 
pharmacologically active cannabinoid that bares a primary amine in its 
structure.  
To investigate SAR of cannabibimetic indoles in this chapter, a number of 
chemical modifications on prototypical cannabinoids such as WIN 55,212-2 
were attempted. Additionally, a number of novel cannabibimetic indoles with 
were synthesised in-house and their pharmacological activity investigated to 
assess the importance of different sites of cannabibimemtic indoles on their 
pharmacological activity. The overall strategy for all the modifications that 
were attempted and achieved is outlined in Schematic ‎3.1. 
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Schematic ‎3.1 Outlined Strategy for SAR studies in cannabinoid compounds 
 
Strategy 2 
Attaching a spacer or amine via 
position 5’ of the indole ring 
Benzophenone used as a 
cheap chemical model 
Method 4 is applied on prototype 
cannabibemtic indole WIN 55,212-2  
FAIL: Carbonyl 
on WIN 
55,212-2 was 
not reduced 
into a primary 
amine 
5’ 
Different modifications were applied on position 5’ as 
part of the cannabinoid’s synthesis to form new 
cannabinoids. The effect of these modifications upon 
pharmacological activity was tested 
JWH007 was synthesised in 
house as a chemical model 
that is also pharmacologically 
active. 
Name 
Strategy 1 
Introducing a spacer or an  
amine via the carbonyl group 
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3.2 Material and Methods 
 
3.2.1 Materials 
 
Organic Solvents Dichloromethane, Ethanol, Methanol, Cyclohexane, Ethyl 
acetate, Toluene, Dimethyl formamide (DMF), Dimethyl sulfoxide (DMSO) were 
purchased from Fisher Scientific (UK). LPS (Escherichia coli 0111:B4), and all 
other used chemicals used in organic reactions were from Sigma-Aldrich inc., 
unless otherwise stated. 
Murine macrophage cell line RAW 264.7 was obtained from the European 
Tissue Culture Collection ECACC (London, UK). DMEM, Penicillin/streptomycin, 
and foetal bovine serum were obtained from Invitrogen (UK).  
TNF-ɑ analysis was performed using an ELISA kit from R&D systems, UK.  
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3.2.2 Methods 
Chemical Reactions 
Chemical reactions were generally performed in glass round bottom flasks 
(100mL size) and magnetic stirring. Primary analyses were performed using 
thin layer chromatography on silica plates using Cyclohexane-Ethylacetate 
solvent systems. Desired compounds were then purified using silica flash 
chromatography.  
NMR analyses were performed using a 500Mhz NMR. ESI+ Mass spectrometry 
analyses were performed using a Quatro-ultima Mass spectrometer as a 
service supplied by the Chemistry Department, Cardiff University.   
Cell Culture 
RAW 264.7 cells were cultured using Dulbeco’s Modified Eagle medium 
(DEMEM) supplemented with 10% (v/v) heat inactivated FBS and 2% penicillin 
G/Streptomycin (100U/mL). Cell cultures were maintained at 37oC in 5% CO2/ 
95% atmospheric air and relative humidity. While cells were grown in T-25 and 
T-75 culture flasks, they were routinely cultured to 70-80% confluence. RAW 
264.7 cells were seeded at a density of 50,000 cells/cm2 on 24-well culture 
plates for 5-6 days prior to inducing TNF-ɑ release using LPS.  
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LPS induced TNF-a   production by RAW 264.7 cells 
Cells were cultured on 24 well plates for 5-6 days in DMEM full media 
supplemented with antibiotics. Before executing LPS-induced TNF-ɑ 
suppression experiments, cells were treated with different concentrations of 
various cannabinoid drugs (10µM-25µM in DMEM full media) and 0.1% DMSO 
as a control treatment as all the used cannabinoid drugs described in this 
chapter were prepared as 100x stock solutions in DMSO to be used in cell 
culture studies. After 1 hour of the treatment, cells were challenged with LPS, 
which was added as a 10µL saline solution to each well to create a final 
concentration of 200ng/mL in each of these wells. The cells were then 
incubated for 16 hours at 37oC. The media was collected and centrifuged for 10 
minutes at 200g and the supernatants were collected for TNF-ɑ analysis.  
 
ELISA based TNF-a analysis 
TNF-ɑ levels in supernatants obtained from RAW 264.7 cells after LPS induced 
TNF-ɑ production were analysed using a mouse TNF-ɑ sandwich ELISA kit. 
Briefly, 96 well plates were coated overnight with TNF-ɑ antibody at room 
temperature. Supernatants in all experiments were diluted 1:3 to achieve a 
TNF-ɑ concentration that lies within the concentration capacity of the method 
for detection (30-2000pg/mL) and were then added along with supplied TNF-ɑ 
standards to the antibody pre-coated plates. The conjugate antibody was 
added to all wells after thorough washing and this was followed by the addition 
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of Streptavidin HRP and the addition of substrate solution (1:1 mixture 
peroxide : chromogen solutions). 2.5M aqueous sulphuric acid solution was 
added to all wells to stop the experiment. The plate was then analysed using 
UV-visible spectroscopy at a wavelength of 450nm. TNF-ɑ was quantified 
according to a 7-point calibration curve that ranges between 0-2000pg/mL that 
is generated in each ELISA experiment. Statistical analysis to assess the 
performance of a certain cannabinoid drug was performed by comparing the 
quantity of TNF-ɑ released by RAW 264.7 cells when treated with this drug, and 
when they are subject to the control treatment (0.1% DMSO, or the final 
concentration of the solvent to use the drug). 
 
Toxicity Studies 
After collecting supernatant media in RAW 264.7 TNF-ɑ studies, 0.5mL of fresh 
full DMEM media was added directly to the each of the wells in the 24-well 
culture plate. 50µL of a 5mg/mL PBS solution of Thiazolyl Blue Tetrazolium 
Bromide (MTT) were added to each well. The culture plate was then incubated 
for 4 hours at 37oC, 5% CO2 and relative humidity. The media containing the 
MTT was then aspirated and discarded and 400µL of DMSO were added to 
every well to resuspend the MTT metabolic product (formazan) which indicates 
cell viability. 200µL of DMSO containing formazan were transferred from each 
well to a separate well in a 96 well plate. Optical density was then measured on 
a UV plate reader at a wavelength of 560nm.  
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3.3 Results and Discussion 
 
WIN 55,212-2 is cannabibimimmetic indole that has been established as a 
prototype cannabinoid extensively used in the cannabinoid literature since its 
development two decades ago [216]. The understanding of its SAR has been 
well established with both CB1 and CB2 receptors. It is also commercially 
available albeit expensive. It was hence decided to further investigate its SAR 
to identify sites where modifications can be attempted without loss in 
pharmacological activity, and where amines can be introduced in the ultimate 
aim of conjugating the cannabinoid to a dendrimer.  
WIN 55,212-2 like other cannabinoids doesn’t comprise many reactive 
functional groups where it can be chemically manipulated or modified to study 
the effect of such modifications upon SAR. The carbonyl group that connects 
the naphthalene group to the indole part of the compound (shown in 
Figure ‎3.8) however, can be reactive, and it was hence chosen as an initial 
target for a chemical modification. 
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Figure ‎3.8 Structure of WIN 55,212-2 showing carbonyl group 
Although it is speculated that this oxygen plays an important role in the 
interaction with CB receptors and contributes to hydrogen bonding at these 
sites [205], as it is correlated with the phenolic oxygen in THC which plays the 
same role, manipulating it doesn’t necessarily abolish activity. As previously 
discussed, conversion of the phenolic alcohol in THC, for instance, into an ester 
doesn’t affect the natural cannabinoid’s pharmacological activity, and hence 
modifications that maintain a polar group that achieves hydrogen bonding to 
the receptor can result in pharmacologically active compounds. Additionally, 
conversion of this oxygen atom into an amine (through reductive amination for 
instance) shouldn’t necessarily abolish pharmacological activity because 
nitrogen, like oxygen can also contribute to hydrogen bonding. 
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3.3.1 Choice of a model for WIN 55,212-2  
WIN 55,212-2 is a commercially available drug. However, its extremely 
expensive price (like most other commercially available cannabinoid 
compounds) has necessitated the use of a model compound to perform 
chemical experiments which require high quantities of any compound. The use 
of such quantities of the expensive WIN 55,212-2 for chemical reactions is not 
financially feasible. 
A useful chemical model compound should comprise the functional groups 
needed to be modified on the cannabinoid drug, contain similar structure to 
the drug and be relatively cheap in large quantities to allow multiple 
experimentations using different methods.  
As the target in WIN 55,212-2 was to modify the carbonyl group present on the 
junction between the indolic and naphthoylic groups, a model that comprises 
the same group connected to similar conjugated structures was needed. 
Figure  3.9 shows Benzophenone, a cheap compound comprising a carbonyl 
group between two conjugated systems (benzene rings).  The carbonyl group 
on benzophenone is expected to have similar properties to that present in the 
WIN 55,212-2.  
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Figure ‎3.9 Benzophenone, chosen as model to manipulate carbonyl group on cannabinoidal 
drug. 
 
Different chemical strategies can be tested on the cheap benzophenone, and 
successful ones can be optimised and applied on WIN 55,212-2 to save on 
costs. 
 
Table  3.1 shows different attempts the different attempts used to manipulate 
the carbonyl group on benzophenone either by attaching an amine-containing 
spacer or transforming the entire group into an amine by reductive amination. 
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Table ‎3.1 Strategies used to manipulate carbonyl group and introduce an 
amine in benzophenone 
STRATEGY FOR ADDING THE 
SPACER OR ALTERING THE 
CARBONYL GROUP 
OUTCOME 
Structure of expected 
product 
(1) Conjugation to ethylene 
diamine via an imine linkage 
FAIL 
 
(2a) Simple reduction using 
Sodium borohydride 
Success (>85% 
yield) 
 
(2b) Addition of tert-Butyl 5-
bromopentylcarbamate to (2) via 
williamson synthesis 
FAIL 
 
(3) Reductive amination using 
sodium cyanoborohydride 
FAIL 
 
(4) Reductive amination using 
Titanium isopropoxide, ammonia 
and sodium borohydride  . 
Success (>60% 
yield) 
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Strategy 1 
A primary amine can be attached to a compound comprising a ketone via the 
formation of an imine bond where the nitrogen in the amine compound 
replaces the oxygen in the ketone [217]. 
 
  Schematic ‎3.2 Failed reaction of benzophenone and ethylene diamine to produce (1) 
 
Ethylenediamine (EDA) was reacted with benzophenone in methanol in an 
attempt to produce an imine linkage between EDA and benzophenone as 
shown in Schematic  3.2. Activated molecular sieves were used to quench the 
generated water from the reaction, as imines are highly sensitive to water. If 
the reaction was successful, the imine bond can be later reduced to a stable 
amine using a previously described method of hydrogenation [218]. 
The reaction did not work as evidenced from TLC analysis using the amine 
reactive dye ninhydrin to visualise the spots. It is unknown why this reaction 
hasn’t worked. One explanation can be the high stability of the ketone’s 
electrons as the ketone attached to two strong electron withdrawing groups 
(benzene rings).  
(1) 
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Note: All reactions are detailed in Appendix A at the end of this chapter.  
Strategy 2a 
In this strategy, the ketone was attempted to be reduced into the 
corresponding alcohol using a reducing agent, so  a halide containing spacer 
can be later attached to the formed alcohol using williamson ether synthesis. A 
ketone group can be simply reduced into an alcohol by using the reducing 
agent sodium borohydride [219]. 
 
Schematic ‎3.3 reduction of the carbonyl group in benzophenone to the corresponding alcohol to 
produce (2) 
 
Reduction of benzophenone to diphenyl methanol using sodim borohydride as 
shown in Schematic  3.3 was successful as evident from TLC and NMR analyses. 
The use of another stronger reducing agent, LiAlH4, was also successful in 
reducing the carbonyl to achieving the same end product.  
 
 
 
 
(2) 
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Strategy 2b  
A compound baring a halide can be attached via an ether linkage to an alcohol 
group using Williamson ether synthesis which has been extensively used in 
organic syntheses [219]. 
 
Schematic ‎3.4 Failed attempt to attach tert-Butyl 5-bromopropylcarbamate to diphenyl 
methanol via Williamson ether synthesis 
 
Addition of a halide containing spacer baring a BOC protected amine on its 
terminus to diphenyl methanol using Williamson ether synthesis as shown in 
Schematic ‎3.4 was unsuccessful. The failure of this reaction might be due to the 
high electron withdrawing power of the conjugated rings making the electron 
on the nucleophilic alkoxide (formed by the addition of sodium hydride [NaH]) 
less prone to attack the electron deficient spacer.   
 
 
 
 
(3) 
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Strategy 3 
Sodium Cyanoborohydride (NaBH3CN) has been used in the literature as an 
agent in the reductive amination of aldehydes and ketones in the presence of 
ammonia [220]. 
 
 
Schematic ‎3.5 Reductive amination of benzophenone using Sodium cyanoborohydride and 
ammonia 
 
 The reducing agent sodium cyanoborohydride was used to convert the 
carbonyl group present on benzophenone into a primary amine using ammonia 
as a source of nitrogen atoms as shown in Schematic ‎3.5.  
The reaction however has failed as evidenced from TLC analysis. The reason of 
why this reaction hasn’t worked is not known, although it might be due to the 
same reason suggested for the failure of previous reactions and that is the high 
electron stability on the oxygen atom that stems from the strong electron 
withdrawing effect exerted by the benzene rings. 
 
 
(4) 
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Strategy 4 
A method previously described by Sukanta et al. [221] which employs the use 
of titanium isopropoxide and sodium borohydride in the reductive amination of 
various compounds, including benzophenone itself, was used to achieve 
reductive amination in this strategy.   
 
Schematic 3.6 Reductive amination of benzophenone with ammonia using titanium 
isopropoxide and sodium borohydride. 
 
Unlike reductive amination using sodium cyanoborohydride, reductive 
amination using Titanium isopropoxide and sodium borohydride was successful 
in converting the carbonyl group into an amine as evident from TLC and 1H 
NMR analysis. 
The results from these 4 strategies with benzophenone show that the only 
applicable strategy to alter the carbonyl moiety and introduce an amine to it 
would be the reductive amination using Titanium isopropoxide and sodium 
borohydride. Other strategies to attach an amine through the use of an imine 
linkage or through reducing the carbonyl into an alcohol and then attaching a 
spacer via Williamson ether synthesis weren’t successful, most possibly due to 
the strong electron withdrawing effect exerted by the two benzene rings; the 
(4) 
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same electron withdrawing effect upon the carbonyl’s electrons is also 
expected with WIN 55,212-2. It was hence decided to apply the successful 
reductive amination strategy of benzophenone  to WIN 55,212,2 and convert 
its carbonyl group into a primary amine. This would allow investigating the 
effect of altering the carbonyl group in WIN 55,212-2 upon its pharmacological 
activity and to assess if it is feasible to attach a PAMAM dendrimer through this 
site. 
 
3.3.2 Reductive Amination with WIN 55,212-2  
The successful reductive amination strategy with benzophenone was identically 
applied to WIN 55,212-2 to convert its carbonyl into an amine (both groups 
circled in Schematic 3.6) to generate a cannabinoid that can be attached to the 
anionic PAMAM dendrimer. 
 
Schematic ‎3.7 Reductive amination of WIN 55,212-2 using Titanium isopropoxide and sodium 
borohydride. 
 
(5) 
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The reductive amination with WIN 55,212-2 using the Titanium isopropoxide 
strategy, however, hasn’t worked as obvious from TLC and ESI+ Mass 
Spectroscopic analysis.  
The reason of why the reductive amination strategy has worked with 
benzophenone but not with WIN 55,212-2 can be attributed the high stability 
of the carbonyl group in WIN 55,212-2 when compared to the one on 
benzophenone. Although the chosen model (benzophenone) contained two 
strong withdrawing groups as in the cannabinoid, WIN 55,212-2 contains an 
amine on a distance that might play role in further stabilisation the carbonyl 
group via electron delocalisation as shown in Schematic ‎3.8. The conjugation 
with the indole amine means that the carnbonyl acts as a vinylogous amide. 
 
Schematic ‎3.8 The oxygen’s electrons are more delocalised in WIN 55212,2 than in 
benzophenone. This might be due to the conjugated indolic amine which further delocalises 
electrons. 
 
To further prove this hypothesis, the reduction of the carbonyl group in WIN 
55,212-2 with the reducing agent sodium borohydride was attempted as 
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previously described with benzophenone. Sodium borohydride failed to reduce 
the carbonyl as evidenced from TLC and ESI+ mass spectroscopic analysis which 
both showed that the carbonyl hasn’t been reduced to the corresponding 
alcohol.  
The high stability of this oxygen makes it increasingly difficult to alter the 
structure of WIN 55,212-2 and to introduce the amine group which is vital for 
conjugation with a carboxylic PAMAM dendrimer. Additionally, the previous 
results have shown that the benzophenone model might fail in predicting the 
reactivity of the carbonyl group in WIN 55,212-2.   
It has hence been decided that a more appropriate indole based model should 
be synthesised for further experimentation with conjugation strategies with 
cannabinoids.  
3.3.3 Synthesis of a new cannabinoid model 
 
The model of choice to be synthesised was a previously developed amino-alkyl 
indole by the group of Huffman et al. [205], JWH 007. This compound (seen as 
the end product in Schematic ‎3.9) is a biologically tested cannabinoid that has 
been shown to interact with both CB1 and CB2 receptors. The synthesis of this 
model cannabinoid can be performed through a cheap and efficient two-step 
process, previously described by Huffman et al. [205] as shown in 
Schematic ‎3.9. The final product was characterised using 1H, 13C NMR and ESI+ 
Spectroscopy. 
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Schematic ‎3.9 Synthesis of JWH-007: an amino alkyl indole cannabinoid.
 
 
JWH-007 has been successfully synthesised starting from 2-methyl indole. All 
the components used in the reactions leading to its synthesis were relatively 
cheap and highly available in bulk quantities. This facilitates the synthesis of 
large quantities of such a model and consequently offers an avenue for further 
experimentations at a low cost.  
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3.3.4 Structural Similarities between JWH007 and WIN 55,212-2 
 
 
 
Figure ‎3.10 Structures of WIN 55,212-2 and JWH007. Moieties contributing to cannabinoid 
pharmacological activity marked in circles. 
 
As seen in Figure ‎3.10, JWH007 shares the major moieties contributing to 
cannabinoid based pharmacological activity. Both compounds contain a 
naphthalene ring which, as discussed before in the introduction to this chapter, 
is vital for activity. Similarly, both compounds contain the carbonyl group which 
should have identical chemical properties. 
The major difference between the two compounds is that the two morphonline 
rings in WIN 55,212-2 are replaced in JWH007 by a simpler alkyl chain 
(compare regions labelled (A) in Figure ‎3.10). The length of this alkyl chain in 
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JWH007 however, is equivalent to the length created by the two morpholine 
rings as shown in the figure above.    
 
3.3.5 Biological Evaluation of JWH007 and WIN 55,212-2 
JWH007 is an active cannabinoid itself, so it is possible to use it as a model 
cannabimimetic indole instead of WIN 55,212-2 if a comparable 
pharmacological activity was demonstrated. 
To assess the pharmacological activity of JWH007, WIN 55,212-2, and indeed 
any other synthesised cannabinoid derivatives, an efficient biological model 
would be needed to achieve quick evaluation of these compounds’ activity. The 
model of choice to assess cannabinoid activity of these compounds was the 
murine macrophage cell line RAW 264.7. These cells have been shown to 
express functional CB2 receptors that regulate the production of nitric oxide 
and TNF-ɑ under stress [211-215]. An efficient method to assess the 
pharmacological activity of different cannabinoids was to test their ability to 
supress the release of the pro-inflammatory cytokine TNF-ɑ from these cells 
when they’re challenged with the endotoxin Lipopolysaccharides (LPS). This 
method provides a quick and cheap tool to predict the biological activities of 
these cannabinoid compounds. 
To assess the activity of JWH007 and WIN 55,212-2, both compounds’ activities 
were evaluated through their ability to supress the LPS induced production of 
TNF-ɑ.  
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Figure  3.11 shows the effect of these compounds upon the suppression of LPS 
(200ng/mL) induced TNF-ɑ production from the murine macrophage cell line. 
At a concentration of 10µM, both compounds exhibited a significant 
suppression in TNF-ɑ release when compared to the vehicle control (0.1% 
DMSO+200ng LPS). 
 
 
Figure ‎3.11 The effect of synthesised JWH007 and WIN 55212,2 (10µM)  to suppress LPS 
induced (200ng/mL for 16 hours)  production of TNF-ɑ in the murine macrophage cell line, RAW 
264.7. Results are mean ± S.D, n=4. * indicates P<0.05 
 
JWH007 showed comparable biological activity to WIN 55,212-2 in suppressing 
the production of TNF-ɑ. These results indicate that JWH007 can serve as a 
good prototype cannabinoid on which different chemical manipulation 
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strategies can be applied and then rapidly screened for biological activity using 
the macrophage model.  
 
3.3.6 Synthesis of Novel Cannabimimetic indoles   
 
 
Schematic ‎3.10 A classical aminoalkyl indole 
 
The ability to synthesise a classical amino-alkyl indole (like JWH007 for 
instance) from basic chemical components gives more flexibility in tailoring the 
compound to specific needs as different building blocks or functional groups 
can be incorporated to the cannabinoid in different sites during the synthesis 
process. 
The moieties marked in circles in Schematic ‎3.10 are crucial for 
pharmacological activity of a classical amino-alkyl indole [216]. Manipulation of 
any of these moieties should be carefully considered before being applied. For 
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instance, previous data in the literature shows that adding different functional 
groups to the naphthalene ring can have significant effects on pharmacological 
activity and the addition of longer carbon chains leads to complete 
abolishment of activity [205]. Similarly, the length of the alkyl chain that 
protrudes from the indole amine (R in Schematic ‎3.10) is vital for activity, with 
shorter or longer chains leading to significant decrease in CB1 and CB2 
interaction [206]. It was hence decided to avoid any manipulation with these 
groups and explore other avenues that hven’t already been shown to be crucial 
for pharmacological activity. Exploiting the carbonyl group would still be a valid 
pathway to be explored. The high stability of this group in an indole system, 
however, has made it extremely difficult to manipulate as it was previously 
shown.  
It has been decided to explore a new site on the cannabimimetic indole that 
hasn’t been investigated before, and that is position 5’ (shown in 
Schematic  3.10). It is clearly very difficult to modify this site in an intact 
cannabibimimetic indole as it is not reactive. Various changes can be applied 
on this position however as a part of its synthesis of the cannabinoid.  
The following sections show the various alterations that were applied to 
position 5’ in a series novel cannabinoids that have been synthesised in-house.  
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3.3.6.1 Synthesis and Pharmacological Evaluation of GA001 
 
To investigate the influence of position 5’ in the classical amino-alkyl indole on 
cannabinoid activity, a simple methyl group was incorporated to this position 
during the synthesis of the new compound. This was simply achieved by 
replacing the indole which was used as the primary building block in the 
synthesis of JWH007 (2-methyl-1H-indole) with another indole containing a 
methyl group at position 5’ (2,5-dimethyl-1H-indole). The synthesis of the new 
compound was then carried on using the previous strategy used to synthesise 
JWH007 as shown in Schematic  3.11. 
   
 
Schematic ‎3.11 Synthesis of GA001 
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The synthesis was successful as confirmed by 1H NMR analysis with similar 
yields to JWH007. The resulting new compound was labelled GA001.  
The pharmacological activity of GA001 was tested using the RAW 264.7 
macrophage cell model used previously to assess pharmacological activity of 
JWH007 and WIN 55,212-2. JWH007 was used as a positive control in the 
assessment of the activity of GA001. Both GA001 and JWH007 were used in a 
range of 6.25µM and 25µM.  
 
Figure ‎3.12 The effect of GA001 and JWH007 (6.25µM - 25µM) in suppressing LPS induced 
(200ng/mL for 16 hours) production of TNF-ɑ in the murine macrophage cell line, RAW 264.7. 
Results are mean ± S.D, n=4. * indicates P<0.05 
 
  CHAPTER 3 
140 
 
The results shown in Figure ‎3.12 clearly demonstrate that GA001 has similar 
pharmacological activity in supressing the LPS induced release of TNF-ɑ in the 
murine cell line RAW 264.7.  
This result suggests that altering position 5’ in an amino-alkyl indole doesn’t 
necessarily alter its activity or reduce it, as GA001 comprising the methyl group 
on position 5’ exhibited similar dose-response relationship to the positive 
control used, JWH007.   
 
3.3.6.2 Synthesis and Pharmacological Evaluation of GA002 
 
After confirming that the addition of a functional group to position 5 in an 
amino-alkyl indole doesn’t necessarily abolish or alter pharmacological activity, 
the effect of adding a bulky group at the same position was investigated. This 
was investigated to predict the effect of attaching the cannabinoid directly to a 
dendrimer which in itself is a chemically bulky entity. A simple method was 
exploited to attach such a bulky group as it is far more complicated to directly 
attach an anionic dendrimer to the cannabinoid.  
Two pentyl alkyl chains were attached to position 5’ through a nitrogen atom 
starting from (2-methyl-1H-indol-5-amine) as the initial indole bloc as shown in 
Schematic ‎3.12.  
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Schematic ‎3.12 Synthesis to GA002 
 
 
GA002 was successfully synthesised as evidenced from NMR analysis. The final 
yields however were significantly lower than yields in the synthesis of JWH007 
and GA001. Lower yields were noticed at both steps of the synthesis of the 
final product.  This is probably due to the bulky nature of the compound where 
steric hindrance can play a role in restricting the reaction process.  
The pharmacological activity of GA002 was assessed using the RAW 264.7 
model and JWH007 used as a positive control.  
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Figure ‎3.13 The effect of GA002 and JWH007 (6.25µM - 25µM) in suppresing LPS induced 
(200ng/mL for 16 hours) production of TNF-ɑ in the murine macrophage cell line, RAW 264.7. 
Results are mean ± S.D, n=4. * indicates P<0.05 (ONE-WAY ANOVA, Dunnett’s post-test). 
 
As Figure ‎3.13 shows, GA002 was inactive and failed to suppress the release of 
LPS induced TNF-ɑ release from RAW 264.7 even at the highest concentration 
used, 25µM, in contrast to JWH007 and GA001 which were both active at 
12.5µM and 25µM. 
The reason of why GA002 was inactive in contrast to GA001 can be attributed 
to the bulkiness of the group which is too close to the cannabinoid drug 
preventing it from moving freely and binding to the receptor. If this was the 
reason of the complete loss in activity with GA002, then this would strongly 
suggest that conjugating a dendrimer directly to an amino-alkyl indole without 
a spacer is likely to completely abolish the cannabinoid’s activity. Attaching an 
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anionic PAMAM dendrimer to the cannabinoid through a long spacer however, 
might have a different effect as this gives the cannabinoid compound more 
flexibility in aligning itself for ideal binding to its receptors.  
Another reason behind the complete loss in activity upon attaching two alkyl 
chains on position 5’ would be the increase in the lipophilicity of the final 
compound that contains two additional hydrophobic chains.  
 
3.3.6.3 Synthesis and Pharmacological Evaluation of GA003 
 
An amino alkyl-indole with a linear alkyl spacer was to be synthesised in order 
to investigate the effect of a less bulky moiety such as a linear spacer upon 
pharmacological activity. This can further elucidate whether the bulkiness at 
position 5’ was the reason behind the loss in activity in GA002. 
A simple alkyl spacer was attached at position 5’ through an ethereal linkage as 
part of the synthesis of the final compound starting from (2-methyl-1H-indol-5-
yl)methanol as shown Schematic  3.13. 
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Schematic ‎3.13 Synthesis of GA003 
 
The synthesis of GA003 was successful as evidenced from 1H NMR analysis. 
However, yields were significantly lower than those achieved during the 
synthesis of JWH007 and GA001.  
The pharmacological activity of GA003 was assessed, and JWH007 was used as 
the positive control.  
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Figure ‎3.14 The effect of GA002 and JWH007 (6.25µM - 25µM) in suppressing LPS induced 
(200ng/mL for 16 hours) production of TNF-ɑ in the murine macrophage cell line, RAW 264.7. 
Results are mean ± S.D, n=4. * indicates P<0.05 (ONE-WAY ANOVA, Dunnett’s post-test). 
  
Results in Figure ‎3.14 show that GA003 which comprises an alkyl chain linked 
via an ethereal bond at position 5’ of the amino-alkyl indole, is significantly less 
active than JWH007 which doesn’t possess this chain. GA003, however, has 
shown significant LPS induced TNF-ɑ suppression activity at the higher 
concentration of 25µM albeit less than that exhibited by JWH007.  
GA003 with a single alkyl chain attached to position 5’ is less bulky than GA002 
which possesses two alkyl chains emanating from the same position. This can 
explain why GA003 was more active at higher concentrations than GA002. 
However, GA003 with a hydrophobic chain at position 5’ is still significantly 
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more lipophilic than JWH007. This can be the reason behind the reduced 
pharmacological activity that was displayed by GA003.  
 
3.3.6.4 Attempts in Synthesising GA004 
 
 
Schematic ‎3.14 Attempts used to synthesise GA004 
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After showing that GA003 which comprises a linear spacer attached via an 
ethereal linkage at position 5’, a spacer with a functional terminus that can be 
linked to an anionic PAMAM dendrimer was to be attached to the same 
position using a similar ethereal linkage. The chosen spacer was tert-Butyl 3-
bromopropylcarbamate which is a propyl chain comprising a protected amine 
on its terminus which can be deprotected at a later stage and reacted with the 
carboxylic PAMAM dendrimer.  
Two strategies were attempted to attach this spacer. As shown in 
Schematic  3.14, strategy 1 incorporates the napthoyl ring to the indole prior to 
attaching the spacer, while in strategy 2, the spacer is incorporated before 
attaching the naphthoyl ring. Both strategies exploit the carboxylate group as a 
protecting group which allows attaching the alkyl chain to the indole nitrogen 
while avoiding side reactions. The carboxylate group can be later reduced using 
Lithium Aluminium Hydride (LiAlH4). 
In strategy 1, attaching the spacer through the alcohol group at position 5’ 
using Williamson ether synthesis was not successful. This was obvious through 
TLC analysis where streaks appeared on the TLC plates indicating that the 
compound has been broken down upon attaching the spacer using Sodium 
Hydride (NaH). Attaching the spacer was successful in strategy 2 as obvious 
from NMR analysis. Attaching the naphthoyl ring at the last step, however, was 
not successful as evidenced from TLC analysis.  
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The reason behind the failure in attaching the spacer in strategy 1 might be due 
to the harsh conditions created by the strong base NaH. These conditions could 
have caused the breakdown of the reactant compound. Attaching the spacer 
using NaH, however, was successful in strategy 2 where it is added at an earlier 
stage (before attachment of the naphthoyl ring). Attaching the naphtoyl ring in 
strategy 2 using the Ethyl Aluminium Chloride catalysed Friedel-Craft acylation, 
however has failed, most likely due to the highly acidic nature of the catalyst 
used in this reaction which causes the breakdown of the Boc protection group, 
which in turn exposes the reactive amine and leads to various side reactions.  
The synthesis of an amino-alkyl indole comprising a spacer attached via an 
ethereal linkage has hence failed using two different strategies and was 
temporarily abandoned.  
3.3.6.5 Synthesis and Pharmacological Evaluation of GA005 and 
GA006 
 
Another strategy was chosen to attach a spacer with a functional terminus that 
can be attached to an anionic PAMAM dendrimer.  
GA005 was synthesised as a cannabimimetic indole that contains a nitro group 
on position 5’. This was achieved by beginning the synthesis of the amino alkyl 
indole from 5-nitro-1H-indole as shown in Schematic 3.15.  
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Schematic 3.15 Synthesis of GA005 
 
The synthesis of an amino alkyl indole that comprises a nitro group at position 
5’ can be helpful as this nitro group can be reduced to the corresponding amine 
which in turn can be incorporated into a functional spacer.  GA005 can hence 
serve as a stable cannabinoid template that can be flexibly altered at position 
5’ upon reducing the nitro group to the reactive amine.  
The pharmacological activity of GA005 was studied using the RAW 264.7 
macrophage cell line and JWH007 as a positive control.  
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Figure ‎3.15 The effect of GA005 and JWH007 (12.5µM - 25µM) in suppressing LPS induced 
(200ng/mL for 16 hours) production of TNF-ɑ in the murine macrophage cell line, RAW 264.7. 
Results are mean ± S.D, n=4. * indicates P<0.05 (ONE-WAY ANOVA, Dunnett’s post-test). 
 
Results presented in Figure  3.15 clearly exhibit the complete loss in 
pharmacological activity of GA005 which comprises the nitro electron 
withdrawing group at position 5’. This comes in contrast with the electron 
donating groups that were attached to the same position such as the methyl 
group which didn’t abolish the pharmacological activity.   
The next step was to reduce the nitro group to the corresponding amine group 
and attach a functional spacer comprising an amine at its terminus that can be 
attached to an anionic PAMAM dendrimer.  
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The first step in attaching a spacer at position 5’ of GA005 was to reduce the 
nitro group to the corresponding amine group at the same position. An amine 
reactive spacer can then be attached to the amine.  
Reducing the nitro group into a primary amine was achieved through 
employing Hydrazine hydrate and Raney Nickel as a catalyst as previously 
described by Balcom et al. [222].  
This was followed by the addition a 6-carbon long spacer baring a Boc-
protected amine on one of its termini and a highly amine reactive succinimidyl 
ester group on the other. The succinimidyl ester would still react with the 
amine group at position 5’ even though its attached to an indole ring (whose 
strong withdrawing group is expected to decrease the amine’s reactivity); 
Pirrung et al. [223] reported 95% yield in a reaction between the same 
succinimidyl ester spacer used in this experiment and an indole compound 
comprising an amine at a similar position. This bocylated amine can be 
deprotected at a later stage and attached to an anionic dendrimer.  
Schematic ‎3.16 shows the synthesis of GA006 starting from GA005 through the 
steps described steps.   
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Schematic ‎3.16 Synthesis of GA006 
 
 
The synthesis of GA006 was successful as evident from NMR analysis and ESI+ 
mass spectrometry.  
Pharmacological activity of GA006 was tested using the macrophage RAW 
264.7 model.  
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Figure ‎3.16 The effect of GA006 and JWH007 (12.5µM – 25µM) in suppressing LPS induced 
(200ng/mL for 16 hours) production of TNF-ɑ in the murine macrophage cell line, RAW 264.7. 
Results are mean ± S.D, n=4. * indicates P<0.05 (ONE-WAY ANOVA, Dunnett’s post-test). 
 
Results in Figure  3.16 show that GA006 which comprises a 12nm long spacer 
with a protected amine terminus is pharmacologically active. Moreover, 
attaching this spacer has not compromised the activity of the amino-alkyl 
indole.   
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3.3.7 Toxicity Studies 
All synthesised compounds that displayed a significant inhibitory effect upon 
the release of TNF-ɑ by LPS-challenged RAW 264.7 cells were subsequently 
tested for their biocompatibility with the macrophage cell line. These tests 
were performed to ensure that the observed decrements in TNF-ɑ production 
are not associated with decreased cell viability, but rather through a 
pharmacological pathway that is mediated by the used cannabinoids.  
The MTT+ assay was used as a tool to assess the viability of cells after the end 
of the experiment. Such a test offers a better assessment of cell viability than 
cell counting as it is more selective for viable cells. Additionally, it offers a 
faster method to determine the viability of the cells with every treatment.  
The effect of LPS and the vehicle used for all treatments (0.1% DMSO) upon cell 
viability were first assessed as shown in Figure ‎3.17. This was performed to 
ensure that all other treatments apart from the cannabinoid drug have no 
impact upon cell viability when the experiments are performed. Results 
indicate that LPS at the concentrations used in these experiments to induce 
TNF-a release, i.e. 200ng/mL LPS, and the final concentrations of DMSO in the 
media systems containing the cannabinoid drug, i.e. 0.1%, have no impact 
upon cell viability over 16 hours (Time course of all reported experiments).  
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Figure ‎3.17 Effect of 0.1% DMSO (The solvent concentration used to prepare all cannabinoid 
treatments on cells) and 200ng/mL LPS over 16 hours (The treatment used to induce TFN-a 
release in all experiments) upon the  viability of RAW 264.7 macrophage cell line as assessed 
using the MTT+ assay. Results are mean ± S.D, n=4. All treatments resulted in no significant effect 
upon RAW 264.7 viability (ONE-WAY ANOVA, Dunnett’s post-test). 
 
Toxicity studies were performed to assess the viability of RAW 264.7 cells 
treated with JWH007, A cannabinoid drug that was synthesised in house as a 
cheap alternative for WIN 55,212-2 and which displayed anti-inflammatory 
properties in RAW 264.7 that are similar, if not superior, to those displayed by 
the prototype cannabinoid WIN 55,212-2. Results show that JWH007 does not 
compromise RAW 264.7 cell viability in concentrations as high as 25µM. WIN 
55,212-2 on the other hand displayed significant toxic effects upon the 
macrophage cell line (52% decrease in cell viability) as shown in Figure ‎2.20.   
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Figure ‎3.18 Effect of the in-house synthesised cannabinoid JWH007 and the prototype amino-
indole alkyl cannabinoid WIN 55,212-2 upon the viability of RAW 264.7 macrophage cell line as 
assessed using the MTT+ assay. Results are mean ± S.D, n=4. * indicates P<0.05 (significant toxic 
effect), (ONE-WAY ANOVA, Dunnett’s post-test). 
 
These results show that the model cannabinoid that was synthesised, JWH007, 
is significantly more biocompatible than its expensive counterpart, WIN 
55,212-2 which makes it a more appealing cannabinoid to be used in further 
studies and applications than WIN 55,212-2.  
Similarly to JWH007, all the synthesised novel cannabinoids did not 
compromise the viability of the murine macrophage cell line RAW 264.7, at the 
used concentrations (12.5µM - 25µM). Figure ‎3.19 shows the toxicity profiles 
of all the novel synthesised cannabinoids that displayed an anti-inflammatory 
effect in the in-vitro system.  
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Figure ‎3.19 Effect of novel synthesised cannabinoids GA001, GA003 and GA006 upon the 
viability of RAW 264.7 macrophage cell line as assessed using the MTT+ assay. Results are 
mean ± S.D, n=4. All these cannabinoids resulted in no significant effect upon RAW 264.7 viability (ONE-
WAY ANOVA, Dunnett’s post-test). 
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Appendix A : Chemical Syntheses 
 
N1-(diphenylmethylene)ethane-1,2-diamine (1) 
Benzophenone (1.05g, 5.8mmol) was dissolved in methanol (20mL). Ethylene 
diamine (1.15mL, 17.3mmol) was added as one portion to the mixture. The 
reaction was allowed to stir over night at 60oC. Upon checking the reaction 
progress on TLC, it was obvious that benzophenone hasn’t reacted with 
ethylenediamine (no new spots formed on the plate).  
 
diphenylmethanol (2) 
Benzophenone (1.00g, 5.5mmol) was dissolved in methanol (20mL). Sodium 
borohydride (1.25g, 33.0 mmol) was added to the methanolic solution. The 
reaction was allowed to stir for 3 hours. Methanol was evaporated in vacuo 
and the product was extracted via solvent extraction with 3 portions of ethyl 
acetate against water. The product was then purified using flash 
chromatography (cyclohexane: ethyl acetate 8.5:1.5). The resulting oil, 
diphenyl methanol was obtained in a yield of 86%.  
1H NMR (500MHz, Methanol-d4) δ 7.52 (3H, t), 7.33-7.27 (3H, m), 7.17-7.11 
(2H, m), 5.89 (1H, d), 5.73 (1H, d) 
 
tert-Butyl 3-(benzhydryloxy)propylcarbamate (3) 
Diphneylmethanol (1.10g, 6.1mmol) was dissolved in DMF (10mL). NaH powder 
was added in small portions while stirring on ice until bubbling stopped. The 
mixture was allowed to stir for a further 30 minutes at room temperature. tert-
Butyl 3-bromopropylcarbamate hydrochloride (3.3g, 12.2mmol) was added in 
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one portion to the mixture. The reaction was allowed to stir for 16 hours. TLC 
analysis showed that the reaction has failed as no new spots were formed on 
the plate as compared to spots taken before the initiation of the reaction.  
Diphenylmethanamine (4) 
Method (1)  
Potassium hydroxide (1.12g, 20mmol) was added and left to dissolve in a 
solution of 2M ammonia in methanol (20mL). Benzophenone (1.05g, 5.8mmol) 
was added in one portion to the mixture after all the potassium hydroxide has 
dissolved. Sodium cyanoborohydride (0.25g, 0.16mmol) was added in one 
portion to the stirring solution. The stirring was continued for 30 minutes and 
Potassium hydroxide (4.48g, 80mmol) was added to the stirring solution. After 
45 minutes the mixture was filtered, and methanol was evaporated in vacuo. 
Solvent extraction was performed. The reaction has failed as evident by TLC as 
no new spots appeared on the plate. 
 
Method (2) 
Benzophenone (1.05g, 5.8mmol) was dissolved in 2M ammonia solution in 
ethanol (20mL) in a nitrogen purged flask. Titanium isopropoxide (3.5mL, 
11.4mmol) was added to the solution using a glass syringe. The mixture was 
allowed to stir under nitrogen for 6 hours. Sodium borohydride (1.25g, 33.0 
mmol) dissolved in dry ethanol was added to the mixture via a glass syringe. 
The mixture was allowed to stir for 2 hours. 5mL of ammonium hydroxide was 
added to quench the solution. The solution was diluted with 20mL of water. 
Solvent extraction was performed against ethyl acetate. The aminated product 
was then extracted and purified using acid/base extraction. 
1H NMR (500MHz, Methanol-d4) δ 7.51-7.42 (10H, m), 5.76 (1H, s), 5.62 (1H, s) 
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JWH007 
Step (1) 
2-Methyl-1H-indole (1.1g, 8.4mmol) were dissolved in dry DMF (15mL) Sodium 
hydride (NaH) was added in small portions until the solution stopped bubbling. 
1-bromopentane (2.5g, 16.8mmol) was added in one portion and the flask was 
immersed in ice for 30 minutes while the solution was stirring. After 16 hours, 
the reaction was quenched by the addition of 15 mL of distilled H2O, and 
extracted with three portions of ethyl acetate. The organic phase was 
evaporated in vacuo and the residue was purified using flash chromatography; 
Cyclohexane : Ethylacetate (8 : 2) giving 91% yield of 2-methyl-1-pentyl-1H-
indole. 
1H NMR (500MHz, DMSO-d6) δ 7.43 (1H, d), 7.33 (1H, d), 7.06 (1H, t), 6.99 (1H, 
t), 6.22 (1H, s), 4.07-4.03 (2H, m), 2.44 (3H, s), 1.66-1.60 (2H, m), 1.46-1.41 (4H, 
m), 0.88-0.82 (3H, m) 
Step (2)  
2-Methyl-1-pentyl-1H-indole (0.85g, 4.2mmol) was dissolved in dry toluene 
(15mL). 1-naphtoyl chloride (0.96g, 5mmol) was added to the mixture. The 
mixture was stirred on ice. Ethylaluminium dichloride, supplied as a 25 wt. % 
solution in toluene, (2.8mL, 5mmol) was added to the solution. The reaction 
was allowed to proceed for 4 days. The reaction was then quenched with 20mL 
of distilled H2O and the product was extracted with three portions of ethyl 
acetate. The organic phase was evaporated in vacuo and the product was 
purified using flash chromatography; Cyclohexane : Ethyl acetate (8:2) giving 
36% yield of JWH007. 
1H NMR (500MHz, DMSO-d6) δ 8.03 (1H, d), 7.86 (1H, d), 7.79 (1H, d), 7.40 (1H, 
d), 7.38 (2H, t), 7.36 (1H, t) , 7.33 (1H, d), 7.20 (2H, t), 6.88 (1H, t), 3.97 (2H, t), 
2.35 (3H, s), 1.65 (2H, s), 1.24-1.21 (4H, m), 0.91-0.78 (3H, m) 
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m/z = 356.2000 [m+H]+ 
 
GA001 
 Step (1) 
2,5-Dimethyl-1H-indole (1.2g, 8.3mmol) was dissolved in dry DMF (15mL) 
Sodium hydride (NaH) was added in small portions until the solution stopped 
bubbling. 1-Bromopentane (2.5g, 16.6mmol) was added in one portion and the 
flask was immersed in ice for 30 minutes while the solution was stirring. After 
16 hours, the reaction was quenched by the addition of 15 mL of distilled H2O, 
and extracted with three portions of ethyl acetate. The organic phase was 
evaporated in vacuo and the residue was purified using flash chromatography; 
Cyclohexane : Ethylacetate (8 : 2) giving 88% yield of 2,5-dimethyl-1-pentyl-1H-
indole. 
1H NMR (500MHz, DMSO-d6) δ 7.39 (1H, s), 7.27 (1H, d) 7.02 (1H, d), 6.23 (1H, 
s), 4.07 (2H, t), 2.51- 2.46 (5H, m), 1.87-1.82 (1H, m), 1.41 (4H, s), 1.00 (3H, t) 
Step (2)  
2,5-Dimethyl-1-pentyl-1H-indole (0.9g, 4.2mmol) was dissolved in dry toluene 
(15mL). 1-Naphtoyl chloride (0.96g, 5mmol) was added to the mixture. The 
mixture was stirred on ice. Ethylaluminium dichloride, supplied as a 25 wt. % 
solution in toluene, (2.8mL, 5mmol) was added to the solution. The reaction 
was allowed to proceed for 4 days. The reaction was then quenched with 20mL 
of distilled H2O and the product was extracted with three portions of ethyl 
acetate. The organic phase was evaporated in vacuo and the product was 
purified using flash chromatography; Cyclohexane : Ethylacetate (7:3) giving 
36% yield of GA001. 
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1H NMR (500MHz, DMSO-d6) δ 8.17 (1H, d), 8.03 (1H, d), 7.96 (1H, d), 7.61 (1H, 
d), 7.50 (2H, t), 7.46 (1H, t), 7.22 (2H, t), 7.10 (1H, d), 4.11 (3H, t), 2.39 (3H, s), 
2.36 (3H, s), 1.75 (1H, s), 1.36 (4H, s), 0.98 (3H, t) 
 
GA002 
 Step (1) 
2-Methyl-1H-indol-5-amine (1.1g, 7.5mmol) were dissolved in dry DMF (15mL) 
Sodium hydride (NaH) was added in small portions until the solution stopped 
bubbling. 1-Bromopentane (4.6g, 30.1mmol) was added in one portion and the 
flask was immersed in ice for 30 minutes while the solution was stirring. After 
16 hours, the reaction was quenched by the addition of 15 mL of distilled H2O, 
and extracted with three portions of ethyl acetate. The organic phase was 
evaporated in vacuo and the residue was purified using flash chromatography; 
Cyclohexane : Ethylacetate (9 : 1) giving 36% yield of 2-methyl-N,N,1-tripentyl-
1H-indol-5-amine. 
1H NMR (500MHz, DMSO-d6) δ 7.14 (1H, d), 6.91 (1H, s), 6.76 (1H, s) 6.12 (1H, 
s), 4.09-4.02 (4H, m), 3.25-3.20 (6H, m), 2.48 (2H, s), 2.2 (2H, s), 1.71- 1.62 (2H, 
m), 1.53- 1.68 (6H, m), 1.48 (3H, s), 1.41 – 1.39 (9H, m)0.99-0.81 (6H, m). 
Step (2)  
2-Methyl-N,N,1-tripentyl-1H-indol-5-amine (0.27g, 0.76mmol) was dissolved in 
dry Toluene (10mL). 1-Naphtoyl chloride (0.19g, 1mmol) was added to the 
mixture. The mixture was stirred on ice. Ethylaluminium dichloride, supplied as 
a 25 wt. % solution in toluene, (0.56mL, 1mmol) was added to the solution. The 
reaction was allowed to proceed for 4 days. The reaction was then quenched 
with 10mL of distilled H2O and the product was extracted with three portions 
of ethyl acetate. The organic phase was evaporated in vacuo and the product 
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was purified using flash chromatography; Cyclohexane : Ethylacetate (8:2) 
giving 12% yield of GA002. 
1H NMR (500MHz, CDCl3) δ 8.10 (1H, d), 7.96 (1H, d), 7.91 (1H, d), 7.57 (1H, d), 
7.51 (2H, t), 7.49 (1H, t), 7.12 (2H, d), 6.61 (1H, d), 6.14  (1H, s), 4.1-4.01 (2H, 
m), 3.95-2.88 (4H, m), 2.61 (3H, s), 2.19 (6H, s), 1.85- 1.74 (2H, m), 1.47- 1.39 
(3H, m), 1.29-1.20 (6H, s), 1.12 – 1.04 (3H, m), 0.99-0.91 (3H, m), 0.90-0.84 (3H, 
m). 
13C NMR (75.5MHz, CDCl3) δ 12.7, 13.9, 22.9, 14.1, 22.4, 22.6, 26.9, 29.2, 29.32, 
29.4, 29.7, 43.3, 51.8, 103.8, 109.8, 110.07,114.0, 125.1, 125.2, 125.8, 126.1, 
126.7, 128.1, 129.0, 129.3, 130.3, 133.8, 141.3, 144.7, 145.4 
 
GA003 
 Step (1) 
(2-Methyl-1H-indol-5-yl)methanol (1.4g, 8.7mmol) was dissolved in dry DMF 
(15mL). Sodium hydride (NaH) was added in small portions until the solution 
stopped bubbling. 1-bromopentane (4.5g, 30.1mmol) was added in one portion 
and the flask was immersed in ice for 30 minutes while the solution was 
stirring. After 16 hours, the reaction was quenched by the addition of 15 mL of 
distilled H2O, and extracted with three portions of ethyl acetate. The organic 
phase was evaporated in vacuo and the residue was purified using flash 
chromatography; Cyclohexane : Ethylacetate (8 : 2) giving 32% yield of 2-
methyl-1-pentyl-5-(pentyloxymethyl)-1H-indole 
1H NMR (500MHz, DMSO-d6) δ 7.82 (1H, s), 7.33 (1H, d) 7.23 (1H, d), 6.48 (1H, 
s), 1.91-1.82H (6H, t), 1.45-1.28 (9H, m), 0.98-0.91 (6H, t) 
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Step (2)  
2-Methyl-N,N,1-tripentyl-1H-indol-5-amine (0.3g, 1mmol) was dissolved in dry 
toluene (10mL). 1-Naphtoyl chloride (0.24g, 1.25mmol) was added to the 
mixture. The mixture was stirred on ice. Ethylaluminium dichloride, supplied as 
a 25 wt. % solution in toluene, (0.56mL, 1mmol) was added to the solution. The 
reaction was allowed to proceed for 4 days. The reaction was then quenched 
with 10mL of distilled H2O and the product was extracted with three portions 
of ethyl acetate. The organic phase was evaporated in vacuo and the product 
was purified using flash chromatography; Cyclohexane : Ethylacetate (8:2) 
giving 16% yield of GA003. 
1H NMR (500MHz, DMSO-d6) δ 8.23 (1H, d), 8.00 (1H, d), 7.94 (1H, d), 7.67 (1H, 
d), 7.55 (1H, t), 7.48 (1H, t), 7.32-7.28 (2H, m), 7.20 (1H, d), 7.12 (1H, t), 4.12 
(1H, s), 4.08-4.02 (2H, m), 3.75 (2H, q), 2.32 (3H, s), 1.84-1.75 (2H, m), 1.38-
1.22 (12H, m), 0.92-0.81 (3H, m). 
 
GA004 
Step (1) 
Methyl 2-methyl-1H-indole-5-carboxylate (2.0g, 10.6mmol) was dissolved in dry 
DMF (20mL). Sodium hydride (NaH) was added in small portions until the 
solution stopped bubbling. 1-Bromopentane (3.02g, 20.0mmol) was added in 
one portion and the flask was immersed in ice for 30 minutes while the 
solution was stirring. After 16 hours, the reaction was quenched by the 
addition of 20 mL of distilled H2O, and extracted with three portions of ethyl 
acetate. The organic phase was evaporated in vacuo and the residue was 
purified using flash chromatography; Cyclohexane : Ethylacetate (7 : 3) giving 
76% yield of methyl-1-pentyl-1H-indole-5-carboxylate.  
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1H NMR (500MHz, DMSO-d6) δ 7.37 (1H, s), 7.29 (1H, s), 7.21 (1H, d), 7.04 (1H, 
d), 6.21 (1H, s), 4.08-4.00 (2H, m), 2.51–2.40 (3H, m), 1.82-1.71 (2H, 2), 1.45-
1.31 (4H, m), 0.99-0.90 (3H, m) 
 
 
Step (2)  
Methyl 1-pentyl-1H-indole-5-carboxylate (0.96g, 3.9mmol) was dissolved in 10 
mL of anhydrous ether (Solution A). In a separate flask, LiAlH4 (0.61g, 
15.6mmol) was dissolved in 10mL of anhydrous ether (Solution B), the flask 
was immersed in ice. Solution A was added drop wise to Solution B using a 
drop funnel over 30 minutes. The ice was removed, and the reaction was 
allowed to proceed at room temperature for 2 hours. The reaction was 
quenched by the drop-wise addition of ice-cold water until effervescence has 
halted. 10% Aqueous sulphuric acid solution (20mL) was added to the mixture 
afterwards. The organic phase was collected and washed 3 times with water. 
The residue was purified using flash chromatography; Cyclohexane: 
Ethylacetate (6.5 : 3.5) giving 97% yield of (1-pentyl-1H-indol-5-yl)methanol. 
1H NMR (500MHz, DMSO-d6) δ 8.47 (1H, s), 7.95 (1H, d), 7.35 (1H, d), 7.15 (1H, 
s), 6.62 (1H, s), 4.48 (1H, t), 4.19-4.10 (1H, m), 3.95 (1H, s), 1.89-1.78 (3H, m), 
1.40-1.22 (4H, m), 0.92-0.82 (3H, m). 
Step (3) 
(1-Pentyl-1H-indol-5-yl)methanol (0.81g, 3.7mmol) was dissolved in dry 
toluene (10mL). 1-Naphtoyl chloride (1.1g, 5.6mmol) was added to the mixture. 
The mixture was stirred on ice. Ethylaluminium dichloride, supplied as a 25 wt. 
% solution in toluene, (3.1mL, 5.6mmol) was added to the solution. The 
reaction was allowed to proceed for 4 days. The reaction was then quenched 
with 10mL of distilled H2O and the product was extracted with three portions 
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of ethyl acetate. The organic phase was evaporated in vacuo and the product 
was purified using flash chromatography; Cyclohexane : Ethylacetate (8:2) 
giving 37% yield of (5-(hydroxymethyl)-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone. 
1H NMR (500MHz, DMSO-d6) δ 8.21 (1H, d), 8.00 (1h, d), 7.93 (1H, d), 7.59 (1H, 
d), 7.50 (1H, t), 7.45 (1H, t), 7.22 (1H, t), 7.04 (1H, d), 4.07 (2H, t), 2.38 (3H, s), 
2.30 (1H, s), 1.82-1.72 (2H, m), 1.42 (2H, s), 1.35 (3H, s), 0.96-0.82 (3H, m). 
 
Step (4) 
(5-(Hydroxymethyl)-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (0.31g, 
0.84mmol), was dissolved in dry DMF (20mL). Sodium hydride (NaH) was added 
in small portions until the solution stopped bubbling. tert-Butyl 3-
bromopropylcarbamate (0.40, 1.7mmol) was added as a 2mL solution in DMF 
in one portion and the flask was immersed in ice for 30 minutes while the 
solution was stirring. After 16 hours, the reaction was quenched by the 
addition of 20 mL of distilled H2O, and extracted with three portions of ethyl 
acetate. The organic phase was evaporated in vacuo. The residue showed 
multiple streaks upon TLC analysis and no final product could be extracted.  
 
GA005 
 Step (1) 
5-Nitro-1H-indole (2g, 12.3mmol) was dissolved in dry DMF (15mL). Sodium 
Hydride (NaH) was added in small portions until the solution stopped bubbling. 
1-Bromopentane (3.7g, 24.6mmol) was added in one portion and the flask was 
immersed in ice for 30 minutes while the solution was stirring. After 16 hours, 
the reaction was quenched by the addition of 15 mL of distilled H2O, and 
extracted with three portions of ethyl acetate. The organic phase was 
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evaporated in vacuo and the residue was purified using flash chromatography; 
Cyclohexane : Ethylacetate (8 : 2) giving 71% yield of 5-nitro-1-pentyl-1H-indole 
 
1H NMR (500MHz, DMSO-d6) δ9.13 (1H, s), 8.72 (1H, d) 8.62 (1H, d), 6.14 (1H, 
s), 4.63 (2H, t), 2.45- 2.32 (5H, m), 1.88-1.82 (1H, m), 1.31 (3H, t) 
Step (2)  
5-Nitro-1-pentyl-1H-indole (0.3g, 1mmol) was dissolved in dry toluene (10mL). 
1-Naphtoyl chloride (0.24g, 1.25mmol) was added to the mixture. The mixture 
was stirred on ice. Ethylaluminium dichloride, supplied as a 25 wt. % solution in 
toluene, (0.56mL, 1mmol) was added to the solution. The reaction was allowed 
to proceed for 4 days. The reaction was then quenched with 10mL of distilled 
H2O and the product was extracted with three portions of ethyl acetate. The 
organic phase was evaporated in vacuo and the product was purified using 
flash chromatography; Cyclohexane : Ethylacetate (7.5:2.5) giving 67% yield of 
GA005. 
1H NMR (500MHz, DMSO-d6) δ 9.21 (1H, s), 8.22 (1H, d), 8.15 (1H, d), 8.10 (1H, 
d), 7.90 (2H, t), 7.77 (1H, t), 7.59 (2H, t), 7.55 (1H, d), 5.78 (1H, s) , 4.29 (2H, t), 
2.48 (1H, s), 1.80-1.61 (2H, m), 1.39-1.12 (4H, m), 0.85-0.74 (2H, m). 
13C NMR (75.5MHz,DMSO-d6) δ 13.7, 21.55, 28.1, 29.11, 46.6, 111.9, 116.2, 
117.3, 118.0, 124.9, 125.7, 126.9, 127.5, 128.3, 129.8, 130.3, 132.9, 133.4, 
137.4, 139.8, 142.6, 190.9 
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GA006 
Step (1) 
GA005 (0.1g, 0.26mmol), was dissolved in 5 mL of THF. Hydrazine hydrate 
(130µL, 2.5mmol) was added. Raney® Nickel suspension in H2O (0.5mL) was 
added to the stirring solution. The reaction was allowed to stir for 2 hours. The 
contents were filtered to separate the nickel from the contents, and the 
solution was dried in vacuum. The product was purified using flash 
chromatography; Cyclohexane : Ethyl acetate (6 : 4) giving 89% yield of (5-
amino-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (GA005a). 
 
 
Step (2)  
GA005a (0.07g, 0.20 mmol) was dissolved in 5 mL anhydrous DMSO. 100µL of 
dry N,N  diisopropylethylamine (DIPEA) was added. 2,5-Dioxopyrrolidin-1-yl 6-
(tert-butoxycarbonylamino)hexanoate (0.13g, 0.39mmol) was added to the 
stirring solution. The solution was stirred at 65o for 2 days. The reaction was 
quenched by the addition of 5 mL of water and extracted with three portions of 
ethyl acetate. The organic phase was evaporated in vacuo and the residue was 
purified using flash chromatography; Cyclohexane : Ethylacetate (7 : 3) giving 
92% yield of tert-Butyl 5-(3-(1-naphthoyl)-1-pentyl-1H-indol-5-ylamino)-5-
oxopentylcarbamate (GA006).  
1H NMR (500MHz, DMSO-d6) δ 8.37 (1H, s), 8.24 (1H, s), 8.16 (1H, d), 8.02 (1H, 
s), 7.87 (1H, d), 7.51 (1H, s), 7.44 (1H, t), 7.34 (1H,t) 7.25 (1H, t), 7.12 (1H, t), 
7.02 (1H, s), 4.26 (2H, t), 3.45 (9H, s) 3.11 (1H, s), 2.51 (1H, s), 2.09 (2H, m), 1.81 
(3H, t), 1.57 (1H, t), 1.52 (3H, m), 1.51-1.43 (4H, m), 0.96 (3H, d). 
 m/z 556.43 [m + H]+ 
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Chapter 4 
Dendrimer Conjugates 
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4.1 Introduction 
 
4.1.1 Dendrimers as Drug Carriers 
It has been suggested that the compact structure of the dendrimer would 
make it a superior drug carrier to conventional linear polymers such as PEG, 
because its compact structure would not wrap around therapeutic molecules 
and mask their active sites [224].  
Drugs can be associated with dendrimers in various ways:  
 
1- They can be simply encapsulated in a dendrimer’s cavity. As discussed 
previously in Chapter 1, this comes as a result of the dendrimer’s 
architectures whereby drugs can be encapsulated within the 
dendrimer’s interior through hydrophobic interactions [17] or hydrogen 
bonding with abundant nitrogen and oxygen atoms [225].  
2-  Drugs can be electrostatically attached to the surface of a dendrimer 
through the high density of surface functional groups on the polymer. 
Several laboratories have attached weakly acidic compounds such as 
anti-inflammatory and anti-bacterial drugs to cationic dendrimer 
surfaces [53, 226, 227]. 
Note: For the purpose of this thesis, the term dendrimer complexation will be 
used to describe non-covalent drug-dendrimer entities. For covalent linkages 
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formed between drug and dendrimer, the term dendrimer conjugate will be 
applied.  
3- Formation of stable dendrimer-drug conjugates: In contrast to the 
previous two methods, chemical conjugation of drugs to dendrimers 
through covalent linkage can offer stable drug-dendrimer entities. The 
release of drugs covalently attached to dendrimers is dependent on the 
chemical and enzymatic activity of the environment. This offers more 
controlled, slower and targeted release of conjugated drugs. Many 
groups have reported the covalent attachment of different low 
molecular weight drugs to dendrimers  where the conjugated drug can 
be released to its target through enzymatic or chemical cleavage [23, 
162, 228].   
 
Conjugation or complexation of (therapeutic) molecules to dendrimers can 
enhance their delivery through a multitude of pathways:  
1- Solubilisation. The precise structure and multivalent surface 
functionality of dendrimers make them good excipients for enhancing 
the solubility of hydrophobic drugs. The previously described methods 
of encapsulation, electrostatic attraction or covalent bonding between 
a hydrophobic drug and a dendrimer can all lead to enhanced aqueous 
solubility of hydrophobic drugs.  
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2- Enhanced Permeation and Retention (EPR) effect. The discrepancy 
between ‘leaky’ tumour vasculature and more restrictive healthy tissue 
vasculature is one of the most important aspects that can be exploited 
in the specific targeting of tumours, and is often referred to as the EPR 
effect [170]. Dendrimers can offer the platform for a drug carrying 
device that has a molecular size that is too large to leak through healthy 
vasculature while being small enough to leak through the less restrictive 
tumour vasculature achieving specific tumour targeting [23, 229].  
3- Evasion of membrane efflux transporters. Efflux transporters such as P-
glycoprotein are amongst the most limiting factors in the oral 
absorption of small molecular weight drugs. Efflux transporters are also 
the primary reason behind multiple drug resistance properties 
displayed by cancerous cells. It has been reported that P-gp substrates 
such as propranolol [162], terfenadine[163] and doxorubicin[164] can 
evade the P-gp pump when conjugated to PAMAM dendrimers and 
hence had increased  absorptive transport and decreased secretory 
transport across cells expressing P-gp in-vitro. It has also been argued 
that not only do dendrimers by-pass P-glycoprotein transporters but 
can also inhibit them.  It has been reported that the concomitant 
presence of G3 PAMAM dendrimers with P-gp substrates doxorubicin 
and vinblastine significantly improves their accumulation in the gut-sac 
[230].    
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4.1.2 Active Dendrimer-drug conjugates 
An intriguing area of research that is still under-developed is that of generating 
stable dendrimer-drug conjugates that are active in their own right. Although 
most reported dendrimer-drug conjugations in the literature rely on the 
release of the drug from the dendrimer to exert the pharmacological effect, 
some examples exist for stable and intact dendrimer-drug conjugates that 
exert pharmacological activity as the conjugate itself. Wang et al. [224] 
conjugated the thrombolytic agent streptokinase to a PAMAM G3.5 dendrimer 
without any loss in pharmacological activity based on in-vitro fibrinolytic 
assays. Because of their multivalent surface functionality, dendrimers can offer 
an interesting platform where various compounds and drugs can be attached 
to the same dendrimer to achieve combinatorial targeting and activity. Many 
groups [231-234] reported a cationic PAMAM Methtrexate-Folic Acid (FA) 
conjugates where methotrexate maintains its pharmacological (anti-tumour) 
activity in-vitro while FA increases the specific targeting of the whole 
conjugate. Some of these groups have additionally incorporated fluorescein 
into the conjugate to achieve visualisation of the drug inside the target cells. 
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4.1.3 Aims and Objectives 
 
The overall aim of the thesis was to synthesise a dendrimer-cannabinoid 
conjugate that it is active in its own right as the conjugate. The experimental 
objectives specific to this chapter are: 
1- The synthesis of radiolabel-dendrimer conjugate which serves two 
purposes:  
(A) As a model for chemical conjugation to a dendrimer via an amide 
linkage that can serve to assess stability of linkage to biological 
media. 
(B) As a labelled dendrimer that can be analysed in biological fluids for 
future  absorption and biodistribution in-vivo studies 
2- Conjugation of a novel cannabinoid (GA006) to an anionic PAMAM 
dendrimer using a stable amide linkage and the subsequent testing of 
pharmacological activity of the conjugate.  
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4.2 Materials and Methods 
4.2.1 Materials 
[3H] Acetic Anhydride (5mCi, specific activity 72mCi/mmol) was purchased from 
American Radiolabeled Chemicals (St. Louis, USA). PD-10 gel columns were 
purchased from GE Healthcare, (UK). Anionic PAMAM dendrimers were 
purchased from Sigma-Aldrich, (UK). DMEM media and foetal bovine serum 
were purchased from Invitrogen, UK. All other chemicals and solvents were 
purchased from Fisher (UK) unless otherwise stated.  
4.2.2 Methods 
Radiolabeling of Dendrimers  
Two strategies were pursued in the radiolabeling of anionic PAMAM 
dendrimers using [3H] acetic anhydride as the radioactive source. [3H] Acetic 
anhydride was prepared as a 1mCi/mL solution in anhydrous acetonitrile and 
stored at 4oC.  
Method 1  
Anionic PAMAM dendrimers were labelled in a similar approach to that 
previously described by Kitchens et al. [235]. 200µL of anionic PAMAM 
dendrimer G3.5 methanolic solution (containing 20mg of dendrimer) was 
transferred to a round bottom flask and was dried in-vacuo. The flask was 
sealed and flushed with nitrogen, before re-dissolved the residue with 
anhydrous methanol (2mL to achieve a concentration of 10mg/mL) under a 
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stream of nitrogen. Using a dry Hamilton syringe, 60µL (60µCi) of [3H] acetic 
anhydride solution in acetonitrile were transferred to the flask (leading to a 
ratio of 3µCi of radiolabel per 1mg of dendrimer). 10µL of Triethylamine were 
also added to the flask under a stream of nitrogen. The contents of the flask 
were then left stirring for 24 hours before terminating the reaction by the 
addition of 5mL of distilled water adjusted with HCL to pH 3. The contents were 
then dried under vacuum and the residue was re-dissolved in 2.5mL of distilled 
water. Under acidic aqueous conditions, it is expected that unreacted acetic 
anhydride would break down to acetic acid which will consequently evaporate 
under vacuum. To completely separate the dendrimer from unreacted acetic 
anhydride, the polymer was purified using PD-10 gel column. The eluted 
fraction at which the dendrimer is expected to appear was collected and dried 
under vacuum. The purity of the dendrimer was then analysed using a PD-10 
column to ensure no free radio-label was present with the dendrimer.  
Method 2 
Step 1 : Amination of the Carboxylic terminus 
200µL of anionic PAMAM dendrimer G3.5 methanolic solution (containing 
20mg of dendrimer) was transferred to a round bottom flask and was dried in-
vacuo. The residue was then re-dissolved with phosphate buffer saline (PBS, pH 
7.4, 2mL).  10 Molar equivalent of 1-ethyl-3- [3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC) and 10 molar equivalent of  N-hydroxysulfo- 
succinimide (Sulfo-NHS) were added to the dendrimer solution. The solution 
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was left  to stir for 30 minutes. 3 molar equivalent of ethylenediamine were 
added to the stirring solution. The reaction was allowed to stir for 16hrs. The 
solvent was dried in vacuo, and the contents were re-dissolved in 2.5mL of 
ddH2O. To completely separate the dendrimer from unreacted acetic acid, the 
polymer was purified using PD-10 gel column. The eluted fraction at which the 
dendrimer is expected to appear (0-5 mL in a PD-10 as previously shown in 
chapter 2)  was collected and dried under vacuum.  
Step 2: Addition of Radiolabel 
55 µl (55 µCi) of [3H] Acetic anhydride acetonitrile solution was dissolved in 
4mL of PBS. 10 molar equivalent of EDC and 10 molar equivalent of Sulfo-NHS 
were added to the stirring solution. After 30 minutes, 18.3 mg of aminated 
PAMAM G3.5 dendrimer (dissolved in 1mL of PBS) was added to the stirring 
solution (leading to a ratio of 3µCi of radiolabel/1mg dendrimer) and the 
solution was allowed to stir for 16hrs. The reaction solvent was then dried in 
vacuo, and the radiolabelled dendrimer was triple purified using a PD-10 
column as previously described in step 1.  
 
Assessment of Limits of Quantitation 
The limits of quantitation of the radiolabeled dendrimers were calculated 
through serially diluting a radiolabeled PAMAM dendrimer and assessing the 
lowest concentration of radiolabeled PAMAM dendrimer that can be 
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quantified. The limit of quantitation was calculated according to the following 
formula: 
               
LOQ stands of the lower limit of quantitation, BG for background reading and 
SDBR for the standard deviation which is calculated from 10 different 
background readings.  
Stability testing of Radiolabeled dendrimers 
Radiolabeled dendrimers were incubated in either total Foetal bovine serum 
(FBS) or in dulbeco modified eagle medium (DMEM) supplemented with 10% 
FBS proteins (at a concentration of 1µCi/ mL media) at 37oC and relative 
humidity. Several samples were taken at different time intervals from 0-24 
hours and stored at -20oC before analysis. Collected samples were then loaded 
into PD-10 columns and chromatograms were generated by analysing separate 
1mL fractions that were eluted from the column to quantify radiolabel that is 
either associated with the dendrimer or is in a free form.   
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Cannabinoid – Dendrimer Conjugation 
Step 1 
The Boc group protecting the amine group in GA006 was broken by dissolving 
the cannabinoid in an aqueous solution of 1M HCl for 3 hours. The solution was 
then basified by the addition of concentrated sodium hydroxide (NaOH) until a 
pH of 12 was achieved as evident by pH paper. The basified solution was 
extracted with 3 portions of ethylacetate. All ethyl acetate portions were 
pooled and dried in-vacuo. The resulting compound was analysed using 1H 
NMR and used with no further purification.  
Anionic PAMAM dendrimer G3.5, 20 mg (1.61 mmol) was dissolved in in a 
50:50 mixture of MeOH : H2O. 10 molar equivalent of EDC and 10 molar 
equivalent of Sulfo-NHS were added to the stirring solution. After 30 minutes, 
3.66mg (8.02mmol) of the cannabinoid N-(3-(1-naphthoyl)-1-pentyl-1H-indol-5-
yl)-5-aminopentanamide (GA006a) was added to the stirring solution, and the 
solution was allowed to stir for 16hrs. The reaction solvent was then dried in 
vacuo, and the dendrimer-cannabinoid conjugate was triple purified using a 
PD-10 column as previously described in step 1.  
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Pharmacological testing of PAMAM-Cannabinoid Conjugate 
Pharmacological testing of the PAMAM-Cannabinoid conjugate was performed 
with RAW 264.7  as described in the methods section in Chapter 3.  
 
4.3 Results and Discussion 
4.3.1 Radiolabeling of G3.5 PAMAM dendrimers 
This was undertaken to : 
(A) Generate a dendrimer moiety that could be used in in-vivo 
biodistribution studies providing a sensitive analytical tool. 
(B) To mimic the chemistry of coupling via an amide linkage to to the 
surface of a PAMAM G3.5 dendrimer and thus provide a ready model to 
initially explore the stability of this coupling linkage in biological fluids. 
  
Previously described methods in radiolabelling anionic PAMAM dendrimers 
include Wiwattanpatapee’s method [26] in aminating one of the surface 
carboxylic groups on a PAMAM dendrimer followed by attaching radioactive 
iodine (125I) which readily reacts with primary amines. Although this method 
achieves high specific radioactivity, it also depends on the use of radioactive 
species (125I) which imposes more serious health and environmental risks than 
[3H] or [14C] isotopes. Another group used tritiated acetic anhydride to 
radiolabel both cationic and anionic dendrimers [235]. This last strategy 
  CHAPTER 4 
182 
 
exploits (for anionic PAMAM dendrimers) the reactivity of secondary amines 
that are present in the dendrimer’s interior which are present in its interior 
because of inaccuracies in polymer synthesis. This method was repeated in the 
first of the chemical strategies described in results to link acetic anhydride to 
anionic dendrimers (Schematic ‎4.1)   
 
Schematic ‎4.1 Strategy No.1 used in the radiolabeling of PAMAM dendrimers. 
 
4.3.1.1 Purification and Characterisation of PAMAM-radiolabel 
conjugates 
 
Purification of radiolabeled dendrimer was performed using GPC 
chromatography to separate the unreacted free radiolabel (in this case [3H] 
acetic acid as all the free [3H] acetic anhydride will hydrolyse in the aquous 
conditions of the GPC).  A  PD-10 sephadex column with a molecular weight 
cut-off (MWCO) of 5,000Da . This can safely separate the 13,000Da PAMAM 
G3.5 from small molecular weight impurities including the free radiolabel. To 
demonstrate that the column can separate between the dendrimer and the 
free radiolabel, Figure ‎4.1 shows the GPC chromatograms of Oregon-green 
labelled PAMAM G3.5 dendrimer, and the free radio label, [3H] acetic acid. 
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PAMAM G3.5-OG dendrimer completely elutes within the first 5 mL as shown 
in the figure while [3H] acetic acid starts eluting at the 6th mL of the mobile 
phase. It is therefore possible to purify the radiolabeled PAMAM G3.5 using 
GPC chromatography.  
                    
Figure ‎4.1 Over-layed GPC chromatograms generated by analysing eluted 1mL fractions from 
PD-10 columns (containing sephadex G25 gel.) Solid line represents chromatogram of pure 
Dendrimer-OG conjugate, dashed line represents free [3H] acetic acid. 
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Figure ‎4.2 (A) GPC chromatogram of crude reaction mixture of PAMAM G3.5 and acetic 
anhydride displaying two peaks, first one for the radiolabeled G3.5 dendrimer, second for free 
[3H] acetic acid as acetic anhydride is expected to hydrolyse in an aqueous solution. (B) GPC 
chromatogram of radiolabeled anionic PAMAM G3.5 
 
Figure ‎4.2 shows GPC chromatograms for (A) crude PAMAM G3.5-acetic 
anhydride reaction mixture (displaying two peaks corresponding respectively 
to the radio-labelled dendrimer and the free radiolabel) and (B) the pure 
PAMAM G3.5-radiolabel conjugate  after purifying the dendrimer three times 
using GPC. These results show that the reaction was successful in coupling a 
radiolabel to the dendrimer. Having shown that the dendrimer-radiolabel is 
pure from free radiolabel, it is possible to quantify the specific radioactivity of 
the radio-labelled dendrimer. 
The specific radioactivity of the labelled dendrimer was 0.3µCi / mg of polymer. 
The limit of quantitation of the radiolabeled dendrimer was 2µg/mL as 
calculated from the minimum limit of quantitation (LOQ) as described in the 
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methods section of this chapter. This specific activity was significantly lower 
than that achieved by Sweet et al. who used the same method in radiolabeling, 
but generated labelled anionic PAMAM dendrimers with specific radioactivity 
of approximately 1µCi/mg of polymer [236]. This might be due to the fact that 
this method exploits inaccuracies in the dendrimer structure which can be 
variable between different batches leading to different yields during 
radiolabeling. This method is hence not consistently reliable.  
Another disadvantage that is associated with this method is the low stability of 
acetic anhydride which hydrolyses over time to produce acetic acid. This would 
demand very stringent storage conditions for the radiolabel, and even then this 
radiolabel would ultimately breakdown to acetic acid due to its reaction with 
atmospheric moisture overtime once the ampoule seal is broken. Additionally, 
the breakdown of [3H] acetic anhydride during the synthesis due to reactivity 
with atmospheric humidity is inevitable due to the miniscule amounts of 
radioactive acetic anhydride that is used in such reactions which makes any 
presence of atmospheric humidity in the reaction apparatus a considerable 
issue that can limit the reaction specially when the other reactant (i.e. the 
PAMAM dendrimer) is not particularly reactive with the anhydride as described 
earlier.    
The second method however, employs a novel and cheap way to radiolabel 
anionic PAMAM dendrimers. The anionic PAMAM dendrimer radiolabeling 
procedure was carried out in two steps as shown in Schematic ‎4.2.  
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Schematic ‎4.2 Strategy No.2 used in radiolabeling of anionic PAMAM dendrimers. Step 1 
involves aminating one of the 64 surface groups using ethylene diamine . Step 2 involves using 
[
3
H] acetic acid, generated by the hydrolysis of [
3
H] acetic anhydride, in radiolabeling the 
aminated dendrimer.  
  
The method by which anionic PAMAM dendrimers were labelled in these 
studies is novel and has not been reported before. The method depends on 
aminating one of the 64 carboxylic group so it becomes reactive to a carboxylic 
radioactive carboxylic compound. Acetic anhydride was chosen as a chemical 
source for the radioactive chemical because of its high availability and cheap 
price. As it would have been easier and more chemically efficient to use a 
radioactive amine that can directly react with the carboxylic groups on the 
PAMAM dendrimer’s surface, radioactive compounds baring amine termini are 
very expensive and are not readily available.  
The specific radioactivity for the radiolabeled polymers was calculated to be 
0.9µCi/mg and a lower limit of quantitation of 0.71µg/mL. This level of activity 
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was similar to that described previously by Wiwattanapatappee et al. [26] and 
Sweet al.  [236]. This method however is superior to that used by 
Wiwattanapatppee as it employs the use of a safer and cheaper isotope, 
tritium, and is superior to that of Sweet et al. as it is more consistent and 
reliable because it’s not dependant on random secondary amines that can be 
present or absent to varying degrees in anionic PAMAM dendrimers.  
Additionally, stability of the acetic anhydride is not an issue with this method 
as it employs the use of its break-down product, acetic acid, which is generated 
from acetic anhydride once dissolved in an aqueous environment such as that 
used in the dendrimer reaction.  
This method was hence adopted for all future radiolabeling of PAMAM 
dendrimers.  
4.3.1.2 Stability of Radiolabeled Dendrimer 
 
It is of vital importance to assess the stability of the Dendrimer-radiolabel 
conjugate to ensure that the radioactivity measured in any experiment would 
be only dendrimer associated and doesn’t correspond to the free radio label, 
which can skew experimental results.  
Additionally, because the radiolabel is attached using an amide bond, stability 
data generated from dendrimer-radiolabel conjugate would give an indication 
about the stability of the dendrimer-cannabinoid conjugate synthesised earlier. 
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Radiolabeled dendrimers were incubated in Cell culture medium (DMEM) 
supplemented with 10% FBS to assess the stability of these radiolabeled 
dendrimers when using them in in-vitro studies. Additionally, stability was 
tested in total foetal bovine serum to preliminarily assess stability of these 
dendrimers when used in-vivo. 
 
Figure ‎4.3 Stability  of PAMAM-radiolabel conjugates. (A) GPC chromatograms of radiolabeled 
PAMAM incubated in cell culture media containing 10% FBS serum over 24 hours. GPC 
chromatograms of radiolabeled PAMAM incubated in (FBS) over 24 hours. 
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Table ‎4.1 Stability of radiolabeled PAMAM dendrimers. Purity calculated as the ratio 
between the area of the chromatogram representing free radiolabel associated 
radiation and area representing dendrimer associated radiation.  
Time (hrs) Incubation in full cell culture media incubation in total FBS 
 
Area of 
dendrimer 
associated 
radiation 
[%Radiation. 
Elution 
Volume] 
Area of free 
radiolabel 
associated 
radiation 
[%Radiation. 
Elution 
Volume] 
% Purity 
Area of 
dendrimer 
associated 
radiation 
 
[%Radiation. 
Elution 
Volume] 
Area of free 
radiolabel 
associated 
radiation 
[%Radiation. 
Elution 
Volume] 
% Purity 
 
0 
 
 
111.8 
 
1.22 
 
98.9% 
 
136.2 
 
1.148 
 
99.2% 
6 
 
133.1 3.88 97.2% 129.5 5.52 95.9% 
12 
 
117.8 6.76 94.6% 125.6 5.31 95.9% 
24 142.9 12.51 92.0% 140.3 12.93 91.6% 
 
Results presented in Figure  4.3 and Table  4.1 show that the Radiolabel displays 
<5% dissociation from the dendrimer over 6-12 hours when incubated in total 
FBS or in cell culture media while dissociation of the radiolabel does not exceed 
9% over 24 hours. This suggests that the PAMAM-radiolabel conjugate is fairly 
stable in physiological conditions over 24 hours. To overcome the issue of the 
slight radiolabel dissociation over time in physiological conditions, 
experimental analyses can be performed on GPC purified samples to ensure 
that radioactive measurements correspond solely to the PAMAM dendrimer 
and not to the free radiolabel.  
Results from these experiments additionally show that a compound conjugated 
to a dendrimer with an amide bond is stable in physiological conditions over 24 
hours. The previously described Dendrimer-cannabinoid conjugate is hence 
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expected to be stable in physiological conditions as it is attached to the 
dendrimer via an amide bond too.  
 
4.3.2 Cannabinoid-Dendrimer Conjugation 
4.3.2.1 GA006 coupling to PAMAM G3.5 dendrimer 
GA006 which comprises a protected amine separated by a spacer from the 
cannabinoid can be conjugated to an anionic PAMAM dendrimer as this amine, 
once unprotected can react with the carboxylic groups on the shell on the 
PAMAM dendrimer forming a stable amide bond.  
 
Schematic ‎4.3 De-protection of the amine on GA006 and conjugation to a PAMAM G3.5 
dendrimer. 
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Deprotection was swiftly achieved by hydrolysing the Boc group in a 3M HCl 
solution as shown in Schematic  4.3. The NMR spectrum provides evidence for 
the success in deprotecting the amine on GA006: 
1H NMR (500MHz, DMSO-d6) δ 8.46 (1H, s), 8.34 (1H, s), 8.15 (1H, d), 8.10 (1H, 
d), 8.01 (1H, d), 7.66 (1H, d), 7.54 (1H, t), 7.48 (1H,t) 7.38 (1H, t), 7.28 (1H, s), 
7.02 (1H, s), 4.61 (2H, s), 4.07 (1H, t) 3.11 (1H, s), 2.62 (2H, s), 2.13 (1H, t), 1.85-
1.75 (2H, t), 1.61-1.55 (2H, t), 1.54-1.48 (6H, m), 1.38-1.22 (3H, m), 0.85 (2H, t). 
The amine was hence exposed and ready to react with the carboxylic groups on 
the anionic G3.5 PAMAM dendrimer.  
The conjugation was carried out in a 50:50 mixture of methanol : water to 
achieve complete dissolution of the hydrophobic cannabinoid while keeping 
the hydrophilic catalysts (EDC and S-NHS) in solution. The reaction proceeded 
for 16 hours. 
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4.3.2.2 Purification and Characterisation of PAMAM G3.5-GA006 
Conjugate 
 
The dendrimer-cannabinoid conjugate could not be purified using flash 
chromatography as the high hydrophilicity of the PAMAM dendrimer makes 
the affinity of the dendrimer to silica higher than any solvent system that can 
be used in flash chromatography including 100% methanol as evidenced from 
TLC analysis of PAMAM dendrimers with different solvent systems as shown in 
Figure  4.4. 
 
Figure ‎4.4 TLC analysis of PAMAM G3.5 dendrimers, cannabinoid GA006a and the putative 
PAMAM G3.5-cannabinoid conjugate. (A) silica plate developed using 8:2 
Cyclohexane:Ethylacetate which results in an approximate Rf value of 0.3 for Free GA006, but 
PAMAM G3.5 and PAMAM G3.5-GA006 conjugate do not elute. (B) a significantly more polar 
system of Dichloromethane:Methanol (8:2) is used. This results in virtually no retention of 
GA006  but PAMAM G3.5 and the PAMAM-Cannabinoid conjugate still don’t elute. (C) shows a 
TLC plate developed using 100% Methanol which similarly leads to very high elution of the free 
cannabinoid while no elution of PAMAM G3.5 or PAMAM G3.5-GA006 occurs. (D) 50:50 
Methanol : Water is the only elution system that leads to the elution of PAMAM G3.5 and the 
Cannabinoid conjugate, however Rf values for both PAMAM G3.5 and the conjugate are not 
different. 
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As shown in Figure  4.4, the only solvent system that can lead to elution of 
PAMAM G3.5-GA006 involves the addition of water to the solvent system. 
Solvent systems containing more than 10% methanol however can result in 
dissolving the silica [237] that is used in flash chromatography leading to failure 
in extracting the desired pure components. Water naturally is not compatible 
with silica as it leads to dissolving it during flash chromatography because it is 
more polar than methanol. 
Using reverse chromatography by HPLC on the other hand can overcome this 
problem. The large size of the dendrimer however, was not compatible with 
ordinary HPLC columns that where available.  
The conjugate was hence purified using size exclusion chromatography/Gel 
permeation chromatography (GPC), where a sephadex G-25 gel matrix is used 
to separate the large polymer from smaller free molecules as previously 
described in the chapter. Pre-packed PD-10 columns (G-25 Sephadex gel) were 
used for this separation, as their molecular cut off of 5,000Da is ideal for 
separating between the 14,000Da conjugate and the 455Da free cannabinoid.  
It was expected that the dendrimer conjugate would elute at the first 5mL 
fraction. This was confirmed using 1H NMR analyses as shown in Figure  4.5.  
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Figure ‎4.5: NMR spectra for: 
(A) [
1
H] NMR spectrum of PAMAM G3.5-GA00a6 Conjugate as eluted within the first 5mL 
fraction from a PD-10 GPC column. The spectrum shows signals corresponding to both PAMAM 
G3.5 and GA006a. 
(B) [
1
H] NMR spectrum of the first 5mL eluted from a PD-10 column when loading a mixture of 
PAMAM G3.5 and free GA00s6 which essentially represents a typical PAMAM G3.5 spectrum 
with no signals corresponding to GA006a 
(C)  [
1
H] NMR spectrum of GA006a 
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NMR analyses of different GPC fractions of PAMAM G3.5-GA006a conjugate 
and mixtures of PAMAM G3.5 and free GA006a show that an intact PAMAM 
G3.5-GA006a has been achieved. Both GA006a and PAMAM G3.5 signals are 
visible when analysing the first 5 mL fraction that elutes when loading the 
putative conjugate. When loading a mixture of free dendrimer and free 
cannabinoid however, the first 5mL fraction only shows signals that are 
associated with the PAMAM dendrimer and not the cannabinoid which proves 
that the purification process pursued can efficiently separate between the free 
cannabinoid and the dendrimer conjugate.  
Upon analysing the NMR spectrum of the PAMAM G3.5-GA006 conjugate, a 
ratio of 1.5 : 1 of cannabinoid to PAMAM G3.5 can be estimated. This was 
calculated as the ratio between protons corresponding to total PAMAM 
dendrimer (δ 5.5-2.0 ppm as shown in Figure ‎4.5, B)  and signals corresponding 
to the aromatic protons (visible at δ 8.5-7.5 ppm as shown in the NMR 
spectrum of free GA006a in Figure  4.5, A) PAMAM protons, and aromatic 
protons correspondent to aromatic protons in GA006 are completely separate 
and can hence be used to quantify the ratio between the cannabinoid and the 
dendrimer.  
Previous stability studies in biological fluids with PAMAM G3.5-radiolabel show 
that the amide bond used to couple the radiolabel to the dendrimer is stable 
over 24 hours. The linkage between the cannabinoid and the dendrimer being 
an amide one as well, it is expected that the dendrimer-cannabinoid conjugate 
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will be similarly stable over the course of 24 hours. The conjugate is hence 
expected to be intact when administered with minimal dissociation of the 
cannabinoid and therefore decreasing the possibility the cannabinoid 
dissociating and accessing the CNS and causing CNS adverse effects. Clearly 
further in-vivo studies are needed for the complete assessment of the 
dendrimer-cannabinoid conjugate in the future.  
 
4.3.2.3 Pharmacological activity of PAMAM G3.5 – GA006 Conjugate 
 
The pharmacological activity of PAMAM G3.5-GA006 was assessed using the 
RAW 264.7 model with PAMAM G3.5 being used as negative control, and 
JWH007 used as a positive control. Results of TNF-ɑ suppression of each of the 
used compounds are displayed in Figure ‎4.6.  
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Figure ‎4.6 The effect of PAMAM G3.5, PAMAM G3.5-GA006 conjugate and JWH007 (12.5µM – 
25µM) in suppressing LPS induced (200ng/mL for 16 hours) production of TNF-ɑ in the murine 
macrophage cell line, RAW 264.7. Results are mean ± S.D, n=4. * indicates P<0.05 (ONE-WAY 
ANOVA, Dunnett’s post-test). 
 
Results show that the PAMAM G3.5 dendrimer does not have any inherent 
effects in suppressing TNF-a production by RAW 264.7 cells when used at 
equivalent molar concentrations to the highest concentrations used with 
Cannabinoids in these experiments. When treating LPS challenged RAW 264.7 
cells with the previously synthesised and characterised PAMAM G3.5-GA006 
conjugate, no TNF-ɑ suppression effect is displayed indicating that the 
cannabinoid has lost its previous pharmacological activity when it was 
conjugated to a PAMAM G3.5 dendrimer. JWH007, used as a positive control, 
displayed an anti-inflammatory effect as before, which indicates that the assay 
is valid.  
It is unknown why conjugating the cannabinoid to a dendrimer has resulted in 
a complete loss in activity. It is speculated however that the large size of the 
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dendrimer has made the conjugate too bulky to gain access to its receptors in 
the macrophage cell line. Additionally, the loss in activity may be due to the 
high hydrophilicity of the conjugate, this is because cannabinoids generally 
need to be highly hydrophobic to interact with the lipophilic regions of the 
receptor [205]. 
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5.1     General Discussion 
 
The ultimate aim of the work described in this thesis was to utilise PAMAM 
dendrimers as a tool to achieve differential transport across the intestinal 
mucosa and the blood brain barrier, where these dendrimers can be used to 
achieve oral bioavailability but avoid BBB penetration and CNS access.  
It was hypothesised that the large molecular size of the dendrimers combined 
with their compact, multivalent structure may achieve this aim. More precisely, 
dendrimer-drug conjugates would be created that are active in their own right 
but whose penetration to brain is prevented but whose intestinal activity is 
afforded. CNS adverse effects of cannabinoids currently limit their use as a 
therapeutic in IBD [67]. To produce their pharmacological activity in treating 
IBD, cannabinoids must be absorbed across the GI tract [111], and their CNS 
adverse effects clearly must be avoided. 
Work to underpin the value of dendrimers to achieve selective barrier 
transport while creating a stable and pharmacologically active dendrimer-
cannabinoid conjugate would represent a significant contribution.  
 
In Chapter 2, a series of in-vitro epithelial permeability studies were 
undertaken examining the passive transport of cationic and anionic PAMAM 
dendrimers of varying molecular size. These studies aimed at showing a 
discriminative capacity of epithelial barriers of differing paracellular 
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restrictiveness toward the passive transport of dendrimers.  In doing so, 
biological support would be provided for the hypothesis that dendrimers of an 
appropriate size are able to cross the intestinal mucosa but be restricted from 
crossing the BBB. 
 
In-vitro investigations to mimic the intestinal permeability to different 
dendrimers were conducted using the CaCo-2 and MDCK II models. Both 
models have been used by other investigators to predict intestinal absorption 
to a wide variety of therapeutic molecules, although the predictive capacity of 
such in-vitro permeation studies to in-vivo absorption for high molecular 
polymers such as dendrimers has not been examined.  For small molecular 
sized molecules the   Papp data in-vitro in these two cell lines has been shown to 
provide good correlation to extents of oral absorption in humans [151, 156].  
 
This thesis has shown that anionic PAMAM dendrimers at a size range of G1.5 – 
G5.5 display quantifiable transport across CaCo-2 and MDCK II “intestinal 
barrier” models in a size dependant manner, where smaller-sized dendrimers 
show the highest rate of transport.  These anionic PAMAM dendrimers are 
biocompatible and did not compromise the integrity of the in-vitro epithelial 
monolayers as evidenced from maintenance of TEER measurements and of Papp 
data of co-instilled hydrophilic paracellular probes such as [14C] mannitol. 
Indeed, anionic PAMAM dendrimers have been previously shown to be 
biocompatible when administered to rodents in-vivo [23].  The results support 
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the view that anionic PAMAM dendrimers can achieve oral bioavailability in-
vivo to the level that could provide concentrations in intestinal sub mucosal 
tissue sufficient to elicit beneficial therapeutic responses.   
 
In contrast to anionic PAMAM dendrimers, the cationic (G3 and G4) PAMAM 
dendrimers examined showed significantly higher transport rates and displayed 
Papp values that increased with increasing dendrimer size.  These cationic 
dendrimers showed clear signs of epithelial barrier disruption as evidenced by 
significant decreases in TEER values and increases in co-instilled [14C] mannitol. 
A number of groups have reported high Papp values for cationic dendrimers and 
suggested that they would be superior to other polymers in terms of barrier 
transport. However, the toxic effects of these multi-cationic entities are often 
overlooked. The data generated in this current thesis, as well as reports in the 
literature, for cationic PAMAM dendrimers were sufficient to exclude them 
from further consideration as the polymeric component in the development of 
a novel dendrimer-cannabinoid drug.   The anionic PAMAM dendrimers were 
the lead polymer type for later cannabinoid conjugation experiments.  
 
The other element of the hypothesis underpinning the thesis was that 
dendrimers would be effectively excluded from accessing the brain.  The use of 
in-vitro BBB models to predict in-vivo penetration of drugs to the CNS is less 
clear than that for the intestine. In part this reflects the difficulty in quantifying 
brain penetration even in experimental animal models. However, beyond this 
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in-vitro BBB models simply do not establish the same levels of paracellular 
restrictiveness as the fully intact in-vivo BBB. For example, TEER measurements 
across the outer cerebral microvessels (pial vessels) of the brain can reach 8000 
Ω.cm2.  Even the most restrictive in-vitro models reported, i.e. Porcine Brain 
primary microvascular cultures, reach only 1000 Ω.cm2. More significantly 
paracellular permeability of such a model is at least x-10 fold greater than the 
in-vivo barrier. Other in-vitro BBB models are significantly worse at up to 1000-
10000-fold greater paracellular permeability. 
 
With the aim of using a restrictive but simple model for the BBB (but 
nevertheless one that still cannot mimic in quantitative terms the limiting 
nature of the in-vivo barrier) experiments in this thesis utilised the MDCK I cell 
line.  This model has been used in both commercial and academic sectors as a 
surrogate BBB model. Further, MDCK I represents an equivalent cell line to 
MDCI II, except for higher TEER values reflective of differences in tight-
junctional regulation. Nevertheless, MDCK I and II possess the same 
morphology and one anticipates very similar biochemistry. 
 
None of the tested anionic PAMAM dendrimers showed any transport across 
the MDCK I model which contrasted to the findings for the MDCK II model in 
which all the tested anionic PAMAM dendrimers displayed permeation.  
Nevertheless, the permeability of the MDCK I cell monolayer to the small 
hydrophilic probe F-Na was evident, although to a much lesser extent than 
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across MDCK II.  This confirmed that while the MCDKI cell monolayer is 
restrictive it should still be deemed as “leakier” to the passive transport of 
hydrophilic species than the in-vivo BBB barrier.  The data therefore strongly 
support the conclusion that the anionic PAMAM dendrimers under study are 
very unlikely to penetrate the in-vivo BBB having failed to pass across a simpler 
barrier such as the MDCK I.  
 
Therefore data is provided to strongly support the hypothesis that anionic 
PAMAM dendrimers can serve as a tool that affords transport across the 
intestinal mucosa while eliciting exclusion from the CNS. Naturally, in-vivo 
studies investigating both the intestinal transport and the CNS access of 
PAMAM dendrimers are needed in the future to further support the in-vitro 
data that has been generated so far.   
 
In Chapter 3 the structure activity relationships (SAR) of cannabinoid 
compounds were explored as part of a strategy to identify suitable sites within 
the cannabinoid structure that may be used for conjugation to a dendrimer. 
Amongst the different classes of cannabinoid compounds it was decided to 
focus on the amino-alkyl indoles given their high potency and extensive use in 
the literature. After identifying sites within the cannabinoid that had previously 
been shown in the literature to be categorically vital for activity, the remaining 
sites were explored (i.e. carbonyl group and position 5’ as shown in Figure ‎5.1) 
whose contribution to activity had not been previously examined.  
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Figure ‎5.1 an amino alkyl indole showing sites that were manipulated in SAR studies. 
 
Altering the carbonyl group proved to be technically challenging due to the 
high stability of the group.  A variety of reducing agents failed to reduce  this 
site to an alcohol or an amine. After this, position 5’ was explored with various 
modifications applied.   Many of the alterations at this site led to the 
maintenance of pharmacological activity indicating that this position is a 
suitable site to test dendrimer conjugation to allow retention of cannabinoid 
activity.  
This finding was novel and significant to the studies within the cannabinoid 
field as it revealed a position that can be manipulated without any loss in 
activity. It will contribute to understanding of the SAR of this class of 
cannabinoids and opens new avenues in synthesising active cannabinoids with 
improved physicochemical properties; for example, functional groups could be 
attached to improve the aqueous solubility of these lipophilic compounds. 
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Given these findings, it seemed that position 5’ would be the ideal site to 
investigate the conjugation of dendrimer. However, prior to this a reactive 
functional group needed to be introduced at position 5’ in order the provide 
chemistry for the dendrimer linkage. The synthesis of a stable 
cannabibimimetic compound, GA005, is described in chapter 3. This compound 
contains a nitro group at position 5’ that can be reduced to a primary amine. 
The primary amine is reactive to a wide variety of chemical building blocks 
making it easier to manipulate the cannabinoid compound and tailor it as 
appropriate at this position. Using GA005 as a template, a 12Å long spacer 
bearing an amine on its terminus was successfully introduced at position 5’. 
The resulting cannabinoid, GA006, was pharmacologically active as predicted 
and was suitable to be conjugated to a dendrimer. 
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5.2     Conclusions 
Overall the thesis has made the following scientific contributions to the 
respective field(s): 
1. Promoted a strategy whereby an active polymer (dendrimer)-drug 
conjugates could be formed that is active in its own right and where the 
polymer  can serve to provide differential biological barrier transport 
which with regard to cannabinoid pharmacology obviates adverse CNS 
effects. 
2. Probed the SAR of cannabinoids based upon amino-alkyl indole 
chemistry and revealed a site, position 5’, that can be functionally 
altered without loss of pharmacological activity.   
3. Designed and synthesised novel and active cannabinoid structures that 
should have commercial interest 
4. Developed a novel radiolabelling strategy for anionic polymers that 
offers a number of distinct advantages over other approaches 
5. Successfully synthesised a novel Dendrimer-cannabinoid conjugate but 
biological testing revealed it to be inactive.  
 
Clearly future studies will need to address reasons for failure of the dendrimer-
cannabinoid conjugate to display biological activity.  Approaches that could be 
considered include conjugation to a smaller dendrimer, molecular modelling of 
the conjugate interacting with the cannabinoid receptor.  In addition thorough 
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in-vivo biodistribution studies with radiolabel dendrimer should be conducted 
with particular attention to the systemic bioavailability following oral dosing 
and the extent of CNS penetration.  
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